0001493152-23-021239.txt : 20230614 0001493152-23-021239.hdr.sgml : 20230614 20230614161026 ACCESSION NUMBER: 0001493152-23-021239 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 45 CONFORMED PERIOD OF REPORT: 20230430 FILED AS OF DATE: 20230614 DATE AS OF CHANGE: 20230614 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PURE BIOSCIENCE, INC. CENTRAL INDEX KEY: 0001006028 STANDARD INDUSTRIAL CLASSIFICATION: MISCELLANEOUS CHEMICAL PRODUCTS [2890] IRS NUMBER: 330530289 STATE OF INCORPORATION: DE FISCAL YEAR END: 0731 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-14468 FILM NUMBER: 231014207 BUSINESS ADDRESS: STREET 1: 9669 HERMOSA AVENUE CITY: RANCHO CUCAMONGA STATE: CA ZIP: 91730 BUSINESS PHONE: 619-596-8600 MAIL ADDRESS: STREET 1: 9669 HERMOSA AVENUE CITY: RANCHO CUCAMONGA STATE: CA ZIP: 91730 FORMER COMPANY: FORMER CONFORMED NAME: PURE BIOSCIENCE DATE OF NAME CHANGE: 20031029 FORMER COMPANY: FORMER CONFORMED NAME: PURE BIOSCIENCES DATE OF NAME CHANGE: 20031029 FORMER COMPANY: FORMER CONFORMED NAME: INNOVATIVE MEDICAL SERVICES DATE OF NAME CHANGE: 19960122 10-Q 1 form10-q.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE QUARTERLY PERIOD ENDED APRIL 30, 2023

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934

Commission File Number 001-14468

PURE Bioscience, Inc.

(Exact name of registrant as specified in its charter)

Delaware		33-0530289
(State or other jurisdiction of		(I.R.S. Employer
incorporation or organization)		Identification No.)

9669 Hermosa Avenue

Rancho Cucamonga, California

91730

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: (619) 596-8600

Securities registered pursuant to Section 12(b) of the Act: None.

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐

Non-accelerated filer	☐	Smaller reporting company	☒

Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of June 14, 2023, there were 111,356,473 shares of the registrant’s common stock, $0.01 par value per share, outstanding.

PURE Bioscience, Inc.

Form 10-Q

for the Quarterly Period Ended April 30, 2023

Table of Contents

		Page
PART I	FINANCIAL INFORMATION
Item 1.	Condensed Financial Statements	3
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	16
Item 3.	Quantitative and Qualitative Disclosures about Market Risk	23
Item 4.	Controls and Procedures	24

PART II	OTHER INFORMATION
Item 1.	Legal Proceedings	25
Item 1A.	Risk Factors	25
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	26
Item 3.	Defaults Upon Senior Securities	26
Item 4.	Mine Safety Disclosures	26
Item 5.	Other Information	26
Item 6.	Exhibits	27
	Signatures	28

Part I - Financial Information

Item 1. Financial Statements

PURE Bioscience, Inc.

Condensed Consolidated Balance Sheets

	April 30, 2023			July 31, 2022
		(Unaudited)
Assets
Current assets
Cash and cash equivalents	$	781,000		$	3,391,000
Accounts receivable		188,000			201,000
Inventories, net		149,000			179,000
Restricted cash		75,000			75,000
Prepaid expenses		37,000			18,000
Total current assets		1,230,000			3,864,000
Property, plant and equipment, net		594,000			620,000
Total assets	$	1,824,000		$	4,484,000
Liabilities and stockholders’ equity
Current liabilities
Accounts payable	$	432,000		$	488,000
Accrued liabilities		137,000			87,000
Total current liabilities		569,000			575,000
Commitments and contingencies		-			-
Stockholders’ equity
Preferred stock, $0.01 par value: 5,000,000 shares authorized, no shares issued and outstanding		—			—
Common stock, $0.01 par value: 150,000,000 shares authorized, 111,356,473 shares issued and outstanding at April 30, 2023 and at July 31, 2022		1,114,000			1,114,000
Additional paid-in capital		132,354,000			132,079,000
Accumulated deficit		(132,213,000	)		(129,284,000	)
Total stockholders’ equity		1,255,000			3,909,000
Total liabilities and stockholders’ equity	$	1,824,000		$	4,484,000

See accompanying notes.

PURE Bioscience, Inc.

Condensed Consolidated Statements of Operations

(Unaudited)

	2023			2022			2023			2022
	Nine Months Ended						Three months Ended
	April 30,						April 30,
	2023			2022			2023			2022
Net product sales	$	1,269,000		$	1,409,000		$	406,000		$	497,000
Royalty revenue		6,000			32,000			1,000			27,000
Total revenue		1,275,000			1,441,000			407,000			524,000
Cost of goods sold		625,000			553,000			211,000			199,000
Gross profit		650,000			888,000			196,000			325,000
Operating costs and expenses
Selling, general and administrative		3,342,000			3,127,000			997,000			977,000
Research and development		227,000			255,000			74,000			107,000
Total operating costs and expenses		3,569,000			3,382,000			1,071,000			1,084,000
Loss from operations		(2,919,000	)		(2,494,000	)		(875,000	)		(759,000	)
Other income (expense)
Gain on extinguishment of indebtedness, net		—			239,000			—			—
Other income (expense), net		(4,000	)		—			1,000
Interest expense, net		(6,000	)		(3,000	)		(2,000	)		(1,000	)
Total other income (expense)		(10,000	)		236,000			(1,000	)		(1,000	)
Net loss	$	(2,929,000	)	$	(2,258,000	)	$	(876,000	)	$	(760,000	)
Basic and diluted net loss per share	$	(0.03	)	$	(0.03	)	$	(0.01	)	$	(0.01	)
Shares used in computing basic and diluted net loss per share		111,356,473			87,741,639			111,356,473			87,925,388

See accompanying notes.

PURE Bioscience, Inc.

Condensed Consolidated Statement of Stockholders’ Equity

(Unaudited)

	Shares		Amount		Capital		Deficit			Equity			Shares		Amount		Capital			Deficit			Equity
	Nine Months Ended April 30, 2023												Nine Months Ended April 30, 2022
	Common Stock				Additional Paid-In		Accumulated			Total Stockholders’			Common Stock				Additional Paid-In			Accumulated			Total Stockholders’
	Shares		Amount		Capital		Deficit			Equity			Shares		Amount		Capital			Deficit			Equity

Balances at beginning of period		111,356,473	$	1,114,000	$	132,079,000	$	(129,284,000	)	$	3,909,000			87,223,141	$	873,000	$	128,253,000		$	(125,793,000	)	$	3,333,000
Balance		111,356,473	$	1,114,000	$	132,079,000	$	(129,284,000	)	$	3,909,000			87,223,141	$	873,000	$	128,253,000		$	(125,793,000	)	$	3,333,000
Share-based compensation expense - stock options		—		—		213,000		—			213,000			—		—		431,000			—			431,000
Share-based compensation expense - restricted stock units		—		—		62,000		—			62,000			—		—		62,000			—			62,000
Issuance of common stock for vested restricted stock units		—		—		—		—			—			800,000		8,000		(8,000	)		—			—
Net loss		—		—		—		(2,929,000	)		(2,929,000	)		—		—		—			(2,258,000	)		(2,258,000	)
Balances at end of period (Unaudited)		111,356,473	$	1,114,000	$	132,354,000	$	(132,213,000	)	$	1,255,000			88,023,141	$	881,000	$	128,738,000		$	(128,051,000	)	$	1,568,000
Balance		111,356,473	$	1,114,000	$	132,354,000	$	(132,213,000	)	$	1,255,000			88,023,141	$	881,000	$	128,738,000		$	(128,051,000	)	$	1,568,000

	Shares		Amount		Capital		Deficit			Equity			Shares		Amount		Capital			Deficit			Equity
	Three Months Ended April 30, 2023												Three Months Ended April 30, 2022
	Common Stock				Additional Paid-In		Accumulated			Total Stockholders’			Common Stock				Additional Paid-In			Accumulated			Total Stockholders’
	Shares		Amount		Capital		Deficit			Equity			Shares		Amount		Capital			Deficit			Equity

Balances at beginning of period (Unaudited)		111,356,473	$	1,114,000	$	132,290,000	$	(131,337,000	)	$	2,067,000			87,873,141	$	879,000	$	128,617,000		$	(127,291,000	)	$	2,205,000
Balance		111,356,473	$	1,114,000	$	132,290,000	$	(131,337,000	)	$	2,067,000			87,873,141	$	879,000	$	128,617,000		$	(127,291,000	)	$	2,205,000
Share-based compensation expense - stock options		—		—		44,000		—			44,000			—		—		103,000			—			103,000
Share-based compensation expense - restricted stock units		—		—		20,000		—			20,000			—		—		20,000			—			20,000
Issuance of common stock for vested restricted stock units		—		—		—		—			—			150,000		2,000		(2,000	)		—			—
Net loss		—		—		—		(876,000	)		(876,000	)		—		—		—			(760,000	)		(760,000	)
Balances at end of period (Unaudited)		111,356,473	$	1,114,000	$	132,354,000	$	(132,213,000	)	$	1,255,000			88,023,141	$	881,000	$	128,738,000		$	(128,051,000	)	$	1,568,000
Balance		111,356,473	$	1,114,000	$	132,354,000	$	(132,213,000	)	$	1,255,000			88,023,141	$	881,000	$	128,738,000		$	(128,051,000	)	$	1,568,000

See accompanying notes.

PURE Bioscience, Inc.

Condensed Consolidated Statements of Cash Flows

(Unaudited)

	2023			2022
	Nine Months Ended
	April 30,
	2023			2022
Operating activities
Net loss	$	(2,929,000	)	$	(2,258,000	)
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation		275,000			493,000
Depreciation and amortization		102,000			162,000
Reserve for inventory obsolescence		40,000			—
Gain on extinguishment of indebtedness		—			(239,000	)
Changes in operating assets and liabilities:
Accounts receivable		13,000			170,000
Inventories		(10,000	)		31,000
Prepaid expenses		(19,000	)		7,000
Accounts payable and accrued liabilities		(6,000	)		(181,000	)
Net cash used in operating activities		(2,534,000	)		(1,815,000	)
Investing activities
Purchases of property, plant and equipment		(76,000	)		(64,000	)
Net cash used in investing activities		(76,000	)		(64,000	)
Net decrease in cash, cash equivalents, and restricted cash		(2,610,000	)		(1,879,000	)
Cash, cash equivalents, and restricted cash at beginning of period		3,466,000			2,465,000
Cash, cash equivalents, and restricted cash at end of period	$	856,000		$	586,000

Reconciliation of cash, cash equivalents, and restricted cash to the condensed consolidated balance sheets
Cash and cash equivalents	$	781,000		$	511,000
Restricted cash	$	75,000		$	75,000
Total cash, cash equivalents and restricted cash	$	856,000		$	586,000

Supplemental disclosure of cash flow information
Cash paid for taxes	$	5,000		$	—

See accompanying notes.

PURE Bioscience, Inc.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

For the three and nine months ended April 30, 2023 and 2022

1. Basis of Presentation

The accompanying unaudited condensed consolidated financial statements include the consolidated accounts of PURE Bioscience, Inc. and its wholly owned subsidiary, ETI H2O Inc., a Nevada corporation. ETI H2O, Inc. currently has no business operations and no material assets or liabilities and there have been no significant transactions related to ETI H2O, Inc. during the periods presented in the condensed consolidated financial statements. All inter-company balances and transactions have been eliminated. All references to “PURE,” “we,” “our,” “us” and the “Company” refer to PURE Bioscience, Inc. and our wholly owned subsidiary.

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP, for interim financial information pursuant to the instructions to Form 10-Q and Article 10/Rule 8-03 of Regulation S-X. Accordingly, they do not include all of the information and disclosures required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the three and nine months ended April 30, 2023 are not necessarily indicative of the results that may be expected for other quarters or the year ending July 31, 2023. The July 31, 2022 balance sheet was derived from audited financial statements but does not include all disclosures required by GAAP and included in our Annual Report on Form 10-K. For more complete information, these unaudited financial statements and the notes thereto should be read in conjunction with the audited financial statements for the year ended July 31, 2022 included in our Annual Report on Form 10-K covering such period filed with the Securities and Exchange Commission, or SEC, on October 28, 2022.

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. Actual results could differ from those estimates.

2. Liquidity and Going Concern

We have a history of recurring losses, and as of April 30, 2023 we have incurred a cumulative net loss of $132,213,000. During the nine months ended April 30, 2023, we recorded a net loss of $2,929,000 on recorded net revenue of $1,275,000. In addition, during the nine months ended April 30, 2023 we used $2,610,000 in operating and investing activities resulting in a cash balance of $781,000 as of April 30, 2023. Our history of recurring operating losses, and negative cash flows from operating activities give rise to substantial doubt regarding our ability to continue as a going concern. The Company’s independent registered public accounting firm, in its report on the Company’s consolidated financial statements for the year ended July 31, 2022, has also expressed substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from our possible inability to continue as a going concern.

Our future capital requirements depend on numerous forward-looking factors. These factors may include, but are not limited to, the following: the acceptance of, and demand for, our products; our success and the success of our partners in selling our products; our success and the success of our partners in obtaining regulatory approvals to sell our products; the costs of further developing our existing products and technologies; the extent to which we invest in new product and technology development; and the costs associated with the continued operation, and any future growth, of our business. The outcome of these and other forward-looking factors will substantially affect our liquidity and capital resources.

Until we can continually generate positive cash flow from operations, we will need to continue to fund our operations with the proceeds of offerings of our equity and debt securities. However, we cannot ensure that additional financing will be available when needed or that, if available, financing will be obtained on terms favorable to us or to our stockholders. If we raise additional funds from the issuance of equity securities, substantial dilution to our existing stockholders would likely result. If we raise additional funds by incurring debt financing, the terms of the debt may involve significant cash payment obligations as well as covenants and specific financial ratios that may restrict our ability to operate our business.

3. Significant Accounting Policies

Revenue Recognition

We account for revenue in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”), Topic 606, Revenue from Contracts with Customers (“Topic 606”). Under Topic 606, revenue is recognized at an amount that reflects the consideration to which we expect to be entitled in exchange for transferring goods or services to a customer. This principle is applied using the following 5-step process:

	1.	Identify the contract with the customer
	2.	Identify the performance obligations in the contract
	3.	Determine the transaction price
	4.	Allocate the transaction price to the performance obligations in the contract
	5.	Recognize revenue when (or as) each performance obligation is satisfied

Under Topic 606, we recognize revenue when we satisfy a performance obligation by transferring control of the promised goods or services to our customers, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services.

Our technology platform is based on patented stabilized ionic silver, and our initial products contain silver dihydrogen citrate, or SDC. SDC is a broad-spectrum, non-toxic antimicrobial agent, which offers 24-hour residual protection and formulates well with other compounds. We sell various configurations and dilutions of SDC direct to customers and through distributors. We currently offer PURE^® Hard Surface as a food contact surface sanitizer and disinfectant to restaurant chains, food processors and food transportation companies. We also offer PURE Control^® as a direct food contact processing aid.

Contract terms for unit price, quantity, shipping and payment are governed by sales agreements and purchase orders which we consider to be a customer’s contract in all cases. The unit price is considered the observable stand-alone selling price for the arrangements. Any promotional or sales discounts are applied evenly to the units sold for purposes of calculating standalone selling price.

Product sales generally consist of a single performance obligation that we satisfy at a point in time. We recognize product revenue when the following events have occurred: (a) we have transferred physical possession of the products, (b) we have a present right to payment, (c) the customer has legal title to the products, and (d) the customer bears significant risks and rewards of ownership of the products.

Our direct customer and distributor sales are invoiced based on received purchase orders. Our payment terms on invoiced direct customer and distributor sales range between 30 and 90 days after we satisfy our performance obligation. The majority of our customers are on 30 day payment terms. We currently offer no right of return on invoiced sales and maintain no allowance for sales returns.

Shipping and handling are treated as activities to fulfill promises to customers and any amounts billed to a customer, if applicable, represent revenues earned for the goods provided. Costs related to such shipping and handling billings are classified as cost of sales.

We do not have significant categories of revenue that may impact how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors.

A summary of our revenue by product type for the nine months ended April 30, 2023 and 2022 is as follows:

Summary of Revenue by Product

	2023		2022
	April 30,
	2023		2022
PURE Hard Surface	$	1,184,000	$	1,158,000
SILVÉRION		85,000		251,000
Total	$	1,269,000	$	1,409,000

A summary of our revenue by product type for the three months ended April 30, 2023 and 2022 is as follows:

	2023		2022
	April 30,
	2023		2022
PURE Hard Surface	$	406,000	$	352,000
SILVÉRION		—		145,000
Total	$	406,000	$	497,000

Variable Consideration

We record revenue from customers in an amount that reflects the transaction price we expect to be entitled to after transferring control of those goods or services. From time to time, we offer sales promotions on our products such as discounts. Variable consideration is estimated at contract inception only to the extent that it is probable that a significant reversal of revenue will not occur.

Use of Estimates

The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, or GAAP, requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements, and the disclosures made in the accompanying notes to the consolidated financial statements. Actual results could differ materially from those estimates. Those estimates and assumptions include estimates for reserves of uncollectible accounts, inventory obsolescence, depreciable lives of property and equipment, analysis of impairments of recorded long-term tangible and intangible assets, realization of deferred tax assets, accruals for potential liabilities and assumptions made in valuing stock instruments issued for services.

Net Loss Per Share

Basic net loss per common share is computed as net loss divided by the weighted average number of common shares outstanding for the period. Our diluted net loss per common share is the same as our basic net loss per common share because we incurred a net loss during each period presented, and the potentially dilutive securities from the assumed exercise of all outstanding stock options, restricted stock units, and warrants would have an anti-dilutive effect. As of April 30, 2023 and 2022, stock options and shares issuable under restricted stock unit awards of 7,913,125 and 7,391,625, respectively, have been excluded from the computation of diluted shares outstanding.

	2023		2022
	April 30,
	2023		2022
Common stock options		6,700,625		6,179,125
Restricted stock units		1,212,500		1,212,500
Total		7,913,125		7,391,625

Inventory

Inventories are stated at the lower of cost or net realizable value, and net of a valuation allowance for potential excess or obsolete material. Cost is determined using the average cost method. Depreciation related to manufacturing is systematically allocated to inventory produced, and expensed through cost of goods sold at the time inventory is sold.

Inventories consist of the following:

Schedule of Inventories

	April 30, 2023		July 31, 2022
Raw materials	$	26,000	$	19,000
Finished goods		123,000		160,000
Inventories	$	149,000	$	179,000

During the three months ended April 30, 2023, the Company determined that an additional reserve for inventory obsolescence of $40,000 was required. As of April 30, 2023 and July 31, 2022, inventories are stated net of a reserve for inventory obsolescence of $265,000 and $225,000, respectively.

Share-Based Compensation

We periodically issue stock options and restricted stock awards to employees and non-employees in non-capital raising transactions for services and for financing costs. We account for such grants issued and vesting to employees based on ASC 718, whereby the value of the award is measured on the date of grant and recognized as compensation expense on the straight-line basis over the vesting period.

We estimate the fair value of share-based payment awards at the date of grant using the Black-Scholes option valuation model. The Black-Scholes option valuation model requires the input of subjective assumptions, including price volatility of the underlying stock, risk-free interest rate, dividend yield, and expected life of the option. Share-based compensation expense is based on awards ultimately expected to vest, and therefore is reduced by expected forfeitures.

Concentrations

Gross product sales. For the three months ended April 30, 2023, one individual customer accounted for 39% of our net product sales. For the nine months ended April 30, 2023, one customer accounted for 20% of our net product sales. For the three months ended April 30, 2022, three individual customers accounted for 29%, 14% and 11% of our net product sales, respectively. For the nine months ended April 30, 2022, three customers accounted for 14%, 12% and 10% of our net product sales, respectively.

Accounts receivable. As of April 30, 2023, we had accounts receivable from two customers that comprised of 36% and 13% of total accounts receivable, respectively. As of April 30, 2022, we had accounts receivable from four customers that comprised of 15%, 14%, 12% and 11% of total accounts receivable, respectively.

Purchases. For the three months ended April 30, 2023, two vendors accounted for 17% and 13% of our purchases, respectively. For the nine months ended April 30, 2023, one vendor accounted for 19% of our purchases. For the three months ended April 30, 2022, two vendors accounted for 26% and 12% of our purchases, respectively. For the nine months ended April 30, 2022, one vendor accounted for 21% of our purchases.

Accounts payable. As of April 30, 2023, our largest vendor accounted for 20% of the total accounts payable. As of April 30, 2022, our largest vendor accounted for 25% of the total trade accounts payable.

Segments

We operate in one segment for the manufacture and distribution of our products. In accordance with the “Segment Reporting” Topic of the ASC, our chief operating decision maker has been identified as the Chief Executive Officer and President, who reviews operating results to make decisions about allocating resources and assessing performance for the entire Company. Existing guidance, which is based on a management approach to segment reporting, establishes requirements to report selected segment information quarterly and to report annually entity-wide disclosures about products and services, major customers, and the countries in which the entity holds material assets and reports revenue. All material operating units qualify for aggregation under “Segment Reporting” due to their similar customer base and similarities in: economic characteristics; nature of products and services; and procurement, manufacturing and distribution processes. Since the Company operates in one segment, all financial information required by “Segment Reporting” can be found in the accompanying financial statements.

4. Recent Accounting Pronouncements

In June 2016, the FASB issued ASU No. 2016-13, Credit Losses - Measurement of Credit Losses on Financial Instruments or ASC 326. The standard significantly changes how entities will measure credit losses for most financial assets, including accounts and notes receivable. The standard will replace today’s “incurred loss” approach with an “expected loss” model, under which companies will recognize allowances based on expected rather than incurred losses. Entities will apply the standard’s provisions as a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective. As small business filer, the standard will be effective for us for interim and annual reporting periods beginning after December 15, 2022. The Company is currently assessing the impact of adopting this standard on the Company’s financial statements and related disclosures.

In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt — Modifications and Extinguishments (Subtopic 470-50), Compensation — Stock Compensation (Topic 718), and Derivatives and Hedging — Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options or ASU 2021-04. ASU 2021-04 provides guidance as to how an issuer should account for a modification of the terms or conditions or an exchange of a freestanding equity-classified written call option (i.e., a warrant) that remains classified after modification or exchange as an exchange of the original instrument for a new instrument. An issuer should measure the effect of a modification or exchange as the difference between the fair value of the modified or exchanged warrant and the fair value of that warrant immediately before modification or exchange and then apply a recognition model that comprises four categories of transactions and the corresponding accounting treatment for each category (equity issuance, debt origination, debt modification, and modifications unrelated to equity issuance and debt origination or modification). ASU 2021-04 is effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. The adoption of ASU 2021-04 did not have any impact on the Company’s consolidated financial statement presentation or disclosures.

Recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statement presentation or disclosures.

5. Debt

Receipt of CARES funding

In April 2021, we were funded $239,000 under the Payroll Protection Program (“PPP”) through California Bank and Trust. The PPP was established as part of the Coronavirus Aid, Relief and Economic Security Act (the “CARES Act”) and is administered by the U.S. Small Business Administration. The CARES Act was established in order to enable small businesses to pay employees during the economic slowdown caused by COVID-19 by providing forgivable loans to qualifying businesses for up to 2.5 times their average monthly payroll costs. The amount borrowed under the CARES Act is eligible to be forgiven provided that (a) the Company uses the PPP Funds during the eight week period after receipt thereof, and (b) the PPP Funds are only used to cover payroll costs (including benefits), rent, mortgage interest, and utility costs. The amount of loan forgiveness will be reduced if, among other reasons, the Company does not maintain staffing or payroll levels. Principal and interest payments on any unforgiven portion of the PPP Funds (the “PPP Loan”) will be deferred for six months and will accrue interest at a fixed annual rate of 1.0% and carry a two year maturity date. There is no prepayment penalty on the CARES Act Loan.

During the nine months ended April 30, 2022, we applied and received loan forgiveness under the provisions of the CARES Act for the entire $239,000 loan. This amount was recorded as a gain on extinguishment of indebtedness on the Condensed Consolidated Statement of Operations during the nine months ended April 30, 2022.

6. Stockholders’ Equity

Restricted Stock Units

We issue restricted stock unit awards or RSUs, to key management and as compensation for services to consultants and others. The RSUs typically vest over a one to three-year period and carry a ten-year term. Each RSU represents the right to receive one share of common stock, issuable at the time the RSU subsequently settles, as set forth in the Restricted Stock Unit Agreement. We determine that fair value of those awards at the date of grant, and amortize those awards as an expense over the vesting period of the award. The shares earned under the grant are usually issued when the award settles at the end of the term. As of July 31, 2022, there were 1,212,500 RSU’s outstanding of which 1,045,833 were issuable.

During the nine months ended April 30, 2023 and 2022, we recognized $62,000 of compensation cost relating to the vesting of RSU’s, respectively. As of April 30, 2023, there was no unrecognized non-cash compensation cost related to the remaining 166,667 RSUs we expect to vest next quarter.

During the nine months ended April 30, 2023, no RSUs were granted, issued, or forfeited. Of the 1,212,500 RSUs outstanding as of April 30, 2023, 1,045,833 RSUs are vested and issuable. These RSUs are issued upon settlement date which is defined as “for each Vested Unit, the earliest of (i) the ten-year anniversary of the Grant Date; (ii) sixty days after the date the Grantee’s Service ceases for any reason and such cessation constitutes a “separation from service” within the meaning of Section 409A of the Code; (iii) the date of Grantee’s death or (iv) the date of a Change in Control that constitutes a “change in control event” within the meaning of Section 409A of the Code”.

A summary of our restricted stock unit activity and related data is as follows:

Schedule of Restricted Stock Activity

	Total RSU Shares		Vested and Issuable
Outstanding at July 31, 2022		1,212,500		1,045,833
Granted		—		—
Issued		—		—
Forfeited		—		—
Outstanding at April 30, 2023		1,212,500		1,045,833

Stock Option Plans

2007 Equity Incentive Plan

In February 2016, we amended and restated our 2007 Equity Incentive Plan, the (“2007 Plan”), to, among other changes, increase the number of shares of common stock issuable under the 2007 Plan by 4,000,000 shares and extend the term of the 2007 Plan until February 4, 2026. The 2007 Plan provides for the grant of incentive and non-qualified stock options, as well as other share-based payment awards, to our employees, directors, consultants and advisors. These awards have up to a 10-year contractual life and are subject to various vesting periods, as determined by the Compensation Committee of the Board of Directors. As of April 30, 2023, there were approximately 970,000 shares available for issuance under the 2007 Plan.

2017 Equity Incentive Plan

In January 2021, we amended and restated our 2017 Equity Incentive Plan, the (“2017 Plan”), to, among other changes, increase the number of shares of common stock issuable under the 2017 Plan by 5,000,000 shares and extend the term of the 2007 Plan until January 2031. The 2017 Plan provides for the grant of incentive and non-qualified stock options, as well as other share-based payment awards, to our employees, directors, consultants and advisors. These awards have up to a 10-year contractual life and are subject to various vesting periods, as determined by the Compensation Committee of the Board of Directors. As of April 30, 2023, there were approximately 4,750,000 shares available for issuance under the 2017 Plan.

During the nine months ended April 30, 2023, the Compensation Committee of the Board of Directors granted 1,935,000 stock options to our employees, officers, directors and consultants with a fair value of $241,000 as determined by the Black Scholes option pricing model. The vesting terms of the options vary between one and two years and carry a ten year term. There were no stock options granted during the three months ended April 30, 2023.

A summary of our stock option activity is as follows:

Schedule of Stock Option Activity

	Shares			Weighted- Average Exercise Price		Aggregate Intrinsic Value
Outstanding at July 31, 2022		6,079,125		$	0.62	$	—
Granted		1,935,000		$	0.20		—
Exercised		—		$	—		—
Expired		(1,313,500	)	$	0.70		—
Outstanding at April 30, 2023		6,700,625		$	0.48	$	—

The weighted-average remaining contractual term of options outstanding at April 30, 2023 was 7.44 years.

At April 30, 2023, options to purchase 5,831,458 shares of common stock were exercisable. These options had a weighted-average exercise price of $0.52 and a weighted average remaining contractual term of 7.12 years.

For the nine months ended April 30, 2023 share-based compensation expense for stock options that vested during the period was $213,000. For the nine months ended April 30, 2022 share-based compensation expense for stock options that vested during the period was $431,000. The total unrecognized compensation cost related to unvested stock option grants as of April 30, 2023 was approximately $87,000 and the weighted average period over which these grants are expected to vest is 0.58 years.

We use the Black-Scholes valuation model to calculate the fair value of stock options. Stock-based compensation expense is recognized over the vesting period using the straight-line method. The fair value of stock options was estimated at the grant date using the following weighted average assumptions:

Schedule of Fair Value Assumptions

	Nine Months Ended April 30, 2023			Nine Months Ended April 30, 2022
Volatility		91.90	%		88.35.	%
Risk-free interest rate		4.00	%		1.17	%
Dividend yield		0.0	%		0.0	%
Expected life		5.34 years			5.59 years

Volatility is the measure by which our stock price is expected to fluctuate during the expected term of an option. Volatility is derived from the historical daily change in the market price of our common stock, as we believe that historical volatility is the best indicator of future volatility.

The risk-free interest rates used in the Black-Scholes calculations are based on the prevailing U.S. Treasury yield as determined by the U.S. Federal Reserve.

We have never paid dividends on our common stock and do not anticipate paying dividends on our common stock in the foreseeable future. Accordingly, we have assumed no dividend yield for purposes of estimating the fair value of our share-based compensation.

The expected life of options was estimated using the average between the contractual term and the vesting term of the options.

7. Related Party Transactions

As of April 30, 2023 and April 30, 2022, accounts payable include $93,000 and $136,000 in board fees due to officers and directors, respectively.

8. Commitments and Contingencies

COVID-19[done]

The COVID-19 pandemic led to severe disruptions in general economic activities, as businesses and federal, state, and local governments took broad actions to mitigate this public health crisis. While we have experienced some delays related to final third-party validation of certain of our products and product rollouts by customers using PURE Control, we did not experience a material disruption to our business. In addition, we previously benefited from increased demand from our customers for our PURE Hard Surface product due to a focus on surface disinfecting in response to attempting to prevent COVID-19 transmission. We subsequently experienced an abatement in such demand. Such abatement has not stabilized and we cannot assure you that demand will stabilize in the future. Additionally, we experienced supply chain issues with our various plastic packaging configurations and citric acid. Further, on a go-forward basis, we cannot guarantee the overall economic conditions will not affect our business, as these conditions may significantly negatively impact all aspects of our business. Our business is dependent on the continued health and productivity of our employees, including our sales staff and corporate management team.

The extent to which the COVID-19 pandemic or other health-related pandemics impacts our business, sales, results of operations and financial condition will depend on future developments, which are highly uncertain and cannot be predicted. Even after the COVID-19 pandemic or other health-related pandemics has subsided, we may experience significant impacts to our business as a result of its global economic impact, including any economic downturn or recession that has occurred or may occur in the future.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

All references in this Item 2 and elsewhere in this Quarterly Report to “PURE,” “we”, “our,” “us” and the “Company” refer to PURE Bioscience, Inc., a Delaware corporation, and our wholly owned subsidiary, ETI H2O, Inc., a Nevada corporation. ETI H2O, Inc. currently has no business operations and no material assets or liabilities and there have been no significant transactions related to ETI H2O, Inc. during the periods presented in the condensed consolidated financial statements contained elsewhere in this Quarterly Report.

The discussion in this section contains forward-looking statements. These statements relate to future events or our future financial performance. We have attempted to identify forward-looking statements by terminology such as “anticipate,” “believe,” “can,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “should,” “would” or “will” or the negative of these terms or other comparable terminology, but their absence does not mean that a statement is not forward-looking. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, which could cause our actual results to differ from those projected in any forward-looking statements we make. Several risks and uncertainties we face are discussed in more detail under “Risk Factors” in Part II, Item 1A of this Quarterly Report or in the discussion and analysis below. You should, however, understand that it is not possible to predict or identify all risks and uncertainties and you should not consider the risks and uncertainties identified by us to be a complete set of all potential risks or uncertainties that could materially affect us. You should not place undue reliance on the forward-looking statements we make herein because some or all of them may turn out to be wrong. We undertake no obligation to update any of the forward-looking statements contained herein to reflect future events and developments, except as required by law. The following discussion should be read in conjunction with the condensed consolidated financial statements and the notes to those financial statements included elsewhere in this Quarterly Report on Form 10-Q.

Overview

We are focused on developing and commercializing proprietary antimicrobial products that provide safe and cost-effective solutions to the health and environmental challenges of pathogen and hygienic control. Our technology platform is based on patented stabilized ionic silver, and our initial products contain silver dihydrogen citrate, or SDC. SDC is a broad-spectrum, non-toxic antimicrobial agent, which offers 24-hour residual protection and formulates well with other compounds. As a platform technology, we believe SDC is distinguished from existing products in the marketplace because of its superior efficacy, reduced toxicity, non-causticity and the inability of bacteria to form a resistance to it.

We believe there is a significant market opportunity for our safe, non-toxic, non-caustic and effective SDC-based solutions. We currently offer PURE^® Hard Surface as a food contact surface sanitizer and disinfectant to restaurant chains, food processors and food transportation companies. We also offer PURE Control^® as a direct food contact processing aid. In addition to our direct sales efforts with PURE Hard Surface and PURE Control, we market and sell our SDC-based products indirectly through third-party distributors supporting various industries.

Business Strategy

Our goal is to become a sustainable company by commercializing the SDC-based products we have developed with our proprietary technology platform. We are focused on delivering leading antimicrobial products that address food safety risks across the food industry supply chain. Key aspects of our business strategy include:

●

Expanding sales and distribution for our products into the food industry with a focus on a dual track of food safety market opportunities:

		●	*Hard Surface Disinfectant* - commercializing our current EPA registered PURE Hard Surface disinfectant and sanitizer for use in foodservice operations, food manufacturing and food transportation.

		●	*Direct Food Contact* - commercializing FDA approved PURE Control as a direct food contact processing aid for fresh produce; commercializing FDA approved PURE Control as a food processing and intervention aid for food processors treating raw poultry in pre and post on-line reprocessing.

	●	Continuing to grow and establish new strategic alliances to maximize the commercial potential of our technology platform;

	●	Continuing to partner with third parties who are seeking, or intend to seek, approvals to market SDC-based products in markets outside the U.S.

	●	Developing additional proprietary products and applications; and

	●	Protecting and enhancing our intellectual property.

In addition to our current products addressing food safety, we intend to leverage our technology platform through licensing and distribution collaborations in order to develop new products and enter into new markets that could potentially generate multiple sources of revenue.

Financial Overview

This financial overview provides a general description of our revenue and expenses.

Net Product Sales

We contract manufacture and sell SDC-based products for end use, and as a raw material for manufacturing use. We recognize revenue when we satisfy a performance obligation by transferring control of the promised goods or services to our customers, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. Any amounts received prior to satisfying revenue recognition criteria are recorded as deferred revenue. See “Critical Accounting Policies and Estimates – Revenue Recognition”.

Cost of Goods Sold

Cost of goods sold for product sales includes direct and indirect costs to manufacture products, including materials consumed, manufacturing overhead, shipping costs, salaries, benefits, reserved inventory, and related expenses of operations. Depreciation related to manufacturing is systematically allocated to inventory produced, and expensed through cost of goods sold at the time inventory is sold.

Selling, General and Administrative

Selling, general and administrative expense consists primarily of salaries and other related costs for personnel in business development, sales, finance, accounting, information technology, and executive functions. Other selling, general and administrative costs include product marketing, advertising, and trade show costs, as well as public relations and investor relations, facility costs, and legal, accounting and other professional fees.

Research and Development

Our research and development activities are focused on leveraging our technology platform to develop additional proprietary products and applications. Research and development expense consists primarily of personnel and related costs, product registration expenses, and third-party testing. We expense research and development costs as incurred.

Other Income (Expense)

We record interest income, interest expense, the change in derivative liabilities, as well as other non-operating transactions, as other income (expense) in our consolidated statements of operations.

COVID-19

Results of Operations

Fluctuations in Operating Results

Our results of operations have fluctuated significantly from period to period in the past and are likely to continue to do so in the future. We anticipate that our results of operations will be affected for the foreseeable future by several factors that may contribute to these periodic fluctuations, including fluctuations in the buying patterns of our current or potential customers for which we have no visibility, the mix of product sales including a change in the percentage of higher or lower margin formulations and packaging configurations of our products, the cost of product sales including component costs, our inability for any reason to be able to meet demand, the achievement and timing of research and development and regulatory milestones, unforeseen changes in expenses, including non-cash expenses such as the fair value of equity awards granted and the fair value change of derivative liabilities, the calculation of which includes several variable assumptions, and unforeseen manufacturing or supply issues, among other issues. Due to these fluctuations, we believe that the period-to-period comparisons of our operating results are not a reliable indication of our future performance. As of the date of this filing, we are not aware of any trends in these factors or events or conditions that we believe are reasonably likely to impact our results of operations in the future.

Comparison of the Three Months Ended April 30, 2023 and 2022

Net Product Sales

Net product sales were $406,000 and $497,000 for the three months ended April 30, 2023 and 2022, respectively. The decrease of $91,000 was attributable to decreased sales across our distribution network servicing the food processing industry. Our top three customers accounted for $222,000 of net product sales for the three months ended April 30, 2023.

For the three months ended April 30, 2023, one individual customer accounted for 39% of our net product sales. No other individual customer accounted for 10% or more of our net product sales. All of our net product sales were U.S. based sales.

For the three months ended April 30, 2022, three individual customers accounted for 29%, 14% and 11% of our net product sales, respectively. No other individual customer accounted for 10% or more of our net product sales. All of our net product sales were U.S. based sales.

During the three months ended April 30, 2023 and 2022, we recognized $1,000 and $27,000 in royalties from a nonexclusive third-party distributor, respectively.

Cost of Goods Sold

Cost of goods sold was $211,000 and $199,000 for the three months ended April 30, 2023 and 2022, respectively. The increase of $12,000 was primarily attributable to a $40,000 reserve for inventory obsolescence (See Note 3 of the condensed consolidated financial statements).

Gross margin as a percentage of net product sales, or gross margin percentage, was 48% and 60% for the three months ended April 30, 2023 and 2022, respectively. The decrease in gross margin percentage was primarily attributable to the reserve for inventory obsolescence reference above.

Selling, General and Administrative Expense

Selling, general and administrative expense was $997,000 and $977,000 for the three months ended April 30, 2023 and 2022, respectively. The increase of $20,000 was primarily attributable to increased personnel costs and travel expense. These increases were offset by decreased professional service and board of director fees.

Share-based compensation expense, included in selling, general and administrative expense, was $64,000 and $123,000 for the three months ended April 30, 2023 and 2022, respectively. The decrease of $59,000 is primarily due to the prior year vesting of stock options and restricted stock units granted to employees, directors and consultants supporting our selling, general and administrative functions.

Research and Development Expense

Research and development expense, primarily consisting of third-party fees and personnel costs, was $74,000 and $107,000 for the three months ended April 30, 2023 and 2022, respectively. The decrease of $33,000 was due to decreased personnel costs.

Comparison of the Nine Months Ended April 30, 2023 and 2022

Net Product Sales

Net product sales were $1,269,000 and $1,409,000 for the nine months ended April 30, 2023 and 2022, respectively. The decrease of $140,000 was attributable to decreased sales across our distribution network. Our top two customers accounted for $366,000 of net product sales for the nine months ended April 30, 2023.

For the nine months ended April 30, 2023, one individual customers accounted for 20% of our net product sales. No other individual customer accounted for 10% or more of our net product sales. All of our net product sales were U.S. based sales.

For the nine months ended April 30, 2022, three individual customers accounted for 14%, 12% and 10% of our net product sales, respectively. No other individual customer accounted for 10% or more of our net product sales. All of our net product sales were U.S. based sales.

During the nine months ended April 30, 2023 and 2022, we recognized $6,000 and $32,000 in royalties from a nonexclusive third-party distributor, respectively.

Cost of Goods Sold

Cost of goods sold was $625,000 and $553,000 for the nine months ended April 30, 2023 and 2022, respectively. The increase of $72,000 was primarily attributable to the $40,000 inventory reserve referenced above and increased contract manufacturing costs.

Gross margin as a percentage of net product sales, or gross margin percentage, was 51% and 61% for the nine months ended April 30, 2023 and 2022, respectively. The decrease in gross margin percentage was primarily attributable to increased contract manufacturing costs, the inventory reserve and the sale of higher margin formulations and packaging configurations of our products during the nine months ended April 30, 2022, as compared with the current period.

Selling, General and Administrative Expense

Selling, general and administrative expense was $3,342,000 and $3,127,000 for the nine months ended April 30, 2023 and 2022, respectively. The increase of $215,000 was primarily attributable to increased personnel costs and travel expense. These increases were partially offset by decreased professional service costs and board of director fees.

Share-based compensation expense, included in selling, general and administrative expense, was $275,000 and $493,000 for the nine months ended April 30, 2023 and 2022, respectively. The decrease of $218,000 is primarily due to the prior year vesting of stock options and restricted stock units granted to employees, directors and consultants supporting our selling, general and administrative functions.

Research and Development Expense

Research and development expense was $227,000 and $255,000 for the nine months ended April 30, 2023 and 2022, respectively. The decrease of $28,000 was due to decreased personnel costs.

Other Income (Expense)

Liquidity and Capital Resources

As of April 30, 2023, we had $856,000 in cash and cash equivalents compared with $3,466,000 in cash and cash equivalents as of July 31, 2022. The net decrease in cash and cash equivalents was primarily attributable to the use of cash to fund our operations and investments in property, plant and equipment. Additionally, as of April 30, 2023, we had $569,000 of current liabilities, including $432,000 in accounts payable, compared with $575,000 of current liabilities, including $488,000 in accounts payable as of July 31, 2022. The net decrease in current liabilities was primarily due to trade payables due to our contract manufactures.

We have a history of recurring losses, and as of April 30, 2023 we have incurred a cumulative net loss of $132,200,000. During the nine months ended April 30, 2023, we recorded a net loss of $2,929,000 on recorded net revenue of $1,275,000. In addition, during the nine months ended April 30, 2023 we used $2,610,000 in operating and investing activities resulting in a cash balance of $781,000 as of April 30, 2023. Our history of recurring operating losses, and negative cash flows from operating activities give rise to substantial doubt regarding our ability to continue as a going concern. The financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from our possible inability to continue as a going concern.

Until we can continually generate positive cash flow from operations, we will need to continue to fund our operations with the proceeds of offerings of our equity and debt securities. However, we cannot assure you that additional financing will be available when needed or that, if available, financing will be obtained on terms favorable to us or to our stockholders. If we raise additional funds from the issuance of equity securities, substantial dilution to our existing stockholders would likely result. If we raise additional funds by incurring debt financing, the terms of the debt may involve significant cash payment obligations as well as covenants and specific financial ratios that may restrict our ability to operate our business.

Critical Accounting Policies and Estimates

The discussion and analysis of our financial condition and results of operations are based on our condensed consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States, or GAAP. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, expenses, and related disclosures. We evaluate our estimates on an ongoing basis. We base our estimates on historical experience and on other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

In addition, the condensed consolidated financial statements included in this Quarterly Report have been prepared and presented on a basis assuming we will continue as a going concern. Until we can generate significant cash from operations, we expect to continue to fund our operations with the proceeds of offerings of our equity and debt securities. However, we cannot assure you that additional financing will be available when needed or that, if available, financing will be obtained on terms favorable to us or to our stockholders. If we raise additional funds from the issuance of equity securities, substantial dilution to our existing stockholders would likely result. If we raise additional funds by incurring debt financing, the terms of the debt may involve significant cash payment obligations as well as covenants and specific financial ratios that may restrict our ability to operate our business. Further, any contracts or license arrangements we enter into to raise funds may require us to relinquish our rights to our products or technology, and we cannot assure you that we will be able to enter into any such contracts or license arrangements on acceptable terms, or at all. Having insufficient funds may require us to delay or scale back our marketing, distribution and other commercialization activities or cease our operations altogether. Our financial statements do not include any adjustment relating to recoverability or classification of recorded assets and classification of recorded liabilities.

We believe the following accounting policies and estimates are critical to aid you in understanding and evaluating our reported financial results.

Revenue Recognition

We recognize revenue in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”), Topic 606, Revenue from Contracts with Customers (“Topic 606”). Under Topic 606, revenue is recognized at an amount that reflects the consideration to which we expect to be entitled in exchange for transferring goods or services to a customer. This principle is applied using the following 5-step process:

	1.	Identify the contract with the customer
	2.	Identify the performance obligations in the contract
	3.	Determine the transaction price
	4.	Allocate the transaction price to the performance obligations in the contract
	5.	Recognize revenue when (or as) each performance obligation is satisfied

We do not have significant categories of revenue that may impact how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors.

We do not allow for returns, except for damaged products when the damage occurred pre-fulfillment. Damaged product returns have historically been insignificant. Because of this, the stand-alone nature of our products, and our assessment of performance obligations and transaction pricing for our sales contracts, we do not currently maintain a contract asset or liability balance for obligations. We assess our contracts and the reasonableness of our conclusions on a quarterly basis.

The Company’s licensing contracts typically provide for royalties based on the licensee’s sales of various configurations of PURE Hard Surface. The Company records its royalty revenue in the month in which the licensee sold our products to end users. Payments are generally received in the subsequent month.

Variable Consideration

Share-Based Compensation

We grant equity-based awards under share-based compensation plans or stand-alone contracts. We estimate the fair value of share-based payment awards using the Black-Scholes option valuation model. This fair value is then amortized over the requisite service periods of the awards. The Black-Scholes option valuation model requires the input of subjective assumptions, including price volatility of the underlying stock, risk-free interest rate, dividend yield, and expected life of the option. Share-based compensation expense is based on awards ultimately expected to vest, and therefore is reduced by expected forfeitures. Changes in assumptions used under the Black-Scholes option valuation model could materially affect our net loss and net loss per share.

Impairment of Long-Lived Assets

In accordance with GAAP, if indicators of impairment exist, we assess the recoverability of the affected long-lived assets by determining whether the carrying value of such assets can be recovered through undiscounted future operating cash flows. If impairment is indicated, we measure the amount of such impairment by comparing the carrying value of the asset to the fair value of the asset and we record the impairment as a reduction in the carrying value of the related asset and a charge to operating results. Estimating the undiscounted future cash flows associated with long-lived assets requires judgment, and assumptions could differ materially from actual results. During the three and nine months ended April 30, 2023 and 2022, no impairment of long-lived assets was indicated or recorded.

Recent Accounting Pronouncements

See Note 4 to the condensed consolidated financial statements included in Item 1 of this Quarterly Report on Form 10-Q.

Off Balance Sheet Arrangements

We do not have any off balance sheet arrangements.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

As a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934, or the Exchange Act, and as provided in Item 10(f)(1) of Regulation S-K, we are electing scaled disclosure reporting obligations and therefore are not required to provide the information requested by this Item.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified by the rules and forms of the Securities and Exchange Commission, or SEC, and that such information is accumulated and communicated to our management, including our Principal Executive Officer and Principal Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives.

As required by Rule 13a-15(b) under the Exchange Act, our management conducted an evaluation, under the supervision and with the participation of our Principal Executive Officer and our Principal Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report. Based on the foregoing evaluation, our Principal Executive Officer and Principal Financial Officer concluded that as of the end of the period covered by this report our disclosure controls and procedures were effective.

Changes in Internal Control Over Financial Reporting

In connection with the evaluation required by Exchange Act Rule 13a-15(d), our management, under the supervision and with the participation of our Principal Executive Officer and our Principal Financial Officer, concluded that there were no changes in our internal controls over financial reporting during the nine months ended April 30, 2023 that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.

PART II – Other Information

Item 1. Legal Proceedings

From time to time, we may become involved in various lawsuits and legal proceedings that arise in the ordinary course of our business. The impact and outcome of litigation, if any, is subject to inherent uncertainties, and any adverse result in these or other matters may arise from time to time that could harm our business. We are not currently aware of any such legal proceedings or claims to which we or our wholly owned subsidiary is a party or of which any of our property is subject that we believe will have, individually or in the aggregate, a material adverse effect on our business, financial condition or results of operations.

Item 1A. Risk Factors

In evaluating us and our common stock, we urge you to carefully consider the risks and other information in this Quarterly Report on Form 10-Q, including the risk factor included below, as well as the risk factors disclosed in Item 1A. to Part I of our Annual Report on Form 10-K for the fiscal year ended July 31, 2022, which we filed with the SEC on October 28, 2022 (the “Form 10-K”), and Item 1.A. to our Current Report on Form 10-Q for the quarter ended January 31, 2023, which we filed with the SEC on March 17, 2023. Other than the risk factor included below, the risks and uncertainties described in “Item 1A — Risk Factors” of our Form 10-K have not materially changed and “Item 1.A.—Risk Factors” of our Form 10-Q for the quarter ended January 31, 2023. Any of the risks discussed in this Quarterly Report on Form 10-Q, including the risk factor included below, or any of the risks disclosed in “Item 1A — Risk Factors” of our Form 10-K, as well as additional risks and uncertainties not currently known to us or that we currently deem immaterial, could materially and adversely affect our results of operations, financial condition or prospects.

Risks Related to Our Business and Industry

As a result of our historical lack of financial liquidity, we do not currently have sufficient working capital to fund our planned operations and may not be able to continue as a going concern.

We have a history of recurring losses, and as of April 30, 2023 we have incurred a cumulative net loss of $132,200,000. During the nine months ended April 30, 2023, we recorded a net loss of $2,929,000 on recorded net revenue of $1,275,000. In addition, during the nine months ended April 30, 2023 we used $2,610,000 in operating and investing activities resulting in a cash balance of $781,000 as of April 30, 2023. As a result, our existing cash resources are not sufficient to meet our anticipated needs over the next twelve months from the date hereof, and we will need to raise additional capital to continue our operations and to implement our business plan, which capital may not be available on acceptable terms or at all.

Our capital requirements will depend on many factors, including, among others:

	●	the market acceptance of, and demand for, our products;

	●	the timing and costs of executing our sales and marketing strategies;

	●	our ability to successfully complete the in-plant validation trials requested by potential customers and our ability to convert these trials into customer orders for our products;

	●	the costs and time required to obtain the necessary regulatory approvals for our products, including the required USDA approvals:

	●	the extent to which we invest in new testing and product development, including in-plant optimization trials;

	●	the extent to which our customers continue to place product orders as expected and expand their existing use of our products;

	●	the cost and time to satisfy unique customer requirements regarding validation trials or to support the value proposition and benefits of our products;

	●	the timing of vendor payments and the collection of receivables, among other factors affecting our working capital;

	●	our ability to control the timing and amount of our operating expenses, including the costs to attract and retain personnel with the skills required to implement our business plan; and

	●	the costs to file, prosecute and defend our intellectual property rights.

The above factors, along with our history and near term forecast of incurring net losses and negative operating cash flows, raise substantial doubt about our ability to continue as a going concern. If we do not obtain additional capital from external sources, we will not have sufficient working capital to fund our planned operations or be able to continue as a going concern. We cannot assure you that additional financing will be available when needed or that, if available, we can obtain financing on terms favorable to us or to our stockholders. If we raise additional funds from the issuance of equity securities, substantial dilution to our existing stockholders would likely result. If we raise additional funds by incurring debt financing, the terms of the debt may involve significant cash payment obligations as well as covenants and specific financial ratios that may restrict our ability to operate our business. Further, any contracts or license arrangements we enter into to raise funds may require us to relinquish our rights to our products or technology, and we cannot assure you that we will be able to enter into any such contracts or license arrangements on acceptable terms, or at all. Having insufficient funds may require us to delay or scale back our marketing, distribution and other commercialization activities or cease our operations altogether.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not Applicable.

Item 5. Other Information

None.

Item 6. Exhibits

The following Exhibits are filed as part of this report pursuant to Item 601 of Regulation S-K:

3.1		Certificate of Incorporation of PURE Bioscience, Inc. (incorporated by reference to Exhibit 3.1 of the Annual Report on Form 10-K filed with the SEC on October 29, 2012)

3.1.1		Certificate of Amendment to Certificate of Incorporation of PURE Bioscience, Inc. (incorporated by reference to Exhibit 3.1.1 of the Annual Report on Form 10-K filed with the SEC on October 29, 2012)

3.1.2		Certificate of Amendment to Certificate of Incorporation of PURE Bioscience, Inc. (incorporated by reference to Exhibit 3.1 of the Current Report on Form 8-K filed with the SEC on May 19, 2021).

3.2		Bylaws of PURE Bioscience, Inc. (incorporated by reference to Exhibit 3.2 to the Annual Report on Form 10-K, filed with the SEC on October 29, 2012)

3.2.1		Amendment to the Bylaws of PURE Bioscience, Inc. (incorporated by reference to Exhibit 3.2.1 to the Annual Report on Form 10-K, filed with the SEC on October 29, 2012)

31.1 *		Certification of Chief Executive Officer, pursuant to Rule 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

31.2 *		Certification of Principal Financial Officer, pursuant to Rule 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

32.1 *		Certification of Chief Executive Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

32.2 *		Certification of Principal Financial Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

101 *		The following materials from the Company’s Quarterly Report on Form 10-Q for the quarterly period ended April 30, 2023, formatted in iXBRL (Inline eXtensible Business Reporting Language): (i) Condensed Consolidated Balance Sheets at April 30, 2023 and July 31, 2022; (ii) Condensed Consolidated Statements of Operations for the three and nine months ended April 30, 2023 and 2022; (iii) Condensed Consolidated Statements of Stockholders’ equity for the three and nine months ended April 30, 2023 and 2022 ;(iv) Condensed Consolidated Statements of Cash Flows for the nine months ended April 30, 2023 and 2022; and (v) Notes to Condensed Consolidated Financial Statements.

104*		Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

*	Filed herewith.

Signatures

Pursuant to the requirement of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	PURE BIOSCIENCE, INC.

Date: June 14, 2023	By:	/s/ Robert F. Bartlett
		Robert F. Bartlett, Chief Executive Officer (Principal Executive Officer)

Date: June 14, 2023	By:	/s/ MARK S. ELLIOTT
		Mark S. Elliott, Vice President, Finance
		(Principal Financial and Accounting Officer)

EX-31.1 2 ex31-1.htm

Exhibit 31.1

CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE

SARBANES-OXLEY ACT OF 2002

I, Robert F. Bartlett, Chief Executive Officer of PURE Bioscience, Inc., certify that:

1.	I have reviewed this report on Form 10-Q of PURE Bioscience, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	d)	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

	(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: June 14, 2023	By:	/s/ Robert F. Bartlett
		Robert F. Bartlett
		Chief Executive Officer
		(Principal Executive Officer)

EX-31.2 3 ex31-2.htm

Exhibit 31.2

CERTIFICATION OF PRINCIPAL FINANCIAL AND ACCOUNTING OFFICER PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Mark S. Elliott, Vice President, Finance and Principal Financial and Accounting Officer of PURE Bioscience, Inc., certify that:

1.	I have reviewed this report on Form 10-Q of PURE Bioscience, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	d)	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

	(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: June 14, 2023	By:	/s/ MARK S. ELLIOTT
		Mark S. Elliott
		Vice President, Finance
		(Principal Financial and Accounting Officer)

EX-32.1 4 ex32-1.htm

Exhibit 32.1

CERTIFICATION

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and 18 U.S.C. § 1350, as adopted by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Pure Bioscience, Inc. (the “Company”) hereby certifies, to such officer’s knowledge, that:

	(i)	the accompanying report on Form 10-Q of the Company for the period ended April 30, 2023, to which this Certificate is attached (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and

	(ii)	the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: June 14, 2023	By:	/s/ Robert F. Bartlett
		Robert F. Bartlett
		Chief Executive Officer
		(Principal Executive Officer)

A signed original of this written statement required by Section 906 has been provided to Pure Bioscience, Inc. and will be retained by Pure Bioscience, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

This certification has not been, and shall not be deemed, “filed” with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Pure Bioscience, Inc. under the Securities Act of 1933, as amended, or the Exchange Act (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.

EX-32.2 5 ex32-2.htm

Exhibit 32.2

CERTIFICATION

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

	(i)	the accompanying report on Form 10-Q of the Company for the period ended April 30, 2023, to which this Certificate is attached (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and

	(ii)	the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: June 14, 2023	By:	/s/ Mark S. Elliott
		Mark S. Elliott
		Vice President, Finance
		(Principal Financial and Accounting Officer)

EX-101.SCH 6 pure-20230430.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Consolidated Statement of Stockholders' Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Liquidity and Going Concern link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Recent Accounting Pronouncements link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Stockholders’ Equity link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Stockholders’ Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Liquidity and Going Concern (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Summary of Revenue by Product (Details) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Schedule of Anti-dilutive Securities Excluded from Computation of earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Schedule of Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Debt (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Schedule of Restricted Stock Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Schedule of Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Schedule of Fair Value Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Stockholders’ Equity (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Related Party Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 pure-20230430_cal.xml XBRL CALCULATION FILE EX-101.DEF 8 pure-20230430_def.xml XBRL DEFINITION FILE EX-101.LAB 9 pure-20230430_lab.xml XBRL LABEL FILE Product and Service [Axis] Product [Member] Royalty [Member] Equity Components [Axis] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] PURE Hard Surface [Member] SILV?RION [Member] Concentration Risk Type [Axis] Customer Concentration Risk [Member] Concentration Risk Benchmark [Axis] Revenue Benchmark [Member] Customer [Axis] Individual Customer One [Member] Individual Customer Two [Member] Individual Customer Three [Member] Accounts Receivable [Member] Customer One [Member] Customer Two [Member] Customer Three [Member] Customer Four [Member] Purchases [Member] One Vendor [Member] Two Vendor [Member] Accounts Payable [Member] Vendor One [Member] Vendor [Member] Antidilutive Securities [Axis] Common Stock Option [Member] Restricted Stock Units (RSUs) [Member] Credit Facility [Axis] California Bank and Trust [Member] Debt Instrument [Axis] Paycheck Protection Program [Member] Award Type [Axis] Scenario [Axis] Vested and Issuable [Member] Plan Name [Axis] 2007 Equity Incentive Plan [Member] 2017 Equity Incentive Plan [Member] Title of Individual [Axis] Employees Officers Directors and Consultants [Member] Financial Instrument [Axis] Equity Option [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Statement of Financial Position [Abstract] Assets Current assets Cash and cash equivalents Accounts receivable Inventories, net Restricted cash Prepaid expenses Total current assets Property, plant and equipment, net Total assets Liabilities and stockholders’ equity Current liabilities Accounts payable Accrued liabilities Total current liabilities Commitments and contingencies Stockholders’ equity Preferred stock, $0.01 par value: 5,000,000 shares authorized, no shares issued and outstanding Common stock, $0.01 par value: 150,000,000 shares authorized, 111,356,473 shares issued and outstanding at April 30, 2023 and at July 31, 2022 Additional paid-in capital Accumulated deficit Total stockholders’ equity Total liabilities and stockholders’ equity Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Statement [Table] Statement [Line Items] Total revenue Cost of goods sold Gross profit Operating costs and expenses Selling, general and administrative Research and development Total operating costs and expenses Loss from operations Other income (expense) Gain on extinguishment of indebtedness, net Other income (expense), net Interest expense, net Total other income (expense) Net loss Basic and diluted net loss per share Shares used in computing basic and diluted net loss per share Balance Balance, shares Share-based compensation expense - stock options Share-based compensation expense - restricted stock units Issuance of common stock for vested restricted stock units Issuance of common stock for vested restricted stock units, shares Net loss Balance Balance, shares Statement of Cash Flows [Abstract] Operating activities Adjustments to reconcile net loss to net cash used in operating activities: Share-based compensation Depreciation and amortization Reserve for inventory obsolescence Gain on extinguishment of indebtedness Changes in operating assets and liabilities: Accounts receivable Inventories Prepaid expenses Accounts payable and accrued liabilities Net cash used in operating activities Investing activities Purchases of property, plant and equipment Net cash used in investing activities Net decrease in cash, cash equivalents, and restricted cash Cash, cash equivalents, and restricted cash at beginning of period Cash, cash equivalents, and restricted cash at end of period Reconciliation of cash, cash equivalents, and restricted cash to the condensed consolidated balance sheets Cash and cash equivalents Restricted cash Total cash, cash equivalents and restricted cash Supplemental disclosure of cash flow information Cash paid for taxes Organization, Consolidation and Presentation of Financial Statements [Abstract] Basis of Presentation Liquidity And Going Concern Liquidity and Going Concern Accounting Policies [Abstract] Significant Accounting Policies EX-101.PRE 10 pure-20230430_pre.xml XBRL PRESENTATION FILE XML 11 R1.htm IDEA: XBRL DOCUMENT

Cover - shares	9 Months Ended
Cover - shares	Apr. 30, 2023	Jun. 14, 2023
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Apr. 30, 2023
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2023
Current Fiscal Year End Date	--07-31
Entity File Number	001-14468
Entity Registrant Name	PURE Bioscience, Inc.
Entity Central Index Key	0001006028
Entity Tax Identification Number	33-0530289
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	9669 Hermosa Avenue
Entity Address, City or Town	Rancho Cucamonga
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	91730
City Area Code	(619)
Local Phone Number	596-8600
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		111,356,473

XML 12 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets - USD ($)	Apr. 30, 2023	Jul. 31, 2022
Current assets
Cash and cash equivalents	$ 781,000	$ 3,391,000
Accounts receivable	188,000	201,000
Inventories, net	149,000	179,000
Restricted cash	75,000	75,000
Prepaid expenses	37,000	18,000
Total current assets	1,230,000	3,864,000
Property, plant and equipment, net	594,000	620,000
Total assets	1,824,000	4,484,000
Current liabilities
Accounts payable	432,000	488,000
Accrued liabilities	137,000	87,000
Total current liabilities	569,000	575,000
Commitments and contingencies
Stockholders’ equity
Preferred stock, $0.01 par value: 5,000,000 shares authorized, no shares issued and outstanding
Common stock, $0.01 par value: 150,000,000 shares authorized, 111,356,473 shares issued and outstanding at April 30, 2023 and at July 31, 2022	1,114,000	1,114,000
Additional paid-in capital	132,354,000	132,079,000
Accumulated deficit	(132,213,000)	(129,284,000)
Total stockholders’ equity	1,255,000	3,909,000
Total liabilities and stockholders’ equity	$ 1,824,000	$ 4,484,000

XML 13 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Apr. 30, 2023	Jul. 31, 2022
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	111,356,473	111,356,473
Common stock, shares outstanding	111,356,473	111,356,473

XML 14 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Apr. 30, 2023	Apr. 30, 2022	Apr. 30, 2023	Apr. 30, 2022
Total revenue	$ 407,000	$ 524,000	$ 1,275,000	$ 1,441,000
Cost of goods sold	211,000	199,000	625,000	553,000
Gross profit	196,000	325,000	650,000	888,000
Operating costs and expenses
Selling, general and administrative	997,000	977,000	3,342,000	3,127,000
Research and development	74,000	107,000	227,000	255,000
Total operating costs and expenses	1,071,000	1,084,000	3,569,000	3,382,000
Loss from operations	(875,000)	(759,000)	(2,919,000)	(2,494,000)
Other income (expense)
Gain on extinguishment of indebtedness, net				239,000
Other income (expense), net	1,000		(4,000)
Interest expense, net	(2,000)	(1,000)	(6,000)	(3,000)
Total other income (expense)	(1,000)	(1,000)	(10,000)	236,000
Net loss	$ (876,000)	$ (760,000)	$ (2,929,000)	$ (2,258,000)
Basic and diluted net loss per share	$ (0.01)	$ (0.01)	$ (0.03)	$ (0.03)
Shares used in computing basic and diluted net loss per share	111,356,473	87,925,388	111,356,473	87,741,639
Product [Member]
Total revenue	$ 406,000	$ 497,000	$ 1,269,000	$ 1,409,000
Royalty [Member]
Total revenue	$ 1,000	$ 27,000	$ 6,000	$ 32,000

XML 15 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statement of Stockholders' Equity (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance at Jul. 31, 2021	$ 873,000	$ 128,253,000	$ (125,793,000)	$ 3,333,000
Balance, shares at Jul. 31, 2021	87,223,141
Share-based compensation expense - stock options		431,000		431,000
Share-based compensation expense - restricted stock units		62,000		62,000
Issuance of common stock for vested restricted stock units	$ 8,000	(8,000)
Issuance of common stock for vested restricted stock units, shares	800,000
Net loss			(2,258,000)	(2,258,000)
Balance at Apr. 30, 2022	$ 881,000	128,738,000	(128,051,000)	1,568,000
Balance, shares at Apr. 30, 2022	88,023,141
Balance at Jan. 31, 2022	$ 879,000	128,617,000	(127,291,000)	2,205,000
Balance, shares at Jan. 31, 2022	87,873,141
Share-based compensation expense - stock options		103,000		103,000
Share-based compensation expense - restricted stock units		20,000		20,000
Issuance of common stock for vested restricted stock units	$ 2,000	(2,000)
Issuance of common stock for vested restricted stock units, shares	150,000
Net loss			(760,000)	(760,000)
Balance at Apr. 30, 2022	$ 881,000	128,738,000	(128,051,000)	1,568,000
Balance, shares at Apr. 30, 2022	88,023,141
Balance at Jul. 31, 2022	$ 1,114,000	132,079,000	(129,284,000)	3,909,000
Balance, shares at Jul. 31, 2022	111,356,473
Share-based compensation expense - stock options		213,000		213,000
Share-based compensation expense - restricted stock units		62,000		62,000
Issuance of common stock for vested restricted stock units
Net loss			(2,929,000)	(2,929,000)
Balance at Apr. 30, 2023	$ 1,114,000	132,354,000	(132,213,000)	1,255,000
Balance, shares at Apr. 30, 2023	111,356,473
Balance at Jan. 31, 2023	$ 1,114,000	132,290,000	(131,337,000)	2,067,000
Balance, shares at Jan. 31, 2023	111,356,473
Share-based compensation expense - stock options		44,000		44,000
Share-based compensation expense - restricted stock units		20,000		20,000
Issuance of common stock for vested restricted stock units
Net loss			(876,000)	(876,000)
Balance at Apr. 30, 2023	$ 1,114,000	$ 132,354,000	$ (132,213,000)	$ 1,255,000
Balance, shares at Apr. 30, 2023	111,356,473

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482765/220-10-50-6

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-3

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-8

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-9

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-4

Reference 13: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480167/946-830-55-10

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483581/946-220-45-7

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(9))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(1)(d))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B

Reference 32: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-31

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483499/205-20-50-7

Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-28

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A

Reference 37: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B

Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1

+ Details

- Definition

Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481372/852-10-55-10

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480167/946-830-55-12

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(19))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.6-05(4))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(4)(b))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(6))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(7))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 310
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2

+ Details

XML 16 R6.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Apr. 30, 2023	Apr. 30, 2022	Apr. 30, 2023	Apr. 30, 2022
Operating activities
Net loss	$ (876,000)	$ (760,000)	$ (2,929,000)	$ (2,258,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation			275,000	493,000
Depreciation and amortization			102,000	162,000
Reserve for inventory obsolescence			40,000
Gain on extinguishment of indebtedness				(239,000)
Changes in operating assets and liabilities:
Accounts receivable			13,000	170,000
Inventories			(10,000)	31,000
Prepaid expenses			(19,000)	7,000
Accounts payable and accrued liabilities			(6,000)	(181,000)
Net cash used in operating activities			(2,534,000)	(1,815,000)
Investing activities
Purchases of property, plant and equipment			(76,000)	(64,000)
Net cash used in investing activities			(76,000)	(64,000)
Net decrease in cash, cash equivalents, and restricted cash			(2,610,000)	(1,879,000)
Cash, cash equivalents, and restricted cash at beginning of period			3,466,000	2,465,000
Cash, cash equivalents, and restricted cash at end of period	856,000	586,000	856,000	586,000
Reconciliation of cash, cash equivalents, and restricted cash to the condensed consolidated balance sheets
Cash and cash equivalents	781,000	511,000	781,000	511,000
Restricted cash	75,000	75,000	75,000	75,000
Total cash, cash equivalents and restricted cash	$ 856,000	$ 586,000	856,000	586,000
Supplemental disclosure of cash flow information
Cash paid for taxes			$ 5,000

XML 17 R7.htm IDEA: XBRL DOCUMENT

Basis of Presentation

9 Months Ended

Apr. 30, 2023

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Basis of Presentation

1. Basis of Presentation

XML 18 R8.htm IDEA: XBRL DOCUMENT

Liquidity and Going Concern

9 Months Ended

Apr. 30, 2023

Liquidity And Going Concern

Liquidity and Going Concern

2. Liquidity and Going Concern

XML 19 R9.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies

9 Months Ended

Apr. 30, 2023

Accounting Policies [Abstract]

Significant Accounting Policies

3. Significant Accounting Policies

Revenue Recognition

	1.	Identify the contract with the customer
	2.	Identify the performance obligations in the contract
	3.	Determine the transaction price
	4.	Allocate the transaction price to the performance obligations in the contract
	5.	Recognize revenue when (or as) each performance obligation is satisfied

We do not have significant categories of revenue that may impact how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors.

A summary of our revenue by product type for the nine months ended April 30, 2023 and 2022 is as follows:

Summary of Revenue by Product

	2023		2022
	April 30,
	2023		2022
PURE Hard Surface	$	1,184,000	$	1,158,000
SILVÉRION		85,000		251,000
Total	$	1,269,000	$	1,409,000

A summary of our revenue by product type for the three months ended April 30, 2023 and 2022 is as follows:

	2023		2022
	April 30,
	2023		2022
PURE Hard Surface	$	406,000	$	352,000
SILVÉRION		—		145,000
Total	$	406,000	$	497,000

Variable Consideration

Use of Estimates

Net Loss Per Share

	2023		2022
	April 30,
	2023		2022
Common stock options		6,700,625		6,179,125
Restricted stock units		1,212,500		1,212,500
Total		7,913,125		7,391,625

Inventory

Inventories consist of the following:

Schedule of Inventories

	April 30, 2023		July 31, 2022
Raw materials	$	26,000	$	19,000
Finished goods		123,000		160,000
Inventories	$	149,000	$	179,000

Share-Based Compensation

Concentrations

Segments

XML 20 R10.htm IDEA: XBRL DOCUMENT

Recent Accounting Pronouncements

9 Months Ended

Apr. 30, 2023

Accounting Changes and Error Corrections [Abstract]

Recent Accounting Pronouncements

4. Recent Accounting Pronouncements

- Definition

The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480016/944-40-65-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480016/944-40-65-2

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480016/944-40-65-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(iv)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480016/944-40-65-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (h)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480016/944-40-65-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 5
-Subparagraph (SAB Topic 11.M.Q2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480530/250-10-S99-5

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(4)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (i)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480528/815-20-65-6

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 842
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 5
-Subparagraph (f)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479832/842-10-65-5

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 842
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 5
-Subparagraph (f)(3)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479832/842-10-65-5

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (c)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (c)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (c)(3)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 848
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483550/848-10-65-2

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 105
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479343/105-10-65-6

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-1

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 8
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482615/740-10-65-8

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 8
-Subparagraph (e)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482615/740-10-65-8

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 8
-Subparagraph (e)(3)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482615/740-10-65-8

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482833/825-10-65-6

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (e)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482833/825-10-65-6

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (e)(3)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482833/825-10-65-6

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 326
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479654/326-10-65-4

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 326
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (e)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479654/326-10-65-4

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 926
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (f)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483194/926-20-65-2

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 926
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (f)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483194/926-20-65-2

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 926
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (f)(3)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483194/926-20-65-2

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480530/250-10-S99-6

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-1

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-1

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Topic 250
-Publisher FASB
-URI https://asc.fasb.org//250/tableOfContent

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (d)(1)
-SubTopic 20
-Topic 310
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481925/310-20-65-2

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (d)(2)
-SubTopic 20
-Topic 310
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481925/310-20-65-2

+ Details

XML 21 R11.htm IDEA: XBRL DOCUMENT

Debt

9 Months Ended

Apr. 30, 2023

Debt Disclosure [Abstract]

Debt

5. Debt

Receipt of CARES funding

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 470
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//470/tableOfContent

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I

+ Details

XML 22 R12.htm IDEA: XBRL DOCUMENT

Stockholders’ Equity

9 Months Ended

Apr. 30, 2023

Share-Based Payment Arrangement [Abstract]

Stockholders’ Equity

6. Stockholders’ Equity

Restricted Stock Units

A summary of our restricted stock unit activity and related data is as follows:

Schedule of Restricted Stock Activity

	Total RSU Shares		Vested and Issuable
Outstanding at July 31, 2022		1,212,500		1,045,833
Granted		—		—
Issued		—		—
Forfeited		—		—
Outstanding at April 30, 2023		1,212,500		1,045,833

Stock Option Plans

2007 Equity Incentive Plan

2017 Equity Incentive Plan

A summary of our stock option activity is as follows:

Schedule of Stock Option Activity

	Shares			Weighted- Average Exercise Price		Aggregate Intrinsic Value
Outstanding at July 31, 2022		6,079,125		$	0.62	$	—
Granted		1,935,000		$	0.20		—
Exercised		—		$	—		—
Expired		(1,313,500	)	$	0.70		—
Outstanding at April 30, 2023		6,700,625		$	0.48	$	—

The weighted-average remaining contractual term of options outstanding at April 30, 2023 was 7.44 years.

Schedule of Fair Value Assumptions

	Nine Months Ended April 30, 2023			Nine Months Ended April 30, 2022
Volatility		91.90	%		88.35.	%
Risk-free interest rate		4.00	%		1.17	%
Dividend yield		0.0	%		0.0	%
Expected life		5.34 years			5.59 years

The risk-free interest rates used in the Black-Scholes calculations are based on the prevailing U.S. Treasury yield as determined by the U.S. Federal Reserve.

The expected life of options was estimated using the average between the contractual term and the vesting term of the options.

XML 23 R13.htm IDEA: XBRL DOCUMENT

Related Party Transactions

9 Months Ended

Apr. 30, 2023

Related Party Transactions

7. Related Party Transactions

As of April 30, 2023 and April 30, 2022, accounts payable include $93,000 and $136,000 in board fees due to officers and directors, respectively.

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-5

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-6

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483326/850-10-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(g)(3))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(c))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(e))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//850/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483326/850-10-50-6

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483326/850-10-50-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483326/850-10-50-1

+ Details

XML 24 R14.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

9 Months Ended

Apr. 30, 2023

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

8. Commitments and Contingencies

COVID-19[done]

XML 25 R15.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies (Policies)

9 Months Ended

Apr. 30, 2023

Accounting Policies [Abstract]

Revenue Recognition

Revenue Recognition

	1.	Identify the contract with the customer
	2.	Identify the performance obligations in the contract
	3.	Determine the transaction price
	4.	Allocate the transaction price to the performance obligations in the contract
	5.	Recognize revenue when (or as) each performance obligation is satisfied

We do not have significant categories of revenue that may impact how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors.

A summary of our revenue by product type for the nine months ended April 30, 2023 and 2022 is as follows:

Summary of Revenue by Product

	2023		2022
	April 30,
	2023		2022
PURE Hard Surface	$	1,184,000	$	1,158,000
SILVÉRION		85,000		251,000
Total	$	1,269,000	$	1,409,000

A summary of our revenue by product type for the three months ended April 30, 2023 and 2022 is as follows:

	2023		2022
	April 30,
	2023		2022
PURE Hard Surface	$	406,000	$	352,000
SILVÉRION		—		145,000
Total	$	406,000	$	497,000

Variable Consideration

Use of Estimates

Use of Estimates

Net Loss Per Share

Net Loss Per Share

	2023		2022
	April 30,
	2023		2022
Common stock options		6,700,625		6,179,125
Restricted stock units		1,212,500		1,212,500
Total		7,913,125		7,391,625

Inventory

Inventory

Inventories consist of the following:

Schedule of Inventories

	April 30, 2023		July 31, 2022
Raw materials	$	26,000	$	19,000
Finished goods		123,000		160,000
Inventories	$	149,000	$	179,000

Share-Based Compensation

Share-Based Compensation

Concentrations

Concentrations

Segments

Segments

- Definition

Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.

+ References + Details

- Definition

Disclosure of accounting policy for revenue from contract with customer.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 17
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-17

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 19
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-19

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-18

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-18

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 20
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-20

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 20
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-20

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 20
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-20

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 20
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-20

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (e)
-SubTopic 10
-Topic 235
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483426/235-10-50-4

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Topic 606
-Publisher FASB
-URI https://asc.fasb.org//606/tableOfContent

+ Details

- Definition

Disclosure of accounting policy for segment reporting.

+ References + Details

XML 26 R16.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies (Tables)

9 Months Ended

Apr. 30, 2023

Accounting Policies [Abstract]

Summary of Revenue by Product

A summary of our revenue by product type for the nine months ended April 30, 2023 and 2022 is as follows:

Summary of Revenue by Product

	2023		2022
	April 30,
	2023		2022
PURE Hard Surface	$	1,184,000	$	1,158,000
SILVÉRION		85,000		251,000
Total	$	1,269,000	$	1,409,000

A summary of our revenue by product type for the three months ended April 30, 2023 and 2022 is as follows:

	2023		2022
	April 30,
	2023		2022
PURE Hard Surface	$	406,000	$	352,000
SILVÉRION		—		145,000
Total	$	406,000	$	497,000

Schedule of Anti-dilutive Securities Excluded from Computation of earnings Per Share

	2023		2022
	April 30,
	2023		2022
Common stock options		6,700,625		6,179,125
Restricted stock units		1,212,500		1,212,500
Total		7,913,125		7,391,625

Schedule of Inventories

Inventories consist of the following:

Schedule of Inventories

	April 30, 2023		July 31, 2022
Raw materials	$	26,000	$	19,000
Finished goods		123,000		160,000
Inventories	$	149,000	$	179,000

XML 27 R17.htm IDEA: XBRL DOCUMENT

Stockholders’ Equity (Tables)

9 Months Ended

Apr. 30, 2023

Share-Based Payment Arrangement [Abstract]

Schedule of Restricted Stock Activity

A summary of our restricted stock unit activity and related data is as follows:

Schedule of Restricted Stock Activity

	Total RSU Shares		Vested and Issuable
Outstanding at July 31, 2022		1,212,500		1,045,833
Granted		—		—
Issued		—		—
Forfeited		—		—
Outstanding at April 30, 2023		1,212,500		1,045,833

Schedule of Stock Option Activity

A summary of our stock option activity is as follows:

Schedule of Stock Option Activity

	Shares			Weighted- Average Exercise Price		Aggregate Intrinsic Value
Outstanding at July 31, 2022		6,079,125		$	0.62	$	—
Granted		1,935,000		$	0.20		—
Exercised		—		$	—		—
Expired		(1,313,500	)	$	0.70		—
Outstanding at April 30, 2023		6,700,625		$	0.48	$	—

Schedule of Fair Value Assumptions

	Nine Months Ended April 30, 2023			Nine Months Ended April 30, 2022
Volatility		91.90	%		88.35.	%
Risk-free interest rate		4.00	%		1.17	%
Dividend yield		0.0	%		0.0	%
Expected life		5.34 years			5.59 years

XML 28 R18.htm IDEA: XBRL DOCUMENT

Liquidity and Going Concern (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Apr. 30, 2023	Apr. 30, 2022	Apr. 30, 2023	Apr. 30, 2022	Jul. 31, 2022
Liquidity And Going Concern
Cumulative net loss	$ 132,213,000		$ 132,213,000		$ 129,284,000
Net loss	876,000	$ 760,000	2,929,000	$ 2,258,000
Revenue	407,000	524,000	1,275,000	1,441,000
Net cash provided by (used) in operating and investing activities			2,610,000	1,879,000
Cash and cash equivalents	$ 781,000	$ 511,000	$ 781,000	$ 511,000	$ 3,391,000

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

+ Details

- Definition

Amount of accumulated undistributed earnings (deficit).

+ References + Details

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 924
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-5

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-42

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-40

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-41

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-4

+ Details

XML 29 R19.htm IDEA: XBRL DOCUMENT

Summary of Revenue by Product (Details) - USD ($)	3 Months Ended		9 Months Ended
Summary of Revenue by Product (Details) - USD ($)	Apr. 30, 2023	Apr. 30, 2022	Apr. 30, 2023	Apr. 30, 2022
Product Information [Line Items]
Total	$ 406,000	$ 497,000	$ 1,269,000	$ 1,409,000
PURE Hard Surface [Member]
Product Information [Line Items]
Total	406,000	352,000	1,184,000	1,158,000
SILV?RION [Member]
Product Information [Line Items]
Total		$ 145,000	$ 85,000	$ 251,000

- Definition

Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).

+ References

+ Details

XML 30 R20.htm IDEA: XBRL DOCUMENT

Schedule of Anti-dilutive Securities Excluded from Computation of earnings Per Share (Details) - shares	9 Months Ended
	Apr. 30, 2023	Apr. 30, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	7,913,125	7,391,625
Common Stock Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	6,700,625	6,179,125
Restricted Stock Units (RSUs) [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	1,212,500	1,212,500

XML 31 R21.htm IDEA: XBRL DOCUMENT

Schedule of Inventories (Details) - USD ($)	Apr. 30, 2023	Jul. 31, 2022
Accounting Policies [Abstract]
Raw materials	$ 26,000	$ 19,000
Finished goods	123,000	160,000
Inventories	$ 149,000	$ 179,000

XML 32 R22.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies (Details Narrative)	3 Months Ended		9 Months Ended
Significant Accounting Policies (Details Narrative)	Apr. 30, 2023 USD ($)	Apr. 30, 2022	Apr. 30, 2023 USD ($) Segments shares	Apr. 30, 2022 shares	Jul. 31, 2022 USD ($)
Product Information [Line Items]
Dilutive common share \| shares			7,913,125	7,391,625
Reserve for inventory obsolescence	$ 40,000		$ 40,000
Net of reserve for inventory obsolescence	$ 265,000		$ 265,000		$ 225,000
Number of operating segments \| Segments			1
Customer Concentration Risk [Member] \| Revenue Benchmark [Member] \| Individual Customer One [Member]
Product Information [Line Items]
Concentration risk percentage	39.00%	29.00%	20.00%	14.00%
Customer Concentration Risk [Member] \| Revenue Benchmark [Member] \| Individual Customer Two [Member]
Product Information [Line Items]
Concentration risk percentage		14.00%		12.00%
Customer Concentration Risk [Member] \| Revenue Benchmark [Member] \| Individual Customer Three [Member]
Product Information [Line Items]
Concentration risk percentage		11.00%		10.00%
Customer Concentration Risk [Member] \| Accounts Receivable [Member] \| Customer One [Member]
Product Information [Line Items]
Concentration risk percentage			36.00%	15.00%
Customer Concentration Risk [Member] \| Accounts Receivable [Member] \| Customer Two [Member]
Product Information [Line Items]
Concentration risk percentage			13.00%	14.00%
Customer Concentration Risk [Member] \| Accounts Receivable [Member] \| Customer Three [Member]
Product Information [Line Items]
Concentration risk percentage				12.00%
Customer Concentration Risk [Member] \| Accounts Receivable [Member] \| Customer Four [Member]
Product Information [Line Items]
Concentration risk percentage				11.00%
Customer Concentration Risk [Member] \| Purchases [Member] \| One Vendor [Member]
Product Information [Line Items]
Concentration risk percentage	17.00%	26.00%	19.00%	21.00%
Customer Concentration Risk [Member] \| Purchases [Member] \| Two Vendor [Member]
Product Information [Line Items]
Concentration risk percentage	13.00%	12.00%
Customer Concentration Risk [Member] \| Accounts Payable [Member] \| Vendor One [Member]
Product Information [Line Items]
Concentration risk threshold percentage			20.00%
Customer Concentration Risk [Member] \| Accounts Payable [Member] \| Vendor [Member]
Product Information [Line Items]
Concentration risk threshold percentage				25.00%

XML 33 R23.htm IDEA: XBRL DOCUMENT

Debt (Details Narrative) - California Bank and Trust [Member] - Paycheck Protection Program [Member] - USD ($)	1 Months Ended	9 Months Ended
	Apr. 30, 2021	Apr. 30, 2022
Line of Credit Facility [Line Items]
Net proceeds from payroll protection program loan	$ 239,000	$ 239,000
Debt description	The CARES Act was established in order to enable small businesses to pay employees during the economic slowdown caused by COVID-19 by providing forgivable loans to qualifying businesses for up to 2.5 times their average monthly payroll costs. The amount borrowed under the CARES Act is eligible to be forgiven provided that (a) the Company uses the PPP Funds during the eight week period after receipt thereof, and (b) the PPP Funds are only used to cover payroll costs (including benefits), rent, mortgage interest, and utility costs
Debt instrument interest percentage	1.00%
Debt instrument term	2 years

- Definition

Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total.

+ References + Details

XML 34 R24.htm IDEA: XBRL DOCUMENT

Schedule of Restricted Stock Activity (Details) - Restricted Stock Units (RSUs) [Member]	9 Months Ended
	Apr. 30, 2023 shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Outstanding, Beginning balance	1,212,500
Granted
Issued
Forfeited
Outstanding, Ending balance	1,212,500
Vested and Issuable [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Outstanding, Beginning balance	1,045,833
Granted
Issued
Forfeited
Outstanding, Ending balance	1,045,833

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 1D
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480483/718-10-35-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(ii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(01)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(02)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(03)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(04)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(01)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(02)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(03)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iv)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(v)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

+ Details

XML 35 R25.htm IDEA: XBRL DOCUMENT

Schedule of Stock Option Activity (Details) - 2017 Equity Incentive Plan [Member]	9 Months Ended
	Apr. 30, 2023 USD ($) $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Options Outstanding Shares, Beginning Balance \| shares	6,079,125
Weighted- Average Exercise Price Outstanding, Beginning Balance \| $ / shares	$ 0.62
Aggregate Intrinsic Value Outstanding, Beginning Balance \| $
Shares, Granted \| shares	1,935,000
Weighted- Average Exercise Price, Granted \| $ / shares	$ 0.20
Shares, Exercised \| shares
Weighted- Average Exercise Price, Exercised \| $ / shares
Shares, Expired \| shares	(1,313,500)
Weighted- Average Exercise Price, Expired \| $ / shares	$ 0.70
Options Outstanding Shares, Beginning Balance \| shares	6,700,625
Weighted- Average Exercise Price Outstanding, Beginning Balance \| $ / shares	$ 0.48
Aggregate Intrinsic Value Outstanding, Beginning Balance \| $

XML 36 R26.htm IDEA: XBRL DOCUMENT

Schedule of Fair Value Assumptions (Details)	9 Months Ended
Schedule of Fair Value Assumptions (Details)	Apr. 30, 2023	Apr. 30, 2022
Share-Based Payment Arrangement [Abstract]
Volatility	91.90%	88.35%
Risk-free interest rate	4.00%	1.17%
Dividend yield	0.00%	0.00%
Expected life	5 years 4 months 2 days	5 years 7 months 2 days

XML 37 R27.htm IDEA: XBRL DOCUMENT

Stockholders’ Equity (Details Narrative) - USD ($)	1 Months Ended		9 Months Ended
Stockholders’ Equity (Details Narrative) - USD ($)	Jan. 31, 2021	Feb. 29, 2016	Apr. 30, 2023	Apr. 30, 2022	Jul. 31, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-based compensation			$ 213,000	$ 431,000
Unrecognized non-cash compensation costs			$ 87,000
Weighted average contractual term			7 years 5 months 8 days
Options issued to purchase common stock exercisable			5,831,458
Weighted average exercise price			$ 0.52
Weighted average contractual term			7 years 1 month 13 days
Unrecognized non-cash compensation costs for weighted average contractual term grants			6 months 29 days
Employees Officers Directors and Consultants [Member] \| Equity Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Options issued to purchase common stock			1,935,000
Fair value of options issued to purchase common stock			$ 241,000
Option vested description			The vesting terms of the options vary between one and two years and carry a ten year term
2007 Equity Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Common stock shares increase under the plan		4,000,000
Share-based compensation, expiration date		Feb. 04, 2026
Share-based compensation, vesting period		10 years
Number of shares available for issuance under the plan			970,000
2017 Equity Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Common stock shares increase under the plan	5,000,000
Share-based compensation, vesting period	10 years
Number of shares available for issuance under the plan			4,750,000
Restricted Stock Units (RSUs) [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of units, vested and issuable			1,212,500		1,212,500
Share-based compensation			$ 62,000	$ 62,000
Unrecognized non-cash compensation costs			$ 0
Number of restricted stock expected to vest			166,667
Granted, shares
Issued, shares
Forfeited, shares
Restricted stock units vested description			These RSUs are issued upon settlement date which is defined as “for each Vested Unit, the earliest of (i) the ten-year anniversary of the Grant Date; (ii) sixty days after the date the Grantee’s Service ceases for any reason and such cessation constitutes a “separation from service” within the meaning of Section 409A of the Code; (iii) the date of Grantee’s death or (iv) the date of a Change in Control that constitutes a “change in control event” within the meaning of Section 409A of the Code”.
Restricted Stock Units (RSUs) [Member] \| Vested and Issuable [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of units, vested and issuable			1,045,833		1,045,833
Granted, shares
Issued, shares
Forfeited, shares

XML 38 R28.htm IDEA: XBRL DOCUMENT

Related Party Transactions (Details Narrative) - USD ($)	Apr. 30, 2023	Apr. 30, 2022
Related Party Transactions [Abstract]
Other Liability, Current, Related and Nonrelated Party Status [Extensible Enumeration]	Related Party [Member]	Related Party [Member]
Accounts payable, due to officers and directors	$ 93,000	$ 136,000

XML 39 form10-q_htm.xml IDEA: XBRL DOCUMENT 0001006028 2022-08-01 2023-04-30 0001006028 2023-06-14 0001006028 2023-04-30 0001006028 2022-07-31 0001006028 us-gaap:ProductMember 2022-08-01 2023-04-30 0001006028 us-gaap:ProductMember 2021-08-01 2022-04-30 0001006028 us-gaap:ProductMember 2023-02-01 2023-04-30 0001006028 us-gaap:ProductMember 2022-02-01 2022-04-30 0001006028 us-gaap:RoyaltyMember 2022-08-01 2023-04-30 0001006028 us-gaap:RoyaltyMember 2021-08-01 2022-04-30 0001006028 us-gaap:RoyaltyMember 2023-02-01 2023-04-30 0001006028 us-gaap:RoyaltyMember 2022-02-01 2022-04-30 0001006028 2021-08-01 2022-04-30 0001006028 2023-02-01 2023-04-30 0001006028 2022-02-01 2022-04-30 0001006028 us-gaap:CommonStockMember 2022-07-31 0001006028 us-gaap:AdditionalPaidInCapitalMember 2022-07-31 0001006028 us-gaap:RetainedEarningsMember 2022-07-31 0001006028 us-gaap:CommonStockMember 2021-07-31 0001006028 us-gaap:AdditionalPaidInCapitalMember 2021-07-31 0001006028 us-gaap:RetainedEarningsMember 2021-07-31 0001006028 2021-07-31 0001006028 us-gaap:CommonStockMember 2023-01-31 0001006028 us-gaap:AdditionalPaidInCapitalMember 2023-01-31 0001006028 us-gaap:RetainedEarningsMember 2023-01-31 0001006028 2023-01-31 0001006028 us-gaap:CommonStockMember 2022-01-31 0001006028 us-gaap:AdditionalPaidInCapitalMember 2022-01-31 0001006028 us-gaap:RetainedEarningsMember 2022-01-31 0001006028 2022-01-31 0001006028 us-gaap:CommonStockMember 2022-08-01 2023-04-30 0001006028 us-gaap:AdditionalPaidInCapitalMember 2022-08-01 2023-04-30 0001006028 us-gaap:RetainedEarningsMember 2022-08-01 2023-04-30 0001006028 us-gaap:CommonStockMember 2021-08-01 2022-04-30 0001006028 us-gaap:AdditionalPaidInCapitalMember 2021-08-01 2022-04-30 0001006028 us-gaap:RetainedEarningsMember 2021-08-01 2022-04-30 0001006028 us-gaap:CommonStockMember 2023-02-01 2023-04-30 0001006028 us-gaap:AdditionalPaidInCapitalMember 2023-02-01 2023-04-30 0001006028 us-gaap:RetainedEarningsMember 2023-02-01 2023-04-30 0001006028 us-gaap:CommonStockMember 2022-02-01 2022-04-30 0001006028 us-gaap:AdditionalPaidInCapitalMember 2022-02-01 2022-04-30 0001006028 us-gaap:RetainedEarningsMember 2022-02-01 2022-04-30 0001006028 us-gaap:CommonStockMember 2023-04-30 0001006028 us-gaap:AdditionalPaidInCapitalMember 2023-04-30 0001006028 us-gaap:RetainedEarningsMember 2023-04-30 0001006028 us-gaap:CommonStockMember 2022-04-30 0001006028 us-gaap:AdditionalPaidInCapitalMember 2022-04-30 0001006028 us-gaap:RetainedEarningsMember 2022-04-30 0001006028 2022-04-30 0001006028 PURE:PUREHardSurfaceMember 2022-08-01 2023-04-30 0001006028 PURE:PUREHardSurfaceMember 2021-08-01 2022-04-30 0001006028 PURE:SilVerionMember 2022-08-01 2023-04-30 0001006028 PURE:SilVerionMember 2021-08-01 2022-04-30 0001006028 PURE:PUREHardSurfaceMember 2023-02-01 2023-04-30 0001006028 PURE:PUREHardSurfaceMember 2022-02-01 2022-04-30 0001006028 PURE:SilVerionMember 2023-02-01 2023-04-30 0001006028 PURE:SilVerionMember 2022-02-01 2022-04-30 0001006028 PURE:IndividualCustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-02-01 2023-04-30 0001006028 PURE:IndividualCustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-08-01 2023-04-30 0001006028 PURE:IndividualCustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-02-01 2022-04-30 0001006028 PURE:IndividualCustomerTwoMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-02-01 2022-04-30 0001006028 PURE:IndividualCustomerThreeMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-02-01 2022-04-30 0001006028 PURE:IndividualCustomerOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-08-01 2022-04-30 0001006028 PURE:IndividualCustomerTwoMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-08-01 2022-04-30 0001006028 PURE:IndividualCustomerThreeMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-08-01 2022-04-30 0001006028 PURE:CustomerOneMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-08-01 2023-04-30 0001006028 PURE:CustomerTwoMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-08-01 2023-04-30 0001006028 PURE:CustomerOneMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-08-01 2022-04-30 0001006028 PURE:CustomerTwoMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-08-01 2022-04-30 0001006028 PURE:CustomerThreeMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-08-01 2022-04-30 0001006028 PURE:CustomerFourMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-08-01 2022-04-30 0001006028 PURE:OneVendorMember PURE:PurchasesMember us-gaap:CustomerConcentrationRiskMember 2023-02-01 2023-04-30 0001006028 PURE:TwoVendorMember PURE:PurchasesMember us-gaap:CustomerConcentrationRiskMember 2023-02-01 2023-04-30 0001006028 PURE:OneVendorMember PURE:PurchasesMember us-gaap:CustomerConcentrationRiskMember 2022-08-01 2023-04-30 0001006028 PURE:OneVendorMember PURE:PurchasesMember us-gaap:CustomerConcentrationRiskMember 2022-02-01 2022-04-30 0001006028 PURE:TwoVendorMember PURE:PurchasesMember us-gaap:CustomerConcentrationRiskMember 2022-02-01 2022-04-30 0001006028 PURE:OneVendorMember PURE:PurchasesMember us-gaap:CustomerConcentrationRiskMember 2021-08-01 2022-04-30 0001006028 PURE:VendorOneMember PURE:AccountsPayablesMember us-gaap:CustomerConcentrationRiskMember 2022-08-01 2023-04-30 0001006028 PURE:VendorMember PURE:AccountsPayablesMember us-gaap:CustomerConcentrationRiskMember 2021-08-01 2022-04-30 0001006028 PURE:CommonStockOptionMember 2022-08-01 2023-04-30 0001006028 PURE:CommonStockOptionMember 2021-08-01 2022-04-30 0001006028 us-gaap:RestrictedStockUnitsRSUMember 2022-08-01 2023-04-30 0001006028 us-gaap:RestrictedStockUnitsRSUMember 2021-08-01 2022-04-30 0001006028 PURE:CaliforniaBankAndTrustMember PURE:PaycheckProtectionProgramMember 2021-04-01 2021-04-30 0001006028 PURE:CaliforniaBankAndTrustMember PURE:PaycheckProtectionProgramMember 2021-04-30 0001006028 PURE:CaliforniaBankAndTrustMember PURE:PaycheckProtectionProgramMember 2021-08-01 2022-04-30 0001006028 us-gaap:RestrictedStockUnitsRSUMember 2022-07-31 0001006028 PURE:VestedAndIssuableMember us-gaap:RestrictedStockUnitsRSUMember 2022-07-31 0001006028 us-gaap:RestrictedStockUnitsRSUMember 2022-08-01 2023-04-30 0001006028 us-gaap:RestrictedStockUnitsRSUMember 2021-08-01 2022-04-30 0001006028 us-gaap:RestrictedStockUnitsRSUMember 2023-04-30 0001006028 PURE:VestedAndIssuableMember us-gaap:RestrictedStockUnitsRSUMember 2023-04-30 0001006028 PURE:TwoThousandAndSevenEquityIncentivePlanMember 2016-02-01 2016-02-29 0001006028 PURE:TwoThousandAndSevenEquityIncentivePlanMember 2023-04-30 0001006028 PURE:TwoThousandSeventeenEquityIncentivePlanMember 2021-01-01 2021-01-31 0001006028 PURE:TwoThousandSeventeenEquityIncentivePlanMember 2023-04-30 0001006028 PURE:EmployeesOfficersDirectorsAndConsultantsMember us-gaap:StockOptionMember 2022-08-01 2023-04-30 0001006028 PURE:VestedAndIssuableMember us-gaap:RestrictedStockUnitsRSUMember 2022-08-01 2023-04-30 0001006028 PURE:TwoThousandSeventeenEquityIncentivePlanMember 2022-07-31 0001006028 PURE:TwoThousandSeventeenEquityIncentivePlanMember 2022-08-01 2023-04-30 iso4217:USD shares iso4217:USD shares pure PURE:Segments 0001006028 false Q3 2023 --07-31

http://fasb.org/us-gaap/2023#RelatedPartyMember

10-Q true 2023-04-30 false 001-14468 PURE Bioscience, Inc. DE 33-0530289 9669 Hermosa Avenue Rancho Cucamonga CA 91730 (619) 596-8600 Yes Yes Non-accelerated Filer true false false 111356473

781000

3391000

188000

201000

149000

179000

75000

37000

18000

1230000

3864000

594000

620000

1824000

4484000

432000

488000

137000

87000

569000

575000

0.01

5000000

0.01

150000000

111356473

1114000

132354000

132079000

-132213000

-129284000

1255000

3909000

1824000

4484000

1269000

1409000

406000

497000

6000

32000

1000

27000

1275000

1441000

407000

524000

625000

553000

211000

199000

650000

888000

196000

325000

3342000

3127000

997000

977000

227000

255000

74000

107000

3569000

3382000

1071000

1084000

-2919000

-2494000

-875000

-759000

239000

-4000

1000

6000

3000

2000

1000

-10000

236000

-1000

-2929000

-2258000

-876000

-760000

-0.03

-0.01

111356473

87741639

111356473

87925388

111356473

1114000

132079000

-129284000

3909000

87223141

873000

128253000

-125793000

3333000

111356473

1114000

132079000

-129284000

3909000

87223141

873000

128253000

-125793000

3333000

213000

431000

62000

800000

8000

-8000

-2929000

-2258000

111356473

1114000

132354000

-132213000

1255000

88023141

881000

128738000

-128051000

1568000

111356473

1114000

132354000

-132213000

1255000

88023141

881000

128738000

-128051000

1568000

111356473

1114000

132290000

-131337000

2067000

87873141

879000

128617000

-127291000

2205000

111356473

1114000

132290000

-131337000

2067000

87873141

879000

128617000

-127291000

2205000

44000

103000

20000

150000

2000

-2000

-876000

-760000

111356473

1114000

132354000

-132213000

1255000

88023141

881000

128738000

-128051000

1568000

111356473

1114000

132354000

-132213000

1255000

88023141

881000

128738000

-128051000

1568000

-2929000

-2258000

275000

493000

102000

162000

40000

239000

-13000

-170000

10000

-31000

19000

-7000

-6000

-181000

-2534000

-1815000

76000

64000

-76000

-64000

-2610000

-1879000

3466000

2465000

856000

586000

781000

511000

75000

856000

586000

5000

<p id="xdx_80A_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_z0iXuBMJ3NOk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">1. Basis of Presentation The accompanying unaudited condensed consolidated financial statements include the consolidated accounts of PURE Bioscience, Inc. and its wholly owned subsidiary, ETI H2O Inc., a Nevada corporation. ETI H2O, Inc. currently has no business operations and no material assets or liabilities and there have been no significant transactions related to ETI H2O, Inc. during the periods presented in the condensed consolidated financial statements. All inter-company balances and transactions have been eliminated. All references to “PURE,” “we,” “our,” “us” and the “Company” refer to PURE Bioscience, Inc. and our wholly owned subsidiary. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP, for interim financial information pursuant to the instructions to Form 10-Q and Article 10/Rule 8-03 of Regulation S-X. Accordingly, they do not include all of the information and disclosures required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the three and nine months ended April 30, 2023 are not necessarily indicative of the results that may be expected for other quarters or the year ending July 31, 2023. The July 31, 2022 balance sheet was derived from audited financial statements but does not include all disclosures required by GAAP and included in our Annual Report on Form 10-K. For more complete information, these unaudited financial statements and the notes thereto should be read in conjunction with the audited financial statements for the year ended July 31, 2022 included in our Annual Report on Form 10-K covering such period filed with the Securities and Exchange Commission, or SEC, on October 28, 2022. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. Actual results could differ from those estimates.

2. Liquidity and Going Concern We have a history of recurring losses, and as of April 30, 2023 we have incurred a cumulative net loss of $132,213,000. During the nine months ended April 30, 2023, we recorded a net loss of $2,929,000 on recorded net revenue of $1,275,000. In addition, during the nine months ended April 30, 2023 we used $<span id="xdx_90C_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_iN_pp0p0_di_c20220801__20230430_zp6VrGI9dPa7" title="Net cash provided by (used) in operating and investing activities">2,610,000 in operating and investing activities resulting in a cash balance of $781,000 as of April 30, 2023. Our history of recurring operating losses, and negative cash flows from operating activities give rise to substantial doubt regarding our ability to continue as a going concern. The Company’s independent registered public accounting firm, in its report on the Company’s consolidated financial statements for the year ended July 31, 2022, has also expressed substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from our possible inability to continue as a going concern. Our future capital requirements depend on numerous forward-looking factors. These factors may include, but are not limited to, the following: the acceptance of, and demand for, our products; our success and the success of our partners in selling our products; our success and the success of our partners in obtaining regulatory approvals to sell our products; the costs of further developing our existing products and technologies; the extent to which we invest in new product and technology development; and the costs associated with the continued operation, and any future growth, of our business. The outcome of these and other forward-looking factors will substantially affect our liquidity and capital resources. Until we can continually generate positive cash flow from operations, we will need to continue to fund our operations with the proceeds of offerings of our equity and debt securities. However, we cannot ensure that additional financing will be available when needed or that, if available, financing will be obtained on terms favorable to us or to our stockholders. If we raise additional funds from the issuance of equity securities, substantial dilution to our existing stockholders would likely result. If we raise additional funds by incurring debt financing, the terms of the debt may involve significant cash payment obligations as well as covenants and specific financial ratios that may restrict our ability to operate our business.

-132213000

-2929000

1275000

-2610000

781000

3. Significant Accounting Policies Revenue Recognition We account for revenue in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”), Topic 606, Revenue from Contracts with Customers (“Topic 606”). Under Topic 606, revenue is recognized at an amount that reflects the consideration to which we expect to be entitled in exchange for transferring goods or services to a customer. This principle is applied using the following 5-step process: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">1.</td> <td style="font: 10pt Times New Roman, Times, Serif">Identify the contract with the customer</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">2.</td> <td style="font: 10pt Times New Roman, Times, Serif">Identify the performance obligations in the contract</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">3.</td> <td style="font: 10pt Times New Roman, Times, Serif">Determine the transaction price</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">4.</td> <td style="font: 10pt Times New Roman, Times, Serif">Allocate the transaction price to the performance obligations in the contract</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">5.</td> <td style="font: 10pt Times New Roman, Times, Serif">Recognize revenue when (or as) each performance obligation is satisfied</td></tr> </table> Under Topic 606, we recognize revenue when we satisfy a performance obligation by transferring control of the promised goods or services to our customers, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. Our technology platform is based on patented stabilized ionic silver, and our initial products contain silver dihydrogen citrate, or SDC. SDC is a broad-spectrum, non-toxic antimicrobial agent, which offers 24-hour residual protection and formulates well with other compounds. We sell various configurations and dilutions of SDC direct to customers and through distributors. We currently offer PURE® Hard Surface as a food contact surface sanitizer and disinfectant to restaurant chains, food processors and food transportation companies. We also offer PURE Control® as a direct food contact processing aid. Contract terms for unit price, quantity, shipping and payment are governed by sales agreements and purchase orders which we consider to be a customer’s contract in all cases. The unit price is considered the observable stand-alone selling price for the arrangements. Any promotional or sales discounts are applied evenly to the units sold for purposes of calculating standalone selling price. Product sales generally consist of a single performance obligation that we satisfy at a point in time. We recognize product revenue when the following events have occurred: (a) we have transferred physical possession of the products, (b) we have a present right to payment, (c) the customer has legal title to the products, and (d) the customer bears significant risks and rewards of ownership of the products. Our direct customer and distributor sales are invoiced based on received purchase orders. Our payment terms on invoiced direct customer and distributor sales range between 30 and 90 days after we satisfy our performance obligation. The majority of our customers are on 30 day payment terms. We currently offer no right of return on invoiced sales and maintain no allowance for sales returns. Shipping and handling are treated as activities to fulfill promises to customers and any amounts billed to a customer, if applicable, represent revenues earned for the goods provided. Costs related to such shipping and handling billings are classified as cost of sales. We do not have significant categories of revenue that may impact how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors. A summary of our revenue by product type for the nine months ended April 30, 2023 and 2022 is as follows: Summary of Revenue by Product <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"> <tr style="display: none; vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20220801__20230430_zf1kTLVCw034" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49D_20210801__20220430_z9tODVqSapjh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">April 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_401_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--PUREHardSurfaceMember_zPQyK5gy6DTc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left">PURE Hard Surface</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">1,184,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">1,158,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--SilVerionMember_zoXNsEJlD5fi" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">SILVÉRION</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">85,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">251,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--Revenues_zPP18VsNwADh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,269,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,409,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> A summary of our revenue by product type for the three months ended April 30, 2023 and 2022 is as follows: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"> <tr style="display: none; vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20230201__20230430_zV0R4lkZeYK4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20220201__20220430_zx1kAUEFCEM7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"/><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">April 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_409_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--PUREHardSurfaceMember_z18apF9Dhj5d" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left">PURE Hard Surface</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">406,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">352,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--SilVerionMember_zfN8aMG8amP3" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">SILVÉRION</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">—</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">145,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--Revenues_zmK5rb4zuUii" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">406,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">497,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Variable Consideration We record revenue from customers in an amount that reflects the transaction price we expect to be entitled to after transferring control of those goods or services. From time to time, we offer sales promotions on our products such as discounts. Variable consideration is estimated at contract inception only to the extent that it is probable that a significant reversal of revenue will not occur. Use of Estimates The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, or GAAP, requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements, and the disclosures made in the accompanying notes to the consolidated financial statements. Actual results could differ materially from those estimates. Those estimates and assumptions include estimates for reserves of uncollectible accounts, inventory obsolescence, depreciable lives of property and equipment, analysis of impairments of recorded long-term tangible and intangible assets, realization of deferred tax assets, accruals for potential liabilities and assumptions made in valuing stock instruments issued for services. Net Loss Per Share Basic net loss per common share is computed as net loss divided by the weighted average number of common shares outstanding for the period. Our diluted net loss per common share is the same as our basic net loss per common share because we incurred a net loss during each period presented, and the potentially dilutive securities from the assumed exercise of all outstanding stock options, restricted stock units, and warrants would have an anti-dilutive effect. As of April 30, 2023 and 2022, stock options and shares issuable under restricted stock unit awards of 7,913,125 and 7,391,625, respectively, have been excluded from the computation of diluted shares outstanding. <p id="xdx_899_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_z949pWioYY9e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> Schedule of Anti-dilutive Securities Excluded from Computation of earnings Per Share <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"> <tr style="display: none; vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_498_20220801__20230430_zduXUzJcZ7s8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_497_20210801__20220430_zPJ2vFEbjmU5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">April 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_40D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockOptionMember_zWqGKtUJP0H6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left">Common stock options</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 18%; text-align: right">6,700,625</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 18%; text-align: right">6,179,125</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_z748B5Y9hhc2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Restricted stock units</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,212,500</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,212,500</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zDbB0alYuIR1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">7,913,125</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">7,391,625</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Inventory Inventories are stated at the lower of cost or net realizable value, and net of a valuation allowance for potential excess or obsolete material. Cost is determined using the average cost method. Depreciation related to manufacturing is systematically allocated to inventory produced, and expensed through cost of goods sold at the time inventory is sold. Inventories consist of the following: Schedule of Inventories <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49C_20230430_zuQb7bICdldk" style="border-bottom: Black 1.5pt solid; text-align: center">April 30, 2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20220731_zCIT3jsRVlqf" style="border-bottom: Black 1.5pt solid; text-align: center">July 31, 2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_405_eus-gaap--InventoryRawMaterials_iI_maINzkyC_zpDVAbdXniP9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left">Raw materials</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">26,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">19,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--InventoryFinishedGoods_iI_maINzkyC_zZHN1FqDDhO4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Finished goods</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">123,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">160,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--InventoryNet_iTI_mtINzkyC_zCw67Zu9tT5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Inventories</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">149,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">179,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> During the three months ended April 30, 2023, the Company determined that an additional reserve for inventory obsolescence of $40,000 was required. As of April 30, 2023 and July 31, 2022, inventories are stated net of a reserve for inventory obsolescence of $265,000 and $225,000, respectively. Share-Based Compensation We periodically issue stock options and restricted stock awards to employees and non-employees in non-capital raising transactions for services and for financing costs. We account for such grants issued and vesting to employees based on ASC 718, whereby the value of the award is measured on the date of grant and recognized as compensation expense on the straight-line basis over the vesting period. We estimate the fair value of share-based payment awards at the date of grant using the Black-Scholes option valuation model. The Black-Scholes option valuation model requires the input of subjective assumptions, including price volatility of the underlying stock, risk-free interest rate, dividend yield, and expected life of the option. Share-based compensation expense is based on awards ultimately expected to vest, and therefore is reduced by expected forfeitures. Concentrations Gross product sales. For the three months ended April 30, 2023, one individual customer accounted for <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230201__20230430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--IndividualCustomerOneMember_zRLcNvbWfi9c" title="Concentration risk percentage">39% of our net product sales. For the nine months ended April 30, 2023, one customer accounted for <span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220801__20230430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--IndividualCustomerOneMember_zThxz7lhKu76" title="Concentration risk percentage">20% of our net product sales. For the three months ended April 30, 2022, three individual customers accounted for <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220201__20220430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--IndividualCustomerOneMember_zh8LjOlgRPh5" title="Concentration risk percentage">29%, <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220201__20220430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--IndividualCustomerTwoMember_zGHrmAnMnFK8" title="Concentration risk percentage">14% and <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220201__20220430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--IndividualCustomerThreeMember_z2aLdCPIBLA5" title="Concentration risk percentage">11% of our net product sales, respectively. For the nine months ended April 30, 2022, three customers accounted for <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210801__20220430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--IndividualCustomerOneMember_zciXy3htHD49" title="Concentration risk percentage">14%, <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210801__20220430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--IndividualCustomerTwoMember_z1M6XmBoM3t9" title="Concentration risk percentage">12% and <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210801__20220430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--IndividualCustomerThreeMember_z1bbthkfy5Lb" title="Concentration risk percentage">10% of our net product sales, respectively. Accounts receivable. As of April 30, 2023, we had accounts receivable from two customers that comprised of <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220801__20230430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerOneMember_ztm6Npf8trig" title="Concentration risk percentage">36% and <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220801__20230430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerTwoMember_zHY18p6lszI5" title="Concentration risk percentage">13% of total accounts receivable, respectively. As of April 30, 2022, we had accounts receivable from four customers that comprised of <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210801__20220430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerOneMember_z796zHJCnR6a" title="Concentration risk percentage">15%, <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210801__20220430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerTwoMember_ztWgxavuvZb6" title="Concentration risk percentage">14%, <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210801__20220430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerThreeMember_zSNHw2keG2vf" title="Concentration risk percentage">12% and <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210801__20220430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerFourMember_z2IxdLFnWIwj" title="Concentration risk percentage">11% of total accounts receivable, respectively. Purchases. For the three months ended April 30, 2023, two vendors accounted for <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230201__20230430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchasesMember__srt--MajorCustomersAxis__custom--OneVendorMember_z6imFSprKdni" title="Concentration risk percentage">17% and <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230201__20230430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchasesMember__srt--MajorCustomersAxis__custom--TwoVendorMember_ziABpJOxxF1a" title="Concentration risk percentage">13% of our purchases, respectively. For the nine months ended April 30, 2023, one vendor accounted for <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220801__20230430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchasesMember__srt--MajorCustomersAxis__custom--OneVendorMember_zlW6nC0wneg1" title="Concentration risk percentage">19% of our purchases. For the three months ended April 30, 2022, two vendors accounted for <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220201__20220430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchasesMember__srt--MajorCustomersAxis__custom--OneVendorMember_z0QPbJr8BIvd" title="Concentration risk percentage">26% and <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220201__20220430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchasesMember__srt--MajorCustomersAxis__custom--TwoVendorMember_zuJIfAxfFI67" title="Concentration risk percentage">12% of our purchases, respectively. For the nine months ended April 30, 2022, one vendor accounted for <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210801__20220430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchasesMember__srt--MajorCustomersAxis__custom--OneVendorMember_z8gkXYZwe5y4" title="Concentration risk percentage">21% of our purchases. Accounts payable. As of April 30, 2023, our largest vendor accounted for <span id="xdx_901_ecustom--ConcentrationRiskThresholdPercentage_pid_dp_uPure_c20220801__20230430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--AccountsPayablesMember__srt--MajorCustomersAxis__custom--VendorOneMember_z5GMWNrVlFNa" title="Concentration risk threshold percentage">20% of the total accounts payable. As of April 30, 2022, our largest vendor accounted for<span id="xdx_902_ecustom--ConcentrationRiskThresholdPercentage_pid_dp_uPure_c20210801__20220430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--AccountsPayablesMember__srt--MajorCustomersAxis__custom--VendorMember_zbaD9QMe6Mhk" title="Concentration risk threshold percentage"> 25% of the total trade accounts payable. Segments We operate in one segment for the manufacture and distribution of our products. In accordance with the “Segment Reporting” Topic of the ASC, our chief operating decision maker has been identified as the Chief Executive Officer and President, who reviews operating results to make decisions about allocating resources and assessing performance for the entire Company. Existing guidance, which is based on a management approach to segment reporting, establishes requirements to report selected segment information quarterly and to report annually entity-wide disclosures about products and services, major customers, and the countries in which the entity holds material assets and reports revenue. All material operating units qualify for aggregation under “Segment Reporting” due to their similar customer base and similarities in: economic characteristics; nature of products and services; and procurement, manufacturing and distribution processes. Since the Company operates in one segment, all financial information required by “Segment Reporting” can be found in the accompanying financial statements.

Revenue Recognition We account for revenue in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”), Topic 606, Revenue from Contracts with Customers (“Topic 606”). Under Topic 606, revenue is recognized at an amount that reflects the consideration to which we expect to be entitled in exchange for transferring goods or services to a customer. This principle is applied using the following 5-step process: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">1.</td> <td style="font: 10pt Times New Roman, Times, Serif">Identify the contract with the customer</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">2.</td> <td style="font: 10pt Times New Roman, Times, Serif">Identify the performance obligations in the contract</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">3.</td> <td style="font: 10pt Times New Roman, Times, Serif">Determine the transaction price</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">4.</td> <td style="font: 10pt Times New Roman, Times, Serif">Allocate the transaction price to the performance obligations in the contract</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">5.</td> <td style="font: 10pt Times New Roman, Times, Serif">Recognize revenue when (or as) each performance obligation is satisfied</td></tr> </table> Under Topic 606, we recognize revenue when we satisfy a performance obligation by transferring control of the promised goods or services to our customers, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. Our technology platform is based on patented stabilized ionic silver, and our initial products contain silver dihydrogen citrate, or SDC. SDC is a broad-spectrum, non-toxic antimicrobial agent, which offers 24-hour residual protection and formulates well with other compounds. We sell various configurations and dilutions of SDC direct to customers and through distributors. We currently offer PURE® Hard Surface as a food contact surface sanitizer and disinfectant to restaurant chains, food processors and food transportation companies. We also offer PURE Control® as a direct food contact processing aid. Contract terms for unit price, quantity, shipping and payment are governed by sales agreements and purchase orders which we consider to be a customer’s contract in all cases. The unit price is considered the observable stand-alone selling price for the arrangements. Any promotional or sales discounts are applied evenly to the units sold for purposes of calculating standalone selling price. Product sales generally consist of a single performance obligation that we satisfy at a point in time. We recognize product revenue when the following events have occurred: (a) we have transferred physical possession of the products, (b) we have a present right to payment, (c) the customer has legal title to the products, and (d) the customer bears significant risks and rewards of ownership of the products. Our direct customer and distributor sales are invoiced based on received purchase orders. Our payment terms on invoiced direct customer and distributor sales range between 30 and 90 days after we satisfy our performance obligation. The majority of our customers are on 30 day payment terms. We currently offer no right of return on invoiced sales and maintain no allowance for sales returns. Shipping and handling are treated as activities to fulfill promises to customers and any amounts billed to a customer, if applicable, represent revenues earned for the goods provided. Costs related to such shipping and handling billings are classified as cost of sales. We do not have significant categories of revenue that may impact how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors. A summary of our revenue by product type for the nine months ended April 30, 2023 and 2022 is as follows: Summary of Revenue by Product <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"> <tr style="display: none; vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20220801__20230430_zf1kTLVCw034" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49D_20210801__20220430_z9tODVqSapjh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">April 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_401_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--PUREHardSurfaceMember_zPQyK5gy6DTc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left">PURE Hard Surface</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">1,184,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">1,158,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--SilVerionMember_zoXNsEJlD5fi" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">SILVÉRION</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">85,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">251,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--Revenues_zPP18VsNwADh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,269,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,409,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> A summary of our revenue by product type for the three months ended April 30, 2023 and 2022 is as follows: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"> <tr style="display: none; vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20230201__20230430_zV0R4lkZeYK4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20220201__20220430_zx1kAUEFCEM7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"/><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">April 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_409_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--PUREHardSurfaceMember_z18apF9Dhj5d" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left">PURE Hard Surface</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">406,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">352,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--SilVerionMember_zfN8aMG8amP3" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">SILVÉRION</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">—</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">145,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--Revenues_zmK5rb4zuUii" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">406,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">497,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Variable Consideration We record revenue from customers in an amount that reflects the transaction price we expect to be entitled to after transferring control of those goods or services. From time to time, we offer sales promotions on our products such as discounts. Variable consideration is estimated at contract inception only to the extent that it is probable that a significant reversal of revenue will not occur.

A summary of our revenue by product type for the nine months ended April 30, 2023 and 2022 is as follows: Summary of Revenue by Product <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"> <tr style="display: none; vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20220801__20230430_zf1kTLVCw034" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49D_20210801__20220430_z9tODVqSapjh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">April 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_401_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--PUREHardSurfaceMember_zPQyK5gy6DTc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left">PURE Hard Surface</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">1,184,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">1,158,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--SilVerionMember_zoXNsEJlD5fi" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">SILVÉRION</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">85,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">251,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--Revenues_zPP18VsNwADh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,269,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,409,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> A summary of our revenue by product type for the three months ended April 30, 2023 and 2022 is as follows: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"> <tr style="display: none; vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20230201__20230430_zV0R4lkZeYK4" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20220201__20220430_zx1kAUEFCEM7" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"/><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">April 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_409_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--PUREHardSurfaceMember_z18apF9Dhj5d" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left">PURE Hard Surface</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">406,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">352,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--Revenues_hsrt--ProductOrServiceAxis__custom--SilVerionMember_zfN8aMG8amP3" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">SILVÉRION</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">—</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">145,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--Revenues_zmK5rb4zuUii" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">406,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">497,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

1184000

1158000

85000

251000

1269000

1409000

406000

352000

145000

406000

497000

Use of Estimates The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, or GAAP, requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements, and the disclosures made in the accompanying notes to the consolidated financial statements. Actual results could differ materially from those estimates. Those estimates and assumptions include estimates for reserves of uncollectible accounts, inventory obsolescence, depreciable lives of property and equipment, analysis of impairments of recorded long-term tangible and intangible assets, realization of deferred tax assets, accruals for potential liabilities and assumptions made in valuing stock instruments issued for services.

Net Loss Per Share Basic net loss per common share is computed as net loss divided by the weighted average number of common shares outstanding for the period. Our diluted net loss per common share is the same as our basic net loss per common share because we incurred a net loss during each period presented, and the potentially dilutive securities from the assumed exercise of all outstanding stock options, restricted stock units, and warrants would have an anti-dilutive effect. As of April 30, 2023 and 2022, stock options and shares issuable under restricted stock unit awards of 7,913,125 and 7,391,625, respectively, have been excluded from the computation of diluted shares outstanding. <p id="xdx_899_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_z949pWioYY9e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> Schedule of Anti-dilutive Securities Excluded from Computation of earnings Per Share <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"> <tr style="display: none; vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_498_20220801__20230430_zduXUzJcZ7s8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_497_20210801__20220430_zPJ2vFEbjmU5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">April 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_40D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockOptionMember_zWqGKtUJP0H6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left">Common stock options</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 18%; text-align: right">6,700,625</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 18%; text-align: right">6,179,125</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_z748B5Y9hhc2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Restricted stock units</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,212,500</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,212,500</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zDbB0alYuIR1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">7,913,125</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">7,391,625</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

7913125

7391625

<p id="xdx_899_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_z949pWioYY9e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> Schedule of Anti-dilutive Securities Excluded from Computation of earnings Per Share <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"> <tr style="display: none; vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_498_20220801__20230430_zduXUzJcZ7s8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_497_20210801__20220430_zPJ2vFEbjmU5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">April 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_40D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__custom--CommonStockOptionMember_zWqGKtUJP0H6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left">Common stock options</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 18%; text-align: right">6,700,625</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 18%; text-align: right">6,179,125</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--RestrictedStockUnitsRSUMember_z748B5Y9hhc2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Restricted stock units</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,212,500</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,212,500</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_zDbB0alYuIR1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">7,913,125</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">7,391,625</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

6700625

6179125

1212500

7913125

7391625

Inventory Inventories are stated at the lower of cost or net realizable value, and net of a valuation allowance for potential excess or obsolete material. Cost is determined using the average cost method. Depreciation related to manufacturing is systematically allocated to inventory produced, and expensed through cost of goods sold at the time inventory is sold. Inventories consist of the following: Schedule of Inventories <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49C_20230430_zuQb7bICdldk" style="border-bottom: Black 1.5pt solid; text-align: center">April 30, 2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20220731_zCIT3jsRVlqf" style="border-bottom: Black 1.5pt solid; text-align: center">July 31, 2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_405_eus-gaap--InventoryRawMaterials_iI_maINzkyC_zpDVAbdXniP9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left">Raw materials</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">26,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">19,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--InventoryFinishedGoods_iI_maINzkyC_zZHN1FqDDhO4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Finished goods</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">123,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">160,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--InventoryNet_iTI_mtINzkyC_zCw67Zu9tT5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Inventories</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">149,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">179,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> During the three months ended April 30, 2023, the Company determined that an additional reserve for inventory obsolescence of $40,000 was required. As of April 30, 2023 and July 31, 2022, inventories are stated net of a reserve for inventory obsolescence of $265,000 and $225,000, respectively.

Inventories consist of the following: Schedule of Inventories <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 70%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49C_20230430_zuQb7bICdldk" style="border-bottom: Black 1.5pt solid; text-align: center">April 30, 2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20220731_zCIT3jsRVlqf" style="border-bottom: Black 1.5pt solid; text-align: center">July 31, 2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_405_eus-gaap--InventoryRawMaterials_iI_maINzkyC_zpDVAbdXniP9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 56%; text-align: left">Raw materials</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">26,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">19,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--InventoryFinishedGoods_iI_maINzkyC_zZHN1FqDDhO4" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Finished goods</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">123,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">160,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--InventoryNet_iTI_mtINzkyC_zCw67Zu9tT5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Inventories</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">149,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">179,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

26000

19000

123000

160000

149000

179000

40000

265000

225000

Share-Based Compensation We periodically issue stock options and restricted stock awards to employees and non-employees in non-capital raising transactions for services and for financing costs. We account for such grants issued and vesting to employees based on ASC 718, whereby the value of the award is measured on the date of grant and recognized as compensation expense on the straight-line basis over the vesting period. We estimate the fair value of share-based payment awards at the date of grant using the Black-Scholes option valuation model. The Black-Scholes option valuation model requires the input of subjective assumptions, including price volatility of the underlying stock, risk-free interest rate, dividend yield, and expected life of the option. Share-based compensation expense is based on awards ultimately expected to vest, and therefore is reduced by expected forfeitures.

Concentrations Gross product sales. For the three months ended April 30, 2023, one individual customer accounted for <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230201__20230430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--IndividualCustomerOneMember_zRLcNvbWfi9c" title="Concentration risk percentage">39% of our net product sales. For the nine months ended April 30, 2023, one customer accounted for <span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220801__20230430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--IndividualCustomerOneMember_zThxz7lhKu76" title="Concentration risk percentage">20% of our net product sales. For the three months ended April 30, 2022, three individual customers accounted for <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220201__20220430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--IndividualCustomerOneMember_zh8LjOlgRPh5" title="Concentration risk percentage">29%, <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220201__20220430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--IndividualCustomerTwoMember_zGHrmAnMnFK8" title="Concentration risk percentage">14% and <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220201__20220430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--IndividualCustomerThreeMember_z2aLdCPIBLA5" title="Concentration risk percentage">11% of our net product sales, respectively. For the nine months ended April 30, 2022, three customers accounted for <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210801__20220430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--IndividualCustomerOneMember_zciXy3htHD49" title="Concentration risk percentage">14%, <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210801__20220430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--IndividualCustomerTwoMember_z1M6XmBoM3t9" title="Concentration risk percentage">12% and <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210801__20220430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--IndividualCustomerThreeMember_z1bbthkfy5Lb" title="Concentration risk percentage">10% of our net product sales, respectively. Accounts receivable. As of April 30, 2023, we had accounts receivable from two customers that comprised of <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220801__20230430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerOneMember_ztm6Npf8trig" title="Concentration risk percentage">36% and <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220801__20230430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerTwoMember_zHY18p6lszI5" title="Concentration risk percentage">13% of total accounts receivable, respectively. As of April 30, 2022, we had accounts receivable from four customers that comprised of <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210801__20220430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerOneMember_z796zHJCnR6a" title="Concentration risk percentage">15%, <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210801__20220430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerTwoMember_ztWgxavuvZb6" title="Concentration risk percentage">14%, <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210801__20220430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerThreeMember_zSNHw2keG2vf" title="Concentration risk percentage">12% and <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210801__20220430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerFourMember_z2IxdLFnWIwj" title="Concentration risk percentage">11% of total accounts receivable, respectively. Purchases. For the three months ended April 30, 2023, two vendors accounted for <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230201__20230430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchasesMember__srt--MajorCustomersAxis__custom--OneVendorMember_z6imFSprKdni" title="Concentration risk percentage">17% and <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230201__20230430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchasesMember__srt--MajorCustomersAxis__custom--TwoVendorMember_ziABpJOxxF1a" title="Concentration risk percentage">13% of our purchases, respectively. For the nine months ended April 30, 2023, one vendor accounted for <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220801__20230430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchasesMember__srt--MajorCustomersAxis__custom--OneVendorMember_zlW6nC0wneg1" title="Concentration risk percentage">19% of our purchases. For the three months ended April 30, 2022, two vendors accounted for <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220201__20220430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchasesMember__srt--MajorCustomersAxis__custom--OneVendorMember_z0QPbJr8BIvd" title="Concentration risk percentage">26% and <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220201__20220430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchasesMember__srt--MajorCustomersAxis__custom--TwoVendorMember_zuJIfAxfFI67" title="Concentration risk percentage">12% of our purchases, respectively. For the nine months ended April 30, 2022, one vendor accounted for <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210801__20220430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--PurchasesMember__srt--MajorCustomersAxis__custom--OneVendorMember_z8gkXYZwe5y4" title="Concentration risk percentage">21% of our purchases. Accounts payable. As of April 30, 2023, our largest vendor accounted for <span id="xdx_901_ecustom--ConcentrationRiskThresholdPercentage_pid_dp_uPure_c20220801__20230430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--AccountsPayablesMember__srt--MajorCustomersAxis__custom--VendorOneMember_z5GMWNrVlFNa" title="Concentration risk threshold percentage">20% of the total accounts payable. As of April 30, 2022, our largest vendor accounted for<span id="xdx_902_ecustom--ConcentrationRiskThresholdPercentage_pid_dp_uPure_c20210801__20220430__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--AccountsPayablesMember__srt--MajorCustomersAxis__custom--VendorMember_zbaD9QMe6Mhk" title="Concentration risk threshold percentage"> 25% of the total trade accounts payable.

0.39

0.20

0.29

0.14

0.11

0.14

0.12

0.10

0.36

0.13

0.15

0.14

0.12

0.11

0.17

0.13

0.19

0.26

0.12

0.21

0.20 0.25

Segments We operate in one segment for the manufacture and distribution of our products. In accordance with the “Segment Reporting” Topic of the ASC, our chief operating decision maker has been identified as the Chief Executive Officer and President, who reviews operating results to make decisions about allocating resources and assessing performance for the entire Company. Existing guidance, which is based on a management approach to segment reporting, establishes requirements to report selected segment information quarterly and to report annually entity-wide disclosures about products and services, major customers, and the countries in which the entity holds material assets and reports revenue. All material operating units qualify for aggregation under “Segment Reporting” due to their similar customer base and similarities in: economic characteristics; nature of products and services; and procurement, manufacturing and distribution processes. Since the Company operates in one segment, all financial information required by “Segment Reporting” can be found in the accompanying financial statements.

4. Recent Accounting Pronouncements In June 2016, the FASB issued ASU No. 2016-13, Credit Losses - Measurement of Credit Losses on Financial Instruments or ASC 326. The standard significantly changes how entities will measure credit losses for most financial assets, including accounts and notes receivable. The standard will replace today’s “incurred loss” approach with an “expected loss” model, under which companies will recognize allowances based on expected rather than incurred losses. Entities will apply the standard’s provisions as a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective. As small business filer, the standard will be effective for us for interim and annual reporting periods beginning after December 15, 2022. The Company is currently assessing the impact of adopting this standard on the Company’s financial statements and related disclosures. In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt — Modifications and Extinguishments (Subtopic 470-50), Compensation — Stock Compensation (Topic 718), and Derivatives and Hedging — Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options or ASU 2021-04. ASU 2021-04 provides guidance as to how an issuer should account for a modification of the terms or conditions or an exchange of a freestanding equity-classified written call option (i.e., a warrant) that remains classified after modification or exchange as an exchange of the original instrument for a new instrument. An issuer should measure the effect of a modification or exchange as the difference between the fair value of the modified or exchanged warrant and the fair value of that warrant immediately before modification or exchange and then apply a recognition model that comprises four categories of transactions and the corresponding accounting treatment for each category (equity issuance, debt origination, debt modification, and modifications unrelated to equity issuance and debt origination or modification). ASU 2021-04 is effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. The adoption of ASU 2021-04 did not have any impact on the Company’s consolidated financial statement presentation or disclosures. Recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statement presentation or disclosures.

5. Debt Receipt of CARES funding In April 2021, we were funded $<span id="xdx_90B_eus-gaap--ProceedsFromLoans_c20210401__20210430__us-gaap--CreditFacilityAxis__custom--CaliforniaBankAndTrustMember__us-gaap--DebtInstrumentAxis__custom--PaycheckProtectionProgramMember_zcSJ4mubEwA2" title="Net proceeds from payroll protection program loan">239,000 under the Payroll Protection Program (“PPP”) through California Bank and Trust. The PPP was established as part of the Coronavirus Aid, Relief and Economic Security Act (the “CARES Act”) and is administered by the U.S. Small Business Administration. <span id="xdx_906_eus-gaap--DebtInstrumentDescription_c20210401__20210430__us-gaap--CreditFacilityAxis__custom--CaliforniaBankAndTrustMember__us-gaap--DebtInstrumentAxis__custom--PaycheckProtectionProgramMember_zl6UzfehRBs1" title="Debt description">The CARES Act was established in order to enable small businesses to pay employees during the economic slowdown caused by COVID-19 by providing forgivable loans to qualifying businesses for up to 2.5 times their average monthly payroll costs. The amount borrowed under the CARES Act is eligible to be forgiven provided that (a) the Company uses the PPP Funds during the eight week period after receipt thereof, and (b) the PPP Funds are only used to cover payroll costs (including benefits), rent, mortgage interest, and utility costs. The amount of loan forgiveness will be reduced if, among other reasons, the Company does not maintain staffing or payroll levels. Principal and interest payments on any unforgiven portion of the PPP Funds (the “PPP Loan”) will be deferred for six months and will accrue interest at a fixed annual rate of <span id="xdx_907_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20210430__us-gaap--CreditFacilityAxis__custom--CaliforniaBankAndTrustMember__us-gaap--DebtInstrumentAxis__custom--PaycheckProtectionProgramMember_zXRELxxzEc6h" title="Debt instrument interest percentage">1.0% and carry a <span id="xdx_904_eus-gaap--DebtInstrumentTerm_dc_c20210401__20210430__us-gaap--CreditFacilityAxis__custom--CaliforniaBankAndTrustMember__us-gaap--DebtInstrumentAxis__custom--PaycheckProtectionProgramMember_z7BONujGqT9h" title="Debt instrument term">two year maturity date. There is no prepayment penalty on the CARES Act Loan. During the nine months ended April 30, 2022, we applied and received loan forgiveness under the provisions of the CARES Act for the entire $<span id="xdx_908_eus-gaap--ProceedsFromLoans_c20210801__20220430__us-gaap--CreditFacilityAxis__custom--CaliforniaBankAndTrustMember__us-gaap--DebtInstrumentAxis__custom--PaycheckProtectionProgramMember_zRPZCRQSDdne" title="Net proceeds from payroll protection program loan">239,000 loan. This amount was recorded as a gain on extinguishment of indebtedness on the Condensed Consolidated Statement of Operations during the nine months ended April 30, 2022.

239000

The CARES Act was established in order to enable small businesses to pay employees during the economic slowdown caused by COVID-19 by providing forgivable loans to qualifying businesses for up to 2.5 times their average monthly payroll costs. The amount borrowed under the CARES Act is eligible to be forgiven provided that (a) the Company uses the PPP Funds during the eight week period after receipt thereof, and (b) the PPP Funds are only used to cover payroll costs (including benefits), rent, mortgage interest, and utility costs

0.010

P2Y

239000

6. Stockholders’ Equity Restricted Stock Units We issue restricted stock unit awards or RSUs, to key management and as compensation for services to consultants and others. The RSUs typically vest over a one to three-year period and carry a ten-year term. Each RSU represents the right to receive one share of common stock, issuable at the time the RSU subsequently settles, as set forth in the Restricted Stock Unit Agreement. We determine that fair value of those awards at the date of grant, and amortize those awards as an expense over the vesting period of the award. The shares earned under the grant are usually issued when the award settles at the end of the term. As of July 31, 2022, there were <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20220731__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zWOK0o0DwUJe" title="Number of units, outstanding">1,212,500 RSU’s outstanding of which <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20220731__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--StatementScenarioAxis__custom--VestedAndIssuableMember_zsLBKlYSGWI" title="Number of units, issuable">1,045,833 were issuable. During the nine months ended April 30, 2023 and 2022, we recognized $62,000 of compensation cost relating to the vesting of RSU’s, respectively. As of April 30, 2023, there was <span id="xdx_900_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_do_c20230430__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_znA6l4VNRZTd" title="Unrecognized non-cash compensation costs">no unrecognized non-cash compensation cost related to the remaining <span id="xdx_90D_ecustom--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedRemainingShares_iI_pid_c20230430__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_ztqTTBxwOdDh" title="Number of restricted stock expected to vest">166,667 RSUs we expect to vest next quarter. During the nine months ended April 30, 2023, <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_doxL_c20220801__20230430__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z7P88nZX20Wi" title="Granted, shares::XDX::-"><span id="xdx_90D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod_doxL_c20220801__20230430__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zDikt6Vm3Tp2" title="Issued, shares::XDX::-"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_doxL_c20220801__20230430__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z26XIoKOY028" title="Forfeited, shares::XDX::-">no RSUs were granted, issued, or forfeited. Of the <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20230430__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zxR4y5DqqGQ5" title="Number of outstanding shares">1,212,500 RSUs outstanding as of April 30, 2023, <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_pid_c20230430__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--StatementScenarioAxis__custom--VestedAndIssuableMember_zgO3UOwGhYMl" title="Number of units, vested and issuable">1,045,833 RSUs are vested and issuable. <span id="xdx_90E_ecustom--RestrictedStockUnitsVestedDescription_c20220801__20230430__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zl236hiMBJ74" title="Restricted stock units vested description">These RSUs are issued upon settlement date which is defined as “for each Vested Unit, the earliest of (i) the ten-year anniversary of the Grant Date; (ii) sixty days after the date the Grantee’s Service ceases for any reason and such cessation constitutes a “separation from service” within the meaning of Section 409A of the Code; (iii) the date of Grantee’s death or (iv) the date of a Change in Control that constitutes a “change in control event” within the meaning of Section 409A of the Code”. <p id="xdx_89E_eus-gaap--ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_z7FLwVHaYtY5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A summary of our restricted stock unit activity and related data is as follows: Schedule of Restricted Stock Activity <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total RSU Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Vested and Issuable</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Outstanding at July 31, 2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20220801__20230430__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zgdkIA96Lpv2" style="width: 16%; text-align: right" title="Outstanding, Beginning balance">1,212,500</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20220801__20230430__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--StatementScenarioAxis__custom--VestedAndIssuableMember_zdLdXO0qcVO1" style="width: 16%; text-align: right" title="Outstanding, Beginning balance">1,045,833</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20220801__20230430__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zE6sKCo9Hasg" style="text-align: right" title="Granted">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20220801__20230430__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--StatementScenarioAxis__custom--VestedAndIssuableMember_zYVujllom2L" style="text-align: right" title="Granted">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Issued</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod_pid_c20220801__20230430__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zXNCFEwrVOL4" style="text-align: right" title="Issued">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod_c20220801__20230430__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--StatementScenarioAxis__custom--VestedAndIssuableMember_zSY0XlLrdoC7" style="text-align: right" title="Issued">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; padding-left: 10pt">Forfeited</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_pid_c20220801__20230430__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zwFJeVYJhGn2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Forfeited">—</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_pid_c20220801__20230430__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--StatementScenarioAxis__custom--VestedAndIssuableMember_zfvJFwEksvZ6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Forfeited">—</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Outstanding at April 30, 2023</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20220801__20230430__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zxw7gmYHeb75" style="border-bottom: Black 1.5pt solid; text-align: right" title="Outstanding, Ending balance">1,212,500</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20220801__20230430__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--StatementScenarioAxis__custom--VestedAndIssuableMember_zReGcATSQ032" style="border-bottom: Black 1.5pt solid; text-align: right" title="Outstanding, Ending balance">1,045,833</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> Stock Option Plans 2007 Equity Incentive Plan In February 2016, we amended and restated our 2007 Equity Incentive Plan, the (“2007 Plan”), to, among other changes, increase the number of shares of common stock issuable under the 2007 Plan by <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_pid_c20160201__20160229__us-gaap--PlanNameAxis__custom--TwoThousandAndSevenEquityIncentivePlanMember_zh4IvjcPQ7j1" title="Common stock shares increase under the plan">4,000,000 shares and extend the term of the 2007 Plan until <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate_dd_c20160201__20160229__us-gaap--PlanNameAxis__custom--TwoThousandAndSevenEquityIncentivePlanMember_zxg3SatYOXl5" title="Share-based compensation, expiration date">February 4, 2026. The 2007 Plan provides for the grant of incentive and non-qualified stock options, as well as other share-based payment awards, to our employees, directors, consultants and advisors. These awards have up to a <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtY_c20160201__20160229__us-gaap--PlanNameAxis__custom--TwoThousandAndSevenEquityIncentivePlanMember_zyedWERDnT79" title="Share-based compensation, vesting period">10-year contractual life and are subject to various vesting periods, as determined by the Compensation Committee of the Board of Directors. As of April 30, 2023, there were approximately <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20230430__us-gaap--PlanNameAxis__custom--TwoThousandAndSevenEquityIncentivePlanMember_zJTUZdt8zgsi" title="Number of shares available for issuance under the plan">970,000 shares available for issuance under the 2007 Plan. 2017 Equity Incentive Plan In January 2021, we amended and restated our 2017 Equity Incentive Plan, the (“2017 Plan”), to, among other changes, increase the number of shares of common stock issuable under the 2017 Plan by <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_pid_c20210101__20210131__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenEquityIncentivePlanMember_zCJeEGjlICOi" title="Common stock shares increase under the plan">5,000,000 shares and extend the term of the 2007 Plan until January 2031. The 2017 Plan provides for the grant of incentive and non-qualified stock options, as well as other share-based payment awards, to our employees, directors, consultants and advisors. These awards have up to a <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtY_c20210101__20210131__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenEquityIncentivePlanMember_zX4I3XEvEcY7" title="Share-based compensation, vesting period">10-year contractual life and are subject to various vesting periods, as determined by the Compensation Committee of the Board of Directors. As of April 30, 2023, there were approximately <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20230430__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenEquityIncentivePlanMember_zm4D9MZy3Eo2" title="Number of shares available for issuance under the plan">4,750,000 shares available for issuance under the 2017 Plan. During the nine months ended April 30, 2023, the Compensation Committee of the Board of Directors granted <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c20220801__20230430__srt--TitleOfIndividualAxis__custom--EmployeesOfficersDirectorsAndConsultantsMember__us-gaap--FinancialInstrumentAxis__us-gaap--StockOptionMember_zlpXi7VzaLLk" title="Options issued to purchase common stock">1,935,000 stock options to our employees, officers, directors and consultants with a fair value of $<span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_pp0p0_c20220801__20230430__srt--TitleOfIndividualAxis__custom--EmployeesOfficersDirectorsAndConsultantsMember__us-gaap--FinancialInstrumentAxis__us-gaap--StockOptionMember_z1gN4m4KlXSl" title="Fair value of options issued to purchase common stock">241,000 as determined by the Black Scholes option pricing model. <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20220801__20230430__srt--TitleOfIndividualAxis__custom--EmployeesOfficersDirectorsAndConsultantsMember__us-gaap--FinancialInstrumentAxis__us-gaap--StockOptionMember_z7LyyJb9dja4" title="Option vested description">The vesting terms of the options vary between one and two years and carry a ten year term. There were no stock options granted during the three months ended April 30, 2023. A summary of our stock option activity is as follows: Schedule of Stock Option Activity <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Shares</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted- Average Exercise Price</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Aggregate Intrinsic Value</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%">Outstanding at July 31, 2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220801__20230430__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenEquityIncentivePlanMember_zIWhyIMoQZJ6" style="width: 14%; text-align: right" title="Options Outstanding Shares, Beginning Balance">6,079,125</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220801__20230430__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenEquityIncentivePlanMember_zOwEsECdU1M3" style="width: 14%; text-align: right" title="Weighted- Average Exercise Price Outstanding, Beginning Balance">0.62</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iS_c20220801__20230430__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenEquityIncentivePlanMember_zNPIYfrb15Z3" style="width: 14%; text-align: right" title="Aggregate Intrinsic Value Outstanding, Beginning Balance">—</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220801__20230430__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenEquityIncentivePlanMember_zjsDJF5efMT4" style="text-align: right" title="Shares, Granted">1,935,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220801__20230430__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenEquityIncentivePlanMember_zriVBlL9kpu9" style="text-align: right" title="Weighted- Average Exercise Price, Granted">0.20</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20220801__20230430__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenEquityIncentivePlanMember_zNjR1b3341gi" style="text-align: right" title="Shares, Exercised">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20220801__20230430__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenEquityIncentivePlanMember_zwl6hP08kAgf" style="text-align: right" title="Weighted- Average Exercise Price, Exercised">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Expired</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20220801__20230430__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenEquityIncentivePlanMember_znzE9epZiBpk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Shares, Expired">(1,313,500</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20220801__20230430__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenEquityIncentivePlanMember_zx2nW4vbqlze" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted- Average Exercise Price, Expired">0.70</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">—</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding at April 30, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20220801__20230430__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenEquityIncentivePlanMember_zQo7oTqZJwAf" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Outstanding Shares, Beginning Balance">6,700,625</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20220801__20230430__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenEquityIncentivePlanMember_ziFGpyTKKacc" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted- Average Exercise Price Outstanding, Beginning Balance">0.48</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_c20220801__20230430__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenEquityIncentivePlanMember_zziMDvip2ZUg" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value Outstanding, Beginning Balance">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The weighted-average remaining contractual term of options outstanding at April 30, 2023 was <span id="xdx_90C_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220801__20230430_zAbcMwxY2Cs6" title="Weighted average contractual term">7.44 years. At April 30, 2023, options to purchase 5,831,458 shares of common stock were exercisable. These options had a weighted-average exercise price of $<span id="xdx_90D_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20230430_zp6VelZEJcf1" title="Weighted average exercise price">0.52 and a weighted average remaining contractual term of <span id="xdx_908_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_dtY_c20220801__20230430_zib7yLsc3tk7" title="Weighted average contractual term">7.12 years. For the nine months ended April 30, 2023 share-based compensation expense for stock options that vested during the period was $213,000. For the nine months ended April 30, 2022 share-based compensation expense for stock options that vested during the period was $431,000. The total unrecognized compensation cost related to unvested stock option grants as of April 30, 2023 was approximately $87,000 and the weighted average period over which these grants are expected to vest is <span id="xdx_906_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20220801__20230430_z786XisWCVFl" title="Unrecognized non-cash compensation costs for weighted average contractual term grants">0.58 years. We use the Black-Scholes valuation model to calculate the fair value of stock options. Stock-based compensation expense is recognized over the vesting period using the straight-line method. The fair value of stock options was estimated at the grant date using the following weighted average assumptions: Schedule of Fair Value Assumptions <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Nine Months Ended April 30, 2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Nine Months Ended April 30, 2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Volatility</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">91.90</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">88.35.</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.00</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1.17</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.0</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected life</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5.34 years</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5.59 years</td><td style="text-align: left"> </td></tr> </table> Volatility is the measure by which our stock price is expected to fluctuate during the expected term of an option. Volatility is derived from the historical daily change in the market price of our common stock, as we believe that historical volatility is the best indicator of future volatility. The risk-free interest rates used in the Black-Scholes calculations are based on the prevailing U.S. Treasury yield as determined by the U.S. Federal Reserve. We have never paid dividends on our common stock and do not anticipate paying dividends on our common stock in the foreseeable future. Accordingly, we have assumed no dividend yield for purposes of estimating the fair value of our share-based compensation. The expected life of options was estimated using the average between the contractual term and the vesting term of the options.

1212500

1045833

62000

166667

1212500

1045833

These RSUs are issued upon settlement date which is defined as “for each Vested Unit, the earliest of (i) the ten-year anniversary of the Grant Date; (ii) sixty days after the date the Grantee’s Service ceases for any reason and such cessation constitutes a “separation from service” within the meaning of Section 409A of the Code; (iii) the date of Grantee’s death or (iv) the date of a Change in Control that constitutes a “change in control event” within the meaning of Section 409A of the Code”.

<p id="xdx_89E_eus-gaap--ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_z7FLwVHaYtY5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A summary of our restricted stock unit activity and related data is as follows: Schedule of Restricted Stock Activity <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total RSU Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Vested and Issuable</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Outstanding at July 31, 2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20220801__20230430__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zgdkIA96Lpv2" style="width: 16%; text-align: right" title="Outstanding, Beginning balance">1,212,500</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_pid_c20220801__20230430__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--StatementScenarioAxis__custom--VestedAndIssuableMember_zdLdXO0qcVO1" style="width: 16%; text-align: right" title="Outstanding, Beginning balance">1,045,833</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20220801__20230430__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zE6sKCo9Hasg" style="text-align: right" title="Granted">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20220801__20230430__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--StatementScenarioAxis__custom--VestedAndIssuableMember_zYVujllom2L" style="text-align: right" title="Granted">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Issued</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod_pid_c20220801__20230430__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zXNCFEwrVOL4" style="text-align: right" title="Issued">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod_c20220801__20230430__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--StatementScenarioAxis__custom--VestedAndIssuableMember_zSY0XlLrdoC7" style="text-align: right" title="Issued">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; padding-left: 10pt">Forfeited</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_pid_c20220801__20230430__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zwFJeVYJhGn2" style="border-bottom: Black 1.5pt solid; text-align: right" title="Forfeited">—</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_pid_c20220801__20230430__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--StatementScenarioAxis__custom--VestedAndIssuableMember_zfvJFwEksvZ6" style="border-bottom: Black 1.5pt solid; text-align: right" title="Forfeited">—</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt">Outstanding at April 30, 2023</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20220801__20230430__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zxw7gmYHeb75" style="border-bottom: Black 1.5pt solid; text-align: right" title="Outstanding, Ending balance">1,212,500</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_pid_c20220801__20230430__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember__srt--StatementScenarioAxis__custom--VestedAndIssuableMember_zReGcATSQ032" style="border-bottom: Black 1.5pt solid; text-align: right" title="Outstanding, Ending balance">1,045,833</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table>

1212500

1045833

1212500

1045833

4000000

2026-02-04

P10Y

970000

5000000

P10Y

4750000

1935000

241000

The vesting terms of the options vary between one and two years and carry a ten year term

A summary of our stock option activity is as follows: Schedule of Stock Option Activity <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Shares</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted- Average Exercise Price</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Aggregate Intrinsic Value</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%">Outstanding at July 31, 2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220801__20230430__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenEquityIncentivePlanMember_zIWhyIMoQZJ6" style="width: 14%; text-align: right" title="Options Outstanding Shares, Beginning Balance">6,079,125</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20220801__20230430__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenEquityIncentivePlanMember_zOwEsECdU1M3" style="width: 14%; text-align: right" title="Weighted- Average Exercise Price Outstanding, Beginning Balance">0.62</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iS_c20220801__20230430__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenEquityIncentivePlanMember_zNPIYfrb15Z3" style="width: 14%; text-align: right" title="Aggregate Intrinsic Value Outstanding, Beginning Balance">—</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220801__20230430__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenEquityIncentivePlanMember_zjsDJF5efMT4" style="text-align: right" title="Shares, Granted">1,935,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20220801__20230430__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenEquityIncentivePlanMember_zriVBlL9kpu9" style="text-align: right" title="Weighted- Average Exercise Price, Granted">0.20</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_c20220801__20230430__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenEquityIncentivePlanMember_zNjR1b3341gi" style="text-align: right" title="Shares, Exercised">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20220801__20230430__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenEquityIncentivePlanMember_zwl6hP08kAgf" style="text-align: right" title="Weighted- Average Exercise Price, Exercised">—</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">—</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Expired</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_c20220801__20230430__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenEquityIncentivePlanMember_znzE9epZiBpk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Shares, Expired">(1,313,500</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20220801__20230430__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenEquityIncentivePlanMember_zx2nW4vbqlze" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted- Average Exercise Price, Expired">0.70</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">—</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding at April 30, 2023</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20220801__20230430__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenEquityIncentivePlanMember_zQo7oTqZJwAf" style="border-bottom: Black 2.5pt double; text-align: right" title="Options Outstanding Shares, Beginning Balance">6,700,625</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20220801__20230430__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenEquityIncentivePlanMember_ziFGpyTKKacc" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted- Average Exercise Price Outstanding, Beginning Balance">0.48</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_c20220801__20230430__us-gaap--PlanNameAxis__custom--TwoThousandSeventeenEquityIncentivePlanMember_zziMDvip2ZUg" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate Intrinsic Value Outstanding, Beginning Balance">—</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

6079125

0.62

1935000

0.20

1313500

0.70

6700625

0.48

P7Y5M8D

5831458

0.52

P7Y1M13D

213000

431000

87000

P0Y6M29D

Schedule of Fair Value Assumptions <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Nine Months Ended April 30, 2023</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Nine Months Ended April 30, 2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%">Volatility</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">91.90</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">88.35.</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4.00</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1.17</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Dividend yield</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">0.0</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Expected life</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5.34 years</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5.59 years</td><td style="text-align: left"> </td></tr> </table>

0.9190

0.8835

0.0400

0.0117

0.000

P5Y4M2D

P5Y7M2D

7. Related Party Transactions As of April 30, 2023 and April 30, 2022, <span id="xdx_906_eus-gaap--OtherLiabilityCurrentRelatedAndNonrelatedPartyStatusExtensibleEnumeration_iI_dxL_c20230430_zU2i7hJtNPpf" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2023%23RelatedPartyMember"><span id="xdx_90C_eus-gaap--OtherLiabilityCurrentRelatedAndNonrelatedPartyStatusExtensibleEnumeration_iI_dxL_c20220430_zF7aJbUWgTP3" title="::XDX::http%3A%2F%2Ffasb.org%2Fus-gaap%2F2023%23RelatedPartyMember">accounts payable include $93,000 and $136,000 in board fees due to officers and directors, respectively.

93000

136000

8. Commitments and Contingencies COVID-19[done] The COVID-19 pandemic led to severe disruptions in general economic activities, as businesses and federal, state, and local governments took broad actions to mitigate this public health crisis. While we have experienced some delays related to final third-party validation of certain of our products and product rollouts by customers using PURE Control, we did not experience a material disruption to our business. In addition, we previously benefited from increased demand from our customers for our PURE Hard Surface product due to a focus on surface disinfecting in response to attempting to prevent COVID-19 transmission. We subsequently experienced an abatement in such demand. Such abatement has not stabilized and we cannot assure you that demand will stabilize in the future. Additionally, we experienced supply chain issues with our various plastic packaging configurations and citric acid. Further, on a go-forward basis, we cannot guarantee the overall economic conditions will not affect our business, as these conditions may significantly negatively impact all aspects of our business. Our business is dependent on the continued health and productivity of our employees, including our sales staff and corporate management team. The extent to which the COVID-19 pandemic or other health-related pandemics impacts our business, sales, results of operations and financial condition will depend on future developments, which are highly uncertain and cannot be predicted. Even after the COVID-19 pandemic or other health-related pandemics has subsided, we may experience significant impacts to our business as a result of its global economic impact, including any economic downturn or recession that has occurred or may occur in the future.

EXCEL 40 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 42 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 43 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 100 156 1 false 33 0 false 5 false false R1.htm 00000001 - Document - Cover Sheet http://purebio.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - Condensed Consolidated Balance Sheets Sheet http://purebio.com/role/BalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://purebio.com/role/BalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://purebio.com/role/StatementsOfOperations Condensed Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Condensed Consolidated Statement of Stockholders' Equity (Unaudited) Sheet http://purebio.com/role/StatementOfStockholdersEquity Condensed Consolidated Statement of Stockholders' Equity (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://purebio.com/role/StatementsOfCashFlows Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 00000007 - Disclosure - Basis of Presentation Sheet http://purebio.com/role/BasisOfPresentation Basis of Presentation Notes 7 false false R8.htm 00000008 - Disclosure - Liquidity and Going Concern Sheet http://purebio.com/role/LiquidityAndGoingConcern Liquidity and Going Concern Notes 8 false false R9.htm 00000009 - Disclosure - Significant Accounting Policies Sheet http://purebio.com/role/SignificantAccountingPolicies Significant Accounting Policies Notes 9 false false R10.htm 00000010 - Disclosure - Recent Accounting Pronouncements Sheet http://purebio.com/role/RecentAccountingPronouncements Recent Accounting Pronouncements Notes 10 false false R11.htm 00000011 - Disclosure - Debt Sheet http://purebio.com/role/Debt Debt Notes 11 false false R12.htm 00000012 - Disclosure - Stockholders??? Equity Sheet http://purebio.com/role/StockholdersEquity Stockholders??? Equity Notes 12 false false R13.htm 00000013 - Disclosure - Related Party Transactions Sheet http://purebio.com/role/RelatedPartyTransactions Related Party Transactions Notes 13 false false R14.htm 00000014 - Disclosure - Commitments and Contingencies Sheet http://purebio.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 14 false false R15.htm 00000015 - Disclosure - Significant Accounting Policies (Policies) Sheet http://purebio.com/role/SignificantAccountingPoliciesPolicies Significant Accounting Policies (Policies) Policies http://purebio.com/role/SignificantAccountingPolicies 15 false false R16.htm 00000016 - Disclosure - Significant Accounting Policies (Tables) Sheet http://purebio.com/role/SignificantAccountingPoliciesTables Significant Accounting Policies (Tables) Tables http://purebio.com/role/SignificantAccountingPolicies 16 false false R17.htm 00000017 - Disclosure - Stockholders??? Equity (Tables) Sheet http://purebio.com/role/StockholdersEquityTables Stockholders??? Equity (Tables) Tables http://purebio.com/role/StockholdersEquity 17 false false R18.htm 00000018 - Disclosure - Liquidity and Going Concern (Details Narrative) Sheet http://purebio.com/role/LiquidityAndGoingConcernDetailsNarrative Liquidity and Going Concern (Details Narrative) Details http://purebio.com/role/LiquidityAndGoingConcern 18 false false R19.htm 00000019 - Disclosure - Summary of Revenue by Product (Details) Sheet http://purebio.com/role/SummaryOfRevenueByProductDetails Summary of Revenue by Product (Details) Details 19 false false R20.htm 00000020 - Disclosure - Schedule of Anti-dilutive Securities Excluded from Computation of earnings Per Share (Details) Sheet http://purebio.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails Schedule of Anti-dilutive Securities Excluded from Computation of earnings Per Share (Details) Details 20 false false R21.htm 00000021 - Disclosure - Schedule of Inventories (Details) Sheet http://purebio.com/role/ScheduleOfInventoriesDetails Schedule of Inventories (Details) Details 21 false false R22.htm 00000022 - Disclosure - Significant Accounting Policies (Details Narrative) Sheet http://purebio.com/role/SignificantAccountingPoliciesDetailsNarrative Significant Accounting Policies (Details Narrative) Details http://purebio.com/role/SignificantAccountingPoliciesTables 22 false false R23.htm 00000023 - Disclosure - Debt (Details Narrative) Sheet http://purebio.com/role/DebtDetailsNarrative Debt (Details Narrative) Details http://purebio.com/role/Debt 23 false false R24.htm 00000024 - Disclosure - Schedule of Restricted Stock Activity (Details) Sheet http://purebio.com/role/ScheduleOfRestrictedStockActivityDetails Schedule of Restricted Stock Activity (Details) Details 24 false false R25.htm 00000025 - Disclosure - Schedule of Stock Option Activity (Details) Sheet http://purebio.com/role/ScheduleOfStockOptionActivityDetails Schedule of Stock Option Activity (Details) Details 25 false false R26.htm 00000026 - Disclosure - Schedule of Fair Value Assumptions (Details) Sheet http://purebio.com/role/ScheduleOfFairValueAssumptionsDetails Schedule of Fair Value Assumptions (Details) Details 26 false false R27.htm 00000027 - Disclosure - Stockholders??? Equity (Details Narrative) Sheet http://purebio.com/role/StockholdersEquityDetailsNarrative Stockholders??? Equity (Details Narrative) Details http://purebio.com/role/StockholdersEquityTables 27 false false R28.htm 00000028 - Disclosure - Related Party Transactions (Details Narrative) Sheet http://purebio.com/role/RelatedPartyTransactionsDetailsNarrative Related Party Transactions (Details Narrative) Details http://purebio.com/role/RelatedPartyTransactions 28 false false All Reports Book All Reports form10-q.htm ex31-1.htm ex31-2.htm ex32-1.htm ex32-2.htm pure-20230430.xsd pure-20230430_cal.xml pure-20230430_def.xml pure-20230430_lab.xml pure-20230430_pre.xml http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 true true JSON 45 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form10-q.htm": { "axisCustom": 0, "axisStandard": 13, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 438, "http://xbrl.sec.gov/dei/2023": 26 }, "contextCount": 100, "dts": { "calculationLink": { "local": [ "pure-20230430_cal.xml" ] }, "definitionLink": { "local": [ "pure-20230430_def.xml" ] }, "inline": { "local": [ "form10-q.htm" ] }, "labelLink": { "local": [ "pure-20230430_lab.xml" ] }, "presentationLink": { "local": [ "pure-20230430_pre.xml" ] }, "schema": { "local": [ "pure-20230430.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 282, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2023": 60, "http://purebio.com/20230430": 3, "http://xbrl.sec.gov/dei/2023": 5, "total": 68 }, "keyCustom": 5, "keyStandard": 151, "memberCustom": 22, "memberStandard": 10, "nsprefix": "PURE", "nsuri": "http://purebio.com/20230430", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-08-01to2023-04-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://purebio.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-08-01to2023-04-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-08-01to2023-04-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000010 - Disclosure - Recent Accounting Pronouncements", "menuCat": "Notes", "order": "10", "role": "http://purebio.com/role/RecentAccountingPronouncements", "shortName": "Recent Accounting Pronouncements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-08-01to2023-04-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-08-01to2023-04-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000011 - Disclosure - Debt", "menuCat": "Notes", "order": "11", "role": "http://purebio.com/role/Debt", "shortName": "Debt", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-08-01to2023-04-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-08-01to2023-04-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000012 - Disclosure - Stockholders\u2019 Equity", "menuCat": "Notes", "order": "12", "role": "http://purebio.com/role/StockholdersEquity", "shortName": "Stockholders\u2019 Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-08-01to2023-04-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-08-01to2023-04-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000013 - Disclosure - Related Party Transactions", "menuCat": "Notes", "order": "13", "role": "http://purebio.com/role/RelatedPartyTransactions", "shortName": "Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-08-01to2023-04-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-08-01to2023-04-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000014 - Disclosure - Commitments and Contingencies", "menuCat": "Notes", "order": "14", "role": "http://purebio.com/role/CommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-08-01to2023-04-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-08-01to2023-04-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000015 - Disclosure - Significant Accounting Policies (Policies)", "menuCat": "Policies", "order": "15", "role": "http://purebio.com/role/SignificantAccountingPoliciesPolicies", "shortName": "Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-08-01to2023-04-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-08-01to2023-04-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfProductInformationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000016 - Disclosure - Significant Accounting Policies (Tables)", "menuCat": "Tables", "order": "16", "role": "http://purebio.com/role/SignificantAccountingPoliciesTables", "shortName": "Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-08-01to2023-04-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfProductInformationTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-08-01to2023-04-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000017 - Disclosure - Stockholders\u2019 Equity (Tables)", "menuCat": "Tables", "order": "17", "role": "http://purebio.com/role/StockholdersEquityTables", "shortName": "Stockholders\u2019 Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-08-01to2023-04-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-04-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000018 - Disclosure - Liquidity and Going Concern (Details Narrative)", "menuCat": "Details", "order": "18", "role": "http://purebio.com/role/LiquidityAndGoingConcernDetailsNarrative", "shortName": "Liquidity and Going Concern (Details Narrative)", "subGroupType": "details", "uniqueAnchor": null }, "R19": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfProductInformationTableTextBlock", "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-02-012023-04-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000019 - Disclosure - Summary of Revenue by Product (Details)", "menuCat": "Details", "order": "19", "role": "http://purebio.com/role/SummaryOfRevenueByProductDetails", "shortName": "Summary of Revenue by Product (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfProductInformationTableTextBlock", "us-gaap:RevenueFromContractWithCustomerPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-02-012023-04-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-04-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000002 - Statement - Condensed Consolidated Balance Sheets", "menuCat": "Statements", "order": "2", "role": "http://purebio.com/role/BalanceSheets", "shortName": "Condensed Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-04-30", "decimals": "0", "lang": null, "name": "us-gaap:AccountsReceivableNetCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-08-01to2023-04-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000020 - Disclosure - Schedule of Anti-dilutive Securities Excluded from Computation of earnings Per Share (Details)", "menuCat": "Details", "order": "20", "role": "http://purebio.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails", "shortName": "Schedule of Anti-dilutive Securities Excluded from Computation of earnings Per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-08-012023-04-30_custom_CommonStockOptionMember", "decimals": "INF", "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-04-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterials", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000021 - Disclosure - Schedule of Inventories (Details)", "menuCat": "Details", "order": "21", "role": "http://purebio.com/role/ScheduleOfInventoriesDetails", "shortName": "Schedule of Inventories (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-04-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterials", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-08-01to2023-04-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000022 - Disclosure - Significant Accounting Policies (Details Narrative)", "menuCat": "Details", "order": "22", "role": "http://purebio.com/role/SignificantAccountingPoliciesDetailsNarrative", "shortName": "Significant Accounting Policies (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:InventoryPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-07-31", "decimals": "0", "lang": null, "name": "us-gaap:InventoryAdjustments", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-04-012021-04-30_custom_CaliforniaBankAndTrustMember_custom_PaycheckProtectionProgramMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProceedsFromLoans", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000023 - Disclosure - Debt (Details Narrative)", "menuCat": "Details", "order": "23", "role": "http://purebio.com/role/DebtDetailsNarrative", "shortName": "Debt (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2021-04-012021-04-30_custom_CaliforniaBankAndTrustMember_custom_PaycheckProtectionProgramMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProceedsFromLoans", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-07-31_us-gaap_RestrictedStockUnitsRSUMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000024 - Disclosure - Schedule of Restricted Stock Activity (Details)", "menuCat": "Details", "order": "24", "role": "http://purebio.com/role/ScheduleOfRestrictedStockActivityDetails", "shortName": "Schedule of Restricted Stock Activity (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R25": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-07-31_custom_TwoThousandSeventeenEquityIncentivePlanMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000025 - Disclosure - Schedule of Stock Option Activity (Details)", "menuCat": "Details", "order": "25", "role": "http://purebio.com/role/ScheduleOfStockOptionActivityDetails", "shortName": "Schedule of Stock Option Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2022-07-31_custom_TwoThousandSeventeenEquityIncentivePlanMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-08-01to2023-04-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000026 - Disclosure - Schedule of Fair Value Assumptions (Details)", "menuCat": "Details", "order": "26", "role": "http://purebio.com/role/ScheduleOfFairValueAssumptionsDetails", "shortName": "Schedule of Fair Value Assumptions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-08-01to2023-04-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-08-01to2023-04-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000027 - Disclosure - Stockholders\u2019 Equity (Details Narrative)", "menuCat": "Details", "order": "27", "role": "http://purebio.com/role/StockholdersEquityDetailsNarrative", "shortName": "Stockholders\u2019 Equity (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-08-01to2023-04-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-04-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OtherLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000028 - Disclosure - Related Party Transactions (Details Narrative)", "menuCat": "Details", "order": "28", "role": "http://purebio.com/role/RelatedPartyTransactionsDetailsNarrative", "shortName": "Related Party Transactions (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-04-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OtherLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-04-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "menuCat": "Statements", "order": "3", "role": "http://purebio.com/role/BalanceSheetsParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2023-04-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-02-012023-04-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)", "menuCat": "Statements", "order": "4", "role": "http://purebio.com/role/StatementsOfOperations", "shortName": "Condensed Consolidated Statements of Operations (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-02-012023-04-30", "decimals": "0", "lang": null, "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-07-31_us-gaap_CommonStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000005 - Statement - Condensed Consolidated Statement of Stockholders' Equity (Unaudited)", "menuCat": "Statements", "order": "5", "role": "http://purebio.com/role/StatementOfStockholdersEquity", "shortName": "Condensed Consolidated Statement of Stockholders' Equity (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "AsOf2021-07-31_us-gaap_CommonStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2023-02-012023-04-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "menuCat": "Statements", "order": "6", "role": "http://purebio.com/role/StatementsOfCashFlows", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-08-01to2023-04-30", "decimals": "0", "lang": null, "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-08-01to2023-04-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000007 - Disclosure - Basis of Presentation", "menuCat": "Notes", "order": "7", "role": "http://purebio.com/role/BasisOfPresentation", "shortName": "Basis of Presentation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-08-01to2023-04-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-08-01to2023-04-30", "decimals": null, "first": true, "lang": "en-US", "name": "PURE:LiquidityAndGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000008 - Disclosure - Liquidity and Going Concern", "menuCat": "Notes", "order": "8", "role": "http://purebio.com/role/LiquidityAndGoingConcern", "shortName": "Liquidity and Going Concern", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-08-01to2023-04-30", "decimals": null, "first": true, "lang": "en-US", "name": "PURE:LiquidityAndGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-08-01to2023-04-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000009 - Disclosure - Significant Accounting Policies", "menuCat": "Notes", "order": "9", "role": "http://purebio.com/role/SignificantAccountingPolicies", "shortName": "Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-q.htm", "contextRef": "From2022-08-01to2023-04-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 33, "tag": { "PURE_AccountsPayablesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accounts Payable [Member]", "label": "Accounts Payable [Member]" } } }, "localname": "AccountsPayablesMember", "nsuri": "http://purebio.com/20230430", "presentation": [ "http://purebio.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "PURE_CaliforniaBankAndTrustMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "California Bank and Trust [Member]", "label": "California Bank and Trust [Member]" } } }, "localname": "CaliforniaBankAndTrustMember", "nsuri": "http://purebio.com/20230430", "presentation": [ "http://purebio.com/role/DebtDetailsNarrative" ], "xbrltype": "domainItemType" }, "PURE_CommonStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common Stock Option [Member]", "label": "Common Stock Option [Member]" } } }, "localname": "CommonStockOptionMember", "nsuri": "http://purebio.com/20230430", "presentation": [ "http://purebio.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "domainItemType" }, "PURE_ConcentrationRiskThresholdPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Concentration risk threshold percentage.", "label": "Concentration risk threshold percentage" } } }, "localname": "ConcentrationRiskThresholdPercentage", "nsuri": "http://purebio.com/20230430", "presentation": [ "http://purebio.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "percentItemType" }, "PURE_CustomerFourMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer Four [Member]", "label": "Customer Four [Member]" } } }, "localname": "CustomerFourMember", "nsuri": "http://purebio.com/20230430", "presentation": [ "http://purebio.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "PURE_CustomerOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer One [Member]", "label": "Customer One [Member]" } } }, "localname": "CustomerOneMember", "nsuri": "http://purebio.com/20230430", "presentation": [ "http://purebio.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "PURE_CustomerThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer Three [Member]", "label": "Customer Three [Member]" } } }, "localname": "CustomerThreeMember", "nsuri": "http://purebio.com/20230430", "presentation": [ "http://purebio.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "PURE_CustomerTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer Two [Member]", "label": "Customer Two [Member]" } } }, "localname": "CustomerTwoMember", "nsuri": "http://purebio.com/20230430", "presentation": [ "http://purebio.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "PURE_DisclosureLiquidityAndGoingConcernAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liquidity And Going Concern" } } }, "localname": "DisclosureLiquidityAndGoingConcernAbstract", "nsuri": "http://purebio.com/20230430", "xbrltype": "stringItemType" }, "PURE_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedRemainingShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Employee service share based compensation nonvested awards total compensation cost not yet recognized remaining shares.", "label": "Number of restricted stock expected to vest" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedRemainingShares", "nsuri": "http://purebio.com/20230430", "presentation": [ "http://purebio.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "PURE_EmployeesOfficersDirectorsAndConsultantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Employees Officers Directors And Consultants [Member]", "label": "Employees Officers Directors and Consultants [Member]" } } }, "localname": "EmployeesOfficersDirectorsAndConsultantsMember", "nsuri": "http://purebio.com/20230430", "presentation": [ "http://purebio.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "PURE_IndividualCustomerOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Individual Customer One [Member]", "label": "Individual Customer One [Member]" } } }, "localname": "IndividualCustomerOneMember", "nsuri": "http://purebio.com/20230430", "presentation": [ "http://purebio.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "PURE_IndividualCustomerThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Individual Customer Three [Member]", "label": "Individual Customer Three [Member]" } } }, "localname": "IndividualCustomerThreeMember", "nsuri": "http://purebio.com/20230430", "presentation": [ "http://purebio.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "PURE_IndividualCustomerTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Individual Customer Two [Member]", "label": "Individual Customer Two [Member]" } } }, "localname": "IndividualCustomerTwoMember", "nsuri": "http://purebio.com/20230430", "presentation": [ "http://purebio.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "PURE_LiquidityAndGoingConcernTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Liquidity And Going Concern [Text Block]", "label": "Liquidity and Going Concern" } } }, "localname": "LiquidityAndGoingConcernTextBlock", "nsuri": "http://purebio.com/20230430", "presentation": [ "http://purebio.com/role/LiquidityAndGoingConcern" ], "xbrltype": "textBlockItemType" }, "PURE_OneVendorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "One Vendor [Member]", "label": "One Vendor [Member]" } } }, "localname": "OneVendorMember", "nsuri": "http://purebio.com/20230430", "presentation": [ "http://purebio.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "PURE_PUREHardSurfaceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "PURE Hard Surface [Member]", "label": "PURE Hard Surface [Member]" } } }, "localname": "PUREHardSurfaceMember", "nsuri": "http://purebio.com/20230430", "presentation": [ "http://purebio.com/role/SummaryOfRevenueByProductDetails" ], "xbrltype": "domainItemType" }, "PURE_PaycheckProtectionProgramMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Paycheck Protection Program [Member]", "label": "Paycheck Protection Program [Member]" } } }, "localname": "PaycheckProtectionProgramMember", "nsuri": "http://purebio.com/20230430", "presentation": [ "http://purebio.com/role/DebtDetailsNarrative" ], "xbrltype": "domainItemType" }, "PURE_PurchasesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchases [Member]", "label": "Purchases [Member]" } } }, "localname": "PurchasesMember", "nsuri": "http://purebio.com/20230430", "presentation": [ "http://purebio.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "PURE_RestrictedStockUnitsVestedDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Restricted stock units vested description.", "label": "Restricted stock units vested description" } } }, "localname": "RestrictedStockUnitsVestedDescription", "nsuri": "http://purebio.com/20230430", "presentation": [ "http://purebio.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "PURE_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options issued in period.", "label": "Issued", "verboseLabel": "Issued, shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod", "nsuri": "http://purebio.com/20230430", "presentation": [ "http://purebio.com/role/ScheduleOfRestrictedStockActivityDetails", "http://purebio.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "PURE_SilVerionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "SILV?RION [Member]", "label": "SILV?RION [Member]" } } }, "localname": "SilVerionMember", "nsuri": "http://purebio.com/20230430", "presentation": [ "http://purebio.com/role/SummaryOfRevenueByProductDetails" ], "xbrltype": "domainItemType" }, "PURE_TwoThousandAndSevenEquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2007 Equity Incentive Plan [Member]", "label": "2007 Equity Incentive Plan [Member]" } } }, "localname": "TwoThousandAndSevenEquityIncentivePlanMember", "nsuri": "http://purebio.com/20230430", "presentation": [ "http://purebio.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "PURE_TwoThousandSeventeenEquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2017 Equity Incentive Plan [Member]", "label": "2017 Equity Incentive Plan [Member]" } } }, "localname": "TwoThousandSeventeenEquityIncentivePlanMember", "nsuri": "http://purebio.com/20230430", "presentation": [ "http://purebio.com/role/ScheduleOfStockOptionActivityDetails", "http://purebio.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "PURE_TwoVendorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two Vendor [Member]", "label": "Two Vendor [Member]" } } }, "localname": "TwoVendorMember", "nsuri": "http://purebio.com/20230430", "presentation": [ "http://purebio.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "PURE_VendorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Vendor [Member]", "label": "Vendor [Member]" } } }, "localname": "VendorMember", "nsuri": "http://purebio.com/20230430", "presentation": [ "http://purebio.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "PURE_VendorOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Vendor One [Member]", "label": "Vendor One [Member]" } } }, "localname": "VendorOneMember", "nsuri": "http://purebio.com/20230430", "presentation": [ "http://purebio.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "PURE_VestedAndIssuableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Vested and Issuable [Member]", "label": "Vested and Issuable [Member]" } } }, "localname": "VestedAndIssuableMember", "nsuri": "http://purebio.com/20230430", "presentation": [ "http://purebio.com/role/ScheduleOfRestrictedStockActivityDetails", "http://purebio.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r532" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r532" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r531" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r529", "r531", "r532" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r530" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r518" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r531" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r531" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r533" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r521" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r524" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r520" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r520" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r537" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r520" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r534" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r532" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r520" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r520" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r520" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r520" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r535" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r531" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r525" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r526" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r519" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r523" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r522" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r527" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r528" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r536" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://purebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r170", "r504", "r575", "r611", "r612" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://purebio.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r170", "r504", "r575", "r611", "r612" ], "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://purebio.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r168", "r391", "r409", "r410", "r411", "r412", "r413", "r414", "r489", "r503", "r507", "r542", "r571", "r572", "r575", "r611" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://purebio.com/role/StatementsOfOperations", "http://purebio.com/role/SummaryOfRevenueByProductDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r168", "r391", "r409", "r410", "r411", "r412", "r413", "r414", "r489", "r503", "r507", "r542", "r571", "r572", "r575", "r611" ], "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://purebio.com/role/StatementsOfOperations", "http://purebio.com/role/SummaryOfRevenueByProductDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r139", "r274", "r538", "r561" ], "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://purebio.com/role/ScheduleOfRestrictedStockActivityDetails", "http://purebio.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r139", "r274", "r538", "r539", "r561" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://purebio.com/role/ScheduleOfRestrictedStockActivityDetails", "http://purebio.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r563", "r605" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://purebio.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://purebio.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingChangesAndErrorCorrectionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Changes and Error Corrections [Abstract]" } } }, "localname": "AccountingChangesAndErrorCorrectionsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r9", "r506" ], "calculation": { "http://purebio.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableMember": { "auth_ref": [ "r486" ], "lang": { "en-us": { "role": { "documentation": "Due from customers or clients for goods or services that have been delivered or sold.", "label": "Accounts Receivable [Member]" } } }, "localname": "AccountsReceivableMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r171", "r172" ], "calculation": { "http://purebio.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts receivable" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r11" ], "calculation": { "http://purebio.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued liabilities" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r51", "r506", "r614" ], "calculation": { "http://purebio.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r310", "r311", "r312", "r431", "r558", "r559", "r560", "r603", "r616" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/StatementOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for restricted stock unit under share-based payment arrangement.", "label": "Share-based compensation expense - restricted stock units" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/StatementOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.", "label": "Share-based compensation expense - stock options" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/StatementOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r305", "r313" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-Based Payment Arrangement, Expense", "verboseLabel": "Share-based compensation" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r147" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Dilutive common share", "verboseLabel": "Total" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails", "http://purebio.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r20" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r20" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r79", "r102", "r120", "r150", "r162", "r166", "r203", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r232", "r233", "r320", "r322", "r339", "r398", "r452", "r506", "r517", "r573", "r574", "r606" ], "calculation": { "http://purebio.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets [Default Label]", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r98", "r107", "r120", "r203", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r232", "r233", "r320", "r322", "r339", "r506", "r573", "r574", "r606" ], "calculation": { "http://purebio.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current assets" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/ScheduleOfRestrictedStockActivityDetails", "http://purebio.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r18", "r101", "r490" ], "calculation": { "http://purebio.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and cash equivalents", "periodEndLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/BalanceSheets", "http://purebio.com/role/LiquidityAndGoingConcernDetailsNarrative", "http://purebio.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r18", "r66", "r117" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Total cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Reconciliation of cash, cash equivalents, and restricted cash to the condensed consolidated balance sheets" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r18", "r66", "r117" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "periodEndLabel": "Cash, cash equivalents, and restricted cash at end of period", "periodStartLabel": "Cash, cash equivalents, and restricted cash at beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r0", "r66" ], "calculation": { "http://purebio.com/role/StatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "negatedLabel": "Net cash provided by (used) in operating and investing activities", "totalLabel": "Net decrease in cash, cash equivalents, and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/LiquidityAndGoingConcernDetailsNarrative", "http://purebio.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r15", "r42", "r399", "r439" ], "calculation": { "http://purebio.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and contingencies" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r71", "r222", "r223", "r487", "r569" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r508", "r509", "r510", "r512", "r513", "r514", "r515", "r558", "r559", "r603", "r613", "r616" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/StatementOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r50" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock, par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/BalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r50", "r440" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r50" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r4", "r50", "r440", "r458", "r616", "r617" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r50", "r402", "r506" ], "calculation": { "http://purebio.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock, $0.01 par value: 150,000,000 shares authorized, 111,356,473 shares issued and outstanding at April 30, 2023 and at July 31, 2022" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationRelatedCostsPolicyTextBlock": { "auth_ref": [ "r36" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.", "label": "Share-Based Compensation" } } }, "localname": "CompensationRelatedCostsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r22", "r24", "r39", "r40", "r170", "r486" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r22", "r24", "r39", "r40", "r170", "r423", "r486" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r22", "r24", "r39", "r40", "r170", "r486", "r541" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r44", "r88" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentrations" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r22", "r24", "r39", "r40", "r170" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration risk percentage" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r22", "r24", "r39", "r40", "r170", "r486" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r61", "r391" ], "calculation": { "http://purebio.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of goods sold" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/DebtDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/DebtDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r23", "r170" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r72", "r119", "r234", "r240", "r241", "r242", "r243", "r244", "r245", "r250", "r257", "r258", "r260" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/Debt" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r7", "r47", "r48", "r80", "r81", "r121", "r235", "r236", "r237", "r238", "r239", "r241", "r246", "r247", "r248", "r249", "r251", "r252", "r253", "r254", "r255", "r256", "r350", "r498", "r499", "r500", "r501", "r502", "r555" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/DebtDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentDescription": { "auth_ref": [ "r7", "r33", "r43", "r47", "r80", "r81" ], "lang": { "en-us": { "role": { "documentation": "Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total.", "label": "Debt description" } } }, "localname": "DebtInstrumentDescription", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/DebtDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r13", "r236" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt instrument interest percentage" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/DebtDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r14", "r121", "r235", "r236", "r237", "r238", "r239", "r241", "r246", "r247", "r248", "r249", "r251", "r252", "r253", "r254", "r255", "r256", "r350", "r498", "r499", "r500", "r501", "r502", "r555" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/DebtDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Debt instrument term" } } }, "localname": "DebtInstrumentTerm", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/DebtDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r2", "r30" ], "calculation": { "http://purebio.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation and amortization" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r275", "r278", "r306", "r307", "r309", "r505" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Stockholders\u2019 Equity" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/StockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r115", "r131", "r132", "r133", "r134", "r135", "r141", "r142", "r144", "r145", "r146", "r148", "r334", "r335", "r395", "r408", "r494" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Basic and diluted net loss per share" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/StatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r20", "r21" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Net Loss Per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r308" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Unrecognized non-cash compensation costs" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r308" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Unrecognized non-cash compensation costs for weighted average contractual term grants" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r4", "r95", "r110", "r111", "r112", "r122", "r123", "r124", "r128", "r136", "r138", "r149", "r204", "r207", "r263", "r310", "r311", "r312", "r315", "r316", "r324", "r325", "r326", "r327", "r328", "r330", "r333", "r343", "r344", "r345", "r346", "r347", "r348", "r353", "r415", "r416", "r417", "r431", "r481" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/StatementOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r259", "r262", "r331", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r407", "r497", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r564", "r565", "r566", "r567" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_GainLossRelatedToLitigationSettlement": { "auth_ref": [ "r570" ], "calculation": { "http://purebio.com/role/StatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.", "label": "Gain (Loss) Related to Litigation Settlement", "negatedLabel": "Gain on extinguishment of indebtedness" } } }, "localname": "GainLossRelatedToLitigationSettlement", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r2", "r31", "r32" ], "calculation": { "http://purebio.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Gain on extinguishment of indebtedness, net" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r60", "r120", "r150", "r161", "r165", "r167", "r203", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r232", "r233", "r339", "r495", "r573" ], "calculation": { "http://purebio.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r19" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Cash paid for taxes" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r1" ], "calculation": { "http://purebio.com/role/StatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Accounts payable and accrued liabilities" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r1" ], "calculation": { "http://purebio.com/role/StatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r1" ], "calculation": { "http://purebio.com/role/StatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "auth_ref": [ "r1" ], "calculation": { "http://purebio.com/role/StatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.", "label": "Increase (Decrease) in Prepaid Expense", "negatedLabel": "Prepaid expenses" } } }, "localname": "IncreaseDecreaseInPrepaidExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r41", "r84", "r113", "r153", "r349", "r466", "r516", "r615" ], "calculation": { "http://purebio.com/role/StatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest expense, net" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryAdjustments": { "auth_ref": [ "r28", "r553" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of inventory reserves for last-in first-out (LIFO) and other inventory valuation methods.", "label": "Net of reserve for inventory obsolescence" } } }, "localname": "InventoryAdjustments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryFinishedGoods": { "auth_ref": [ "r551" ], "calculation": { "http://purebio.com/role/ScheduleOfInventoriesDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.", "label": "Finished goods" } } }, "localname": "InventoryFinishedGoods", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/ScheduleOfInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r105", "r491", "r506" ], "calculation": { "http://purebio.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://purebio.com/role/ScheduleOfInventoriesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventories, net", "totalLabel": "Inventories" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/BalanceSheets", "http://purebio.com/role/ScheduleOfInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r85", "r100", "r104", "r216", "r217", "r219", "r390", "r493" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryRawMaterials": { "auth_ref": [ "r552" ], "calculation": { "http://purebio.com/role/ScheduleOfInventoriesDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Raw materials" } } }, "localname": "InventoryRawMaterials", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/ScheduleOfInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryValuationReserves": { "auth_ref": [ "r29", "r553" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of valuation reserve for inventory.", "label": "Inventory Valuation Reserves", "verboseLabel": "Reserve for inventory obsolescence" } } }, "localname": "InventoryValuationReserves", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWriteDown": { "auth_ref": [ "r218" ], "calculation": { "http://purebio.com/role/StatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.", "label": "Reserve for inventory obsolescence" } } }, "localname": "InventoryWriteDown", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r55", "r82", "r404", "r506", "r556", "r568", "r604" ], "calculation": { "http://purebio.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r12", "r99", "r120", "r203", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r232", "r233", "r321", "r322", "r323", "r339", "r506", "r573", "r606", "r607" ], "calculation": { "http://purebio.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current liabilities" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityLineItems": { "auth_ref": [ "r555" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Line of Credit Facility [Line Items]" } } }, "localname": "LineOfCreditFacilityLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/DebtDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityTable": { "auth_ref": [ "r10", "r555" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.", "label": "Line of Credit Facility [Table]" } } }, "localname": "LineOfCreditFacilityTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/DebtDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r116" ], "calculation": { "http://purebio.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r66", "r67", "r68" ], "calculation": { "http://purebio.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r59", "r68", "r83", "r97", "r108", "r109", "r112", "r120", "r127", "r131", "r132", "r133", "r134", "r137", "r138", "r143", "r150", "r161", "r165", "r167", "r203", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r232", "r233", "r335", "r339", "r406", "r460", "r479", "r480", "r495", "r516", "r573" ], "calculation": { "http://purebio.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://purebio.com/role/StatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net loss", "negatedLabel": "Net loss", "totalLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/LiquidityAndGoingConcernDetailsNarrative", "http://purebio.com/role/StatementOfStockholdersEquity", "http://purebio.com/role/StatementsOfCashFlows", "http://purebio.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": { "auth_ref": [ "r91", "r92", "r93", "r96", "r125", "r126", "r129", "r130", "r139", "r140", "r205", "r206", "r317", "r318", "r319", "r329", "r332", "r336", "r337", "r338", "r340", "r341", "r342", "r351", "r352", "r354", "r392", "r393", "r394", "r418", "r419", "r420", "r421", "r422" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.", "label": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/RecentAccountingPronouncements" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r63" ], "calculation": { "http://purebio.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total other income (expense)" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other income (expense)" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [ "r562" ], "lang": { "en-us": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of operating segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://purebio.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating costs and expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating costs and expenses" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r150", "r161", "r165", "r167", "r495" ], "calculation": { "http://purebio.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r46", "r77", "r424", "r425" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Basis of Presentation" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/BasisOfPresentation" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r11", "r506" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Accounts payable, due to officers and directors" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilityCurrentRelatedAndNonrelatedPartyStatusExtensibleEnumeration": { "auth_ref": [ "r103", "r231", "r358", "r557" ], "lang": { "en-us": { "role": { "documentation": "Indicates related and nonrelated party status for liability classified as other and current.", "label": "Other Liability, Current, Related and Nonrelated Party Status [Extensible Enumeration]" } } }, "localname": "OtherLiabilityCurrentRelatedAndNonrelatedPartyStatusExtensibleEnumeration", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r64" ], "calculation": { "http://purebio.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other income (expense), net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r65" ], "calculation": { "http://purebio.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property, plant and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/ScheduleOfStockOptionActivityDetails", "http://purebio.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [ "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement." } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/ScheduleOfStockOptionActivityDetails", "http://purebio.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r49", "r261" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred stock, par value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/BalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r49", "r440" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r49", "r261" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r49", "r440", "r458", "r616", "r617" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/BalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r49", "r401", "r506" ], "calculation": { "http://purebio.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred stock, $0.01 par value: 5,000,000 shares authorized, no shares issued and outstanding" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r106", "r220", "r221", "r492" ], "calculation": { "http://purebio.com/role/BalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid expenses" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromLoans": { "auth_ref": [ "r17" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash received from principal payments made on loans related to operating activities.", "label": "Net proceeds from payroll protection program loan" } } }, "localname": "ProceedsFromLoans", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/DebtDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Product Information [Line Items]" } } }, "localname": "ProductInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/SignificantAccountingPoliciesDetailsNarrative", "http://purebio.com/role/SummaryOfRevenueByProductDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ProductMember": { "auth_ref": [ "r503" ], "lang": { "en-us": { "role": { "documentation": "Article or substance produced by nature, labor or machinery.", "label": "Product [Member]" } } }, "localname": "ProductMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/StatementsOfOperations" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r3", "r397", "r405", "r506" ], "calculation": { "http://purebio.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, plant and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r355", "r356", "r357", "r358", "r359", "r428", "r429", "r430", "r463", "r464", "r465", "r484", "r485" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r45", "r314", "r608" ], "calculation": { "http://purebio.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCash": { "auth_ref": [ "r550", "r554", "r609", "r610" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash", "periodEndLabel": "Restricted cash" } } }, "localname": "RestrictedCash", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashAndCashEquivalents": { "auth_ref": [ "r18", "r78", "r101", "r117", "r400" ], "calculation": { "http://purebio.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Restricted cash" } } }, "localname": "RestrictedCashAndCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails", "http://purebio.com/role/ScheduleOfRestrictedStockActivityDetails", "http://purebio.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r52", "r73", "r403", "r418", "r422", "r427", "r441", "r506" ], "calculation": { "http://purebio.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated undistributed earnings (deficit).", "label": "Accumulated deficit", "negatedLabel": "Cumulative net loss" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/BalanceSheets", "http://purebio.com/role/LiquidityAndGoingConcernDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r95", "r122", "r123", "r124", "r128", "r136", "r138", "r204", "r207", "r310", "r311", "r312", "r315", "r316", "r324", "r326", "r327", "r330", "r333", "r415", "r417", "r431", "r616" ], "lang": { "en-us": { "role": { "documentation": "Accumulated undistributed earnings (deficit).", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/StatementOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r151", "r152", "r160", "r163", "r164", "r168", "r169", "r170", "r272", "r273", "r391" ], "calculation": { "http://purebio.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Total revenue", "verboseLabel": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/LiquidityAndGoingConcernDetailsNarrative", "http://purebio.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r94", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r488" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue Recognition" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r114", "r120", "r151", "r152", "r160", "r163", "r164", "r168", "r169", "r170", "r203", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r232", "r233", "r339", "r396", "r573" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Total" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/SummaryOfRevenueByProductDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RoyaltyMember": { "auth_ref": [ "r576" ], "lang": { "en-us": { "role": { "documentation": "Money for usage-based right to asset.", "label": "Royalty [Member]" } } }, "localname": "RoyaltyMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/StatementsOfOperations" ], "xbrltype": "domainItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r170", "r540" ], "lang": { "en-us": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue Benchmark [Member]" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r20" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/ScheduleOfAnti-dilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r20" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Anti-dilutive Securities Excluded from Computation of earnings Per Share" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/SignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r8", "r56", "r57", "r58" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventories" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/SignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfProductInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule detailing quantitative information concerning products or product lines by product or product line.", "label": "Schedule of Product Information [Table]" } } }, "localname": "ScheduleOfProductInformationTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/SignificantAccountingPoliciesDetailsNarrative", "http://purebio.com/role/SummaryOfRevenueByProductDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfProductInformationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of product information that are included in the discussion of the nature of an entity's operations.", "label": "Summary of Revenue by Product" } } }, "localname": "ScheduleOfProductInformationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/SignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r276", "r277", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/ScheduleOfRestrictedStockActivityDetails", "http://purebio.com/role/ScheduleOfStockOptionActivityDetails", "http://purebio.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r5", "r6", "r37" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Schedule of Stock Option Activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r76" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Fair Value Assumptions" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.", "label": "Schedule of Restricted Stock Activity" } } }, "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "auth_ref": [ "r154", "r155", "r156", "r157", "r158", "r159", "r169", "r496" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for segment reporting.", "label": "Segments" } } }, "localname": "SegmentReportingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r62" ], "calculation": { "http://purebio.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r1" ], "calculation": { "http://purebio.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r505" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-based compensation, vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights": { "auth_ref": [ "r35" ], "lang": { "en-us": { "role": { "documentation": "Description of service or performance condition required to be met for earning right to award under share-based payment arrangement. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Option vested description" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r295" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Forfeited", "verboseLabel": "Forfeited, shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/ScheduleOfRestrictedStockActivityDetails", "http://purebio.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r293" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Granted", "verboseLabel": "Granted, shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/ScheduleOfRestrictedStockActivityDetails", "http://purebio.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r290", "r291" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Number of units, vested and issuable", "periodEndLabel": "Outstanding, Ending balance", "periodStartLabel": "Outstanding, Beginning balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/ScheduleOfRestrictedStockActivityDetails", "http://purebio.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate": { "auth_ref": [ "r578" ], "lang": { "en-us": { "role": { "documentation": "Date the equity-based award expires, in YYYY-MM-DD format.", "label": "Share-based compensation, expiration date" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "dateItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r302" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/ScheduleOfFairValueAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r301" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/ScheduleOfFairValueAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r303" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/ScheduleOfFairValueAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [ "r276", "r277", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/ScheduleOfRestrictedStockActivityDetails", "http://purebio.com/role/ScheduleOfStockOptionActivityDetails", "http://purebio.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.", "label": "Common stock shares increase under the plan" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r34" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Number of shares available for issuance under the plan" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r284" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Options issued to purchase common stock exercisable" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "auth_ref": [ "r289" ], "lang": { "en-us": { "role": { "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period", "negatedLabel": "Shares, Expired" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/ScheduleOfStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": { "auth_ref": [ "r584" ], "lang": { "en-us": { "role": { "documentation": "Net number of share options (or share units) granted during the period.", "label": "Options issued to purchase common stock" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r286" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Shares, Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/ScheduleOfStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r282", "r283" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Options Outstanding Shares, Beginning Balance", "periodStartLabel": "Options Outstanding Shares, Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/ScheduleOfStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r282", "r283" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Weighted- Average Exercise Price Outstanding, Beginning Balance", "periodStartLabel": "Weighted- Average Exercise Price Outstanding, Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/ScheduleOfStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "auth_ref": [ "r298" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "periodEndLabel": "Aggregate Intrinsic Value Outstanding, Beginning Balance", "periodStartLabel": "Aggregate Intrinsic Value Outstanding, Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/ScheduleOfStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement." } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/ScheduleOfRestrictedStockActivityDetails", "http://purebio.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r287" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Weighted- Average Exercise Price, Exercised" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/ScheduleOfStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r289" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.", "label": "Weighted- Average Exercise Price, Expired" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/ScheduleOfStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r286" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Weighted- Average Exercise Price, Granted" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/ScheduleOfStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r300" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Expected life" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/ScheduleOfFairValueAssumptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": { "auth_ref": [ "r297" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.", "label": "Fair value of options issued to purchase common stock" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1": { "auth_ref": [ "r38" ], "lang": { "en-us": { "role": { "documentation": "Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.", "label": "Weighted average exercise price" } } }, "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r75" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Remaining Contractual Term", "verboseLabel": "Weighted average contractual term" } } }, "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r74" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Weighted average contractual term" } } }, "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Balance, shares", "periodStartLabel": "Balance, shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/StatementOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r69", "r118" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/SignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r4", "r16", "r95", "r110", "r111", "r112", "r122", "r123", "r124", "r128", "r136", "r138", "r149", "r204", "r207", "r263", "r310", "r311", "r312", "r315", "r316", "r324", "r325", "r326", "r327", "r328", "r330", "r333", "r343", "r344", "r345", "r346", "r347", "r348", "r353", "r415", "r416", "r417", "r431", "r481" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/StatementOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [ "r122", "r123", "r124", "r149", "r391", "r426", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r440", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r453", "r454", "r455", "r456", "r457", "r459", "r461", "r462", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r481", "r511" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/StatementOfStockholdersEquity", "http://purebio.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r122", "r123", "r124", "r149", "r391", "r426", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r440", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r453", "r454", "r455", "r456", "r457", "r459", "r461", "r462", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r481", "r511" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/StatementOfStockholdersEquity", "http://purebio.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "auth_ref": [ "r4", "r73" ], "lang": { "en-us": { "role": { "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.", "label": "Issuance of common stock for vested restricted stock units, shares" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/StatementOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r4", "r49", "r50", "r73", "r287" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "negatedLabel": "Shares, Exercised" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/ScheduleOfStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": { "auth_ref": [ "r4", "r49", "r50", "r73" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.", "label": "Issuance of common stock for vested restricted stock units" } } }, "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/StatementOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockOptionMember": { "auth_ref": [ "r510" ], "lang": { "en-us": { "role": { "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).", "label": "Equity Option [Member]" } } }, "localname": "StockOptionMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r50", "r53", "r54", "r70", "r442", "r458", "r482", "r483", "r506", "r517", "r556", "r568", "r604", "r616" ], "calculation": { "http://purebio.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.", "label": "Equity, Attributable to Parent", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/BalanceSheets", "http://purebio.com/role/StatementOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 equity" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowElementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental disclosure of cash flow information" } } }, "localname": "SupplementalCashFlowElementsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r259", "r262", "r331", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r407", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r564", "r565", "r566", "r567" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r25", "r26", "r27", "r86", "r87", "r89", "r90" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r141", "r146" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Shares used in computing basic and diluted net loss per share" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://purebio.com/role/StatementsOfOperations" ], "xbrltype": "sharesItemType" } }, "unitCount": 5 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19)(a)(5))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aaa)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aaa)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(3)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(4)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "https://asc.fasb.org//330/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-19", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org//718/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.BB)", "Topic": "330", "URI": "https://asc.fasb.org//1943274/2147480581/330-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(i)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(iii)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(iv)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(i)(1)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(i)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(1)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(c)(2)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(c)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(3)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "848", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r355": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org//850/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f(1))", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "330", "Topic": "912", "URI": "https://asc.fasb.org//1943274/2147482105/912-330-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)(1)", "Topic": "926", "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)(2)", "Topic": "926", "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)(3)", "Topic": "926", "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(19))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(21))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(22))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(2)(a))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column A))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column B))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column C))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column D))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column E))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column F))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "(a)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(15))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(16)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(17))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(19))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(2)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(2)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(8))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-05(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-05(4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r46": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org//205/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(9))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(1)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(e)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "47", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(b)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "55", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r518": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r519": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r520": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r521": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r522": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r523": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r524": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r525": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r526": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r527": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r528": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r529": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r530": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r531": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r532": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r533": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r534": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r535": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r536": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r537": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r543": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r544": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r545": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r546": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r547": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r548": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r549": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r569": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org//450/tableOfContent", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "2B", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(18))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(i)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r617": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r69": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org//235/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r71": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org//440/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r72": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org//470/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r77": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org//810/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(d)(1)", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(d)(2)", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r93": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "250", "URI": "https://asc.fasb.org//250/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r94": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "https://asc.fasb.org//606/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "105", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" } }, "version": "2.2" } ZIP 46 0001493152-23-021239-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-23-021239-xbrl.zip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
&LZG5@.1MWI!Y M1F8DYN=RI:+9?$A79:\+4Y,*-%B:@N60H9PF93M-\K!=NKC.%E@^>G"Z:C M;+$PBH,F>&3P!^D'[RTG^*Y<3P8M!EXG[#=>GPGP,%2?2A(,ZXSPY !]=R5: M2T.RM\-RV$RH5CH=%68A(IR+0 M:7NST6::GIFH5_IMI0(&+'U6BG#(O(UBJ(/FBA"[J%%!1Y3R05W\&9(I=2W_ MAW[YK2;WN:F"[!OF*MBH82R'_!S&^@&_OE'5#^$$[P[ M- 6[BFBYNF4=MHBHWXFY?UQ593Y E.QW[>R.P[3$O'K.VQ2P*'[ M,"4%,.3="+;L1(A$4._I]>"4_5RP&>5I49(%\V]T=\/&0CXIIP;8I]10 @QE ME+#&E&!"_,QF)Q:<#Z<1Y9$O>%@>L9[@9K.L6CX9XUB$/H4L*F XY893%1J) M/ZB"F!H2>L%IUCTVY,8OO7B0)YX<&*63!4,E"T!=@/[P*X.ZY4\W)CEK>YX3 M3"G2:#+@H@J&=M/PFO9SCB$]@BB.+G._4)2+%%^/*4Y(R?^DK0B#AE_R6:$/ M":<5!T0R&T9Y7MG3".^%W> YG^->XR5_BK$Y:.HX5CKJ>CTE/*4X@T/"+HI@ M:#<%K639:ET U(OO<5*E;.YR1?.DBLOS];7Y6_ZLA)5_$Q+P2L+)!1LPT5D; M#AVG0I:C*BP6$7_:\UR/(ER)_3V,@I#_&U7E+J#;"L7@!UIRT63.ER3$>]Q/*O#-B^T MS@RUN2'>RJB7']?"38Z IOKKVNOFD,<5I>Q/$X<3FWJ8/N56*'5/,>L"Y+\3 M8!.K(;WSMR[6^ESA<'K:1K02YZ0&0;/$+Y\S4A;-$P6KB63>199A.L#N*D_= M:;:?'\".MK-"FCIG+\RA2 VU*4'KJA_&%2/@7B[K\V?/Z) ;)1RPVSVC(@R= M:X-4H7:AS8MBZBAU[ZA3@=U)FI/ 1X\13?I%YQ%QZR T15$MZM\V[C#/R21T MYWE^!=DZTN8Y@.Y4SRZ6J8.=180B$;49]9()%$_[&I<1R7#2SN:.XKA:5&+K MX@3/2$PTY[AM6KXB:;N_)#HU"OZ 6U%@]O_D-GK:X#28*AG/\>! Y=<^J[AL7F;D"__?\#<6OQV]SYPE,)]X$A):X0G6^ LZ-JT_![@EH.1)^PT,*4: E.]> M!&_F[>U .@U]V\ED/_>X[8/J-G( 0_^=%,NVKSUY6_M4VM8&,\0_L]IL_L#V MDO<:6:='2UX2+[=M$>;]A[UMV%U M;+&SU0E#6[#;9J%@^HO=.9WKZ/&GJ,241*ENA-'(!KE8I8*KO%75%P1CR$WH MI(7>Z!$M6ADX?#DC&2F8L_8QSQ,K84;"01BC!*RDS$ 2'F=4\,:D:670G L% MVB3H$&O?@EM_][Q94W+C:[+\2FRZJXZ69>S?[G#NMU%WZ#J/RB-%3&V]YCA? M+)A?7( X3]UQN#MI<8T+3!^TBX FA2 V6PM<:48D:6CNI!6IXCEI_EF\,TE: M993?%2S#(L:L(N&0["CY>U74 7=LQ1^(!B&6 JR24CTY,*;, $ZU.\OFZ!0^ MC:2+N,SR\A^B.7ZKVP$WJ@2]&*T ;[P9W9,'0S,'D,:[T8@R';3LE';TX)L$ M\Y:)%SQ4[1KOJ(03]+P]^S:E&-W+;RY*P?DT%:D#J8OT>OZ+,M7B#M/+ MV65[Y*6]J*T[O:>7]_KVBPWVX$"D3C@XRUP12B.DD.>#Y/JH4@'EAOT%R7@4 M;Q&2XBR*2=I>0= 4WB#ODU)6V'U*:87!4,J&4'ZP,A/[E[4&:E7 [$.JRG-A MV5RTZ(1FEP3?QK +<'M[+BB=F78!: /NBN8QQDG!UU@N\B@SG&<;RWD^Q::& M.3J[-A0"0Q\=,M6,<-G(UONYRVC%4D_YKV7]4!__XYQ&"Y2RA(+SA[]&=)X5 M):WXH'S")JR4B%L^FIHPR/M^/_Q^E%(8#+]L")5/D25K,6 T.L]*S*JH MY"?<;TH1\E\W6]PD@7!$C7!ZJG&9<"2J<>-!MM&&D6P7EBN\7>>\.L^+!27\IU.^K[[/1#7^!^ M5K5,"8+@G#B8/K#M$AE#(F@BL_:?VROX+3+EDWP\)S S:6MEZ>K*-MW>1L)> MN]O6*F+0SYZ=*IP.MJVBN,8Y'CQ>:>Y,D!8+-JZG^C'"]3A>7);WF-[>1UD3 M;>)3+BZ?XJ1>\=UV.TW/?R_ZYZ;5NI5N/#5SK[U]*:Y0LQD'+4U'/GP7?FP? M+JNR**.,W^H^0!_PG&3\7!.ZBY@4@&W_W57/1Y9$69QG]55W[ZTSSOYE]'9U MI?KI[,.\]W]DWZS X_XMA'"RH\,5NRO<>5%4.-%T3\]Y>SODX;LZNX,BOC(. MWBM#E%8Z%2Z$7O#0>I;3&2:EMOL&0? R!EAMU?H98Z7L@W?H<&66KM2TOQ&YG!^KXS4L[C3S!AJRW_AC;.X4_'?_9_"-770*]MNEF;T^>S%F&&KIJUT M4UTF+VI)Q5)(J=/5XJ@G7R^C%OV5E \OKQO^C,G\GAFEHP=,HSD^?<(T)@6^ MHB36;A/ZRGU/NZQ+E>ZH(YNR?N'=VZ'HXT[?JARB1@FU6DBH(J8_F8GFY+F5(059:J51)][$KW_AEF6XG/V1]F*N;[G)E#GMDS4P5-4V^[DB MF_U?[[&637F"@KGT6]I)V7T_TY[ 4A9]%\[\-A& ZI?;K]I)_75[V>]//]YZ MF:=Z](!Z/G\J_G-,60+OQLD%"7OOAQ@4==*?)J4![ MPV'C$NC&L$XN/)>?V^_;H@0=R":"V*NQ;*,*WNIP-@G!RQG1-BGV]$%MCTR! MM;Z6I([^L;/C?*:<0'7JS:MJFQ-'13;@AM:=%5$_]C*-?>AN=OLD%3W,V#L1 M!JB.NJ-*WO+X.PG#2QJ!-RGX)F.PU20 'DP"G3AX20> K(7 5U&WQ ME\U!IZ)[W!@'S-47LB_[ OG\_,KX_SNS_/%T4<+>T^EM=7[)^2/=/)P8CZRR M[4:[?YX[ULKZ[B#KX5>5I?E\73/*,;]4$@^*E^=[]YV M5U,U[JRSJC)]F5W54%+IV0,F>CACLNO07&RZ_D('VA/"WTW/$M_#[##?O>VU MIFK<^1#;S_1E]EI#2>5'<&H1M"(X!;(.?F>OAKLIU<##P^G>H]AEAMZ[YTXK M3NJ7.\D-5H?<91''/;&502F9[=W*RWY=5WT/BV5>RZQ_2Z'*2%DXSB? M9^2?VB.B.\S/)_EW7FW]_K*SS,",(;LNX;@[?LYH)X*R/#N,H^)^T#'97XKG MO\2C"6^UL^)>XT5$^!Y!O7<[JFW/>7L+;^6[.KOP5KXR#MY/0Y16[^7QA3E* MQ$2CX(?5$6[G'64N?+\7-_4 %/_0[Y:N@U_FO>2:4(@']>O+OE_D_HT$^ -# MNS#%5L?Z"T2YWV X.C#T"UEX;60Z%QX^PUV^[L9[<3?M,U_DJ8_AZ%_EFJ+H MS5&=5)#.QCIIP7 1IT!5O#D_].K$8EZ[E@?I2:^-^U[[2.Q1DA"N$J6UQWM4 ME?]_S](7RKU[/=3JJ+XP ML+^]JQW!FW'[(2(IW^MF\S*Q)K4KAT&;W5[T.L=*VZH;J",5ZQTQ2"&PC6OJ]Z=\<8:C<(N=*=MCO.LI%%<5E'* M#_6_FV0, Z +/YP&:Q+[Z.L=&BS+ :8^=.%+V!2WCEX2K_50R11A6)]GS#V: M2N2S]YV^HZ7(9R_&=%LU;3= XB@36+UT!R7;<)*+\#H]&#UP6Q:L5U%J"S90 MF38I]@5I;T?Z#2M_9\/[1#RPK$782K .Y+@-0[;D:K\Q(Q)T$O$<="_7M(2; M1&P.#>2I6C#5LG]SB9U=$6I64G/:_,3E=+Z+;Q OXMZIL8*]7$95(@#CD00I M]J;75L4N^J/-6J"YV#4,;C3$!80+$MV)$'G'%:5L[G>-TZB.L\DJE=9_N8IH MN;HIH[)BUK9D12;,M)YFU0+79^4T3;?%]'UV]:U72[\7;RUQ,!UTVR62%A9X M^JC+X U61R@)A,1;F2=#1+YH#HC],LZ*]3+Z[]@=3Z"BZ94+I7I+;) MPFHH.U#I3FVG@5H5Q'30+[46D*:Y?V6W4L!MDZM% F.&7(P/>)/C;F@ 69>K M9F.YT-3ZZ#NL&E>#&]=V)Q6THIE1^X*S)*>:BAY]AU71:G#2Z@*SV[58T)IF MQLQ8TZ/OL&I:#6Y ZAI,??CZ[&\-/S= 6[/BOL\Y0O"_$LTQ[(==U"" MU283$,M1!GJJB#)=5+;*_.9FH_U=B-9K5V*NZH48W0B@%H/50D:,VA6H1CIH M%ZI[L=ZW'WV'5>UJ<-++0;6A"NW5&\<$N ."PV@ 822(4C++:4:B#U'V]2A+ M;BGS<76>O$$85N4[()4L?J>"N(Y8S19:8=W\:!7?X_CK%U4\S;C>1/U7VNRE'*PFL8,4C9DW9,'K3R( M98DS5C&658FU"*P&T.+3KDEPR:"U_O(C88-BB.=22\_M--FCHLZ_CJ:!Y(@W M_*Q0^R:* (%*CD(^.<0$2[3")>J=,Z(MEB981Y )U^:!N/8EP#$H8GLNM3)R MDXK'T1H!NEL-^+ZL4=0$1UC@0&0-!.7B $_)H(ROV).LB005A-J[# H+BE13 M(&\<'#9($]X^YK?W>54P[XOY:S?X 6=M1^"K5.0!\R/B^C559V58#;H!\G&[ MLMS^C&HEU&DAKA9Z';PMF2A6B3=L4;LVV"9UABZWZ5N(;=IZ2\5E6A-HTY3A]6J&V'7>9L%:E-!73+B4%LOH; +-NQ?_\:<@)N* MSJ)8MP:@E(+5;":(TI(,DT5<ᰩO@AJ1?N$>ELY"C[["J70U.\E'/+[[\ M_G=_>O_C]?GEI\!;B?Q>>^\^FFZ]12T'J_+-(#61R(4X:@+\N#2%EZ/UU[W[ M!L,F:0IL$O1YH%X/M'^67I8""TV>1O3O9@3JM-V#HD6!2]/MA8& YR=H M3-6MQB7M%0NI[IY,T$K6URZX:K74)_KE!,\BYF:A"ZX=BKMNUV\4-UO@5+J)$^TKPHKF@^(TK+U/L,J.I5 MJ.37)ID,JH4"U>WE4EQ?S>;-F^?*X542 E3/>FQR.+%&$K6B@>K\/"LQ?_>V M@:&J\9$(H/K6(9-O$=5R;64'JNM/>9:W[7Z>Q?D"&VI=*PRH_NT8I1<:>AJH M5D'?-$K?AGQNM.A%Z%1Z/F.A7]^#:08]-N4&*/,U>[*AQM&(9!=LQ&EFSK?Y M!1O@YW58)%R6J=B+58ZP+HJ ^L@TO-*HS+31-US_VRX>!/-3UVF@=2+!1I#Z MA;X37/_W/&M/S:T>2(*3#ZO/!3^JU,T!CN*2/(CYK=(1=-8&U) ;@)9<15PBG@9J M$^$GL[[AZ;"6_1:M9U#KM *U;W-0K;C-C^)_5(1BAIBA*U?\;$)YE(G3:TN= M0^.N#:A]-P"M..Q?'Z!C_DR3"&I3.1#'.LJ#;KUG&=#!T7#Y/&N>>]RH^RJT M 37O!J G=M\NJ?#=EZ/D_W">/40I%BY=>RR0?V!T'O[0DZS/F\KC5IQ6B5@( MBN_YR=)KYKF?SF8X5IH OP@ S5P#%5R^(%;<']1L[:7/(_!UIT-K$6Z.1C\. M-6I,2.&.'* .&6JA(8X-U>#VD?Q=B4Y(L510DE4X:0;J M/%.:1Y_YOQ3B;UKLW=%^3>T6$A*8A&8?%5K#"D3X8:VJ#Z3T)0"-RAI@AC/M M7&X?#ZQ2>=-*!V=@ IKV(T M*JC30:U2R,V19[ROU-MIV-WS5%(F@$;ZW95-N;ES*-)!_;S0T?!V6U^NR1") M' ^:HZ[##:(#5.>[_P0T/<^S8UJ:LGZ99'4JL3<*=T^<-'!0BP==V5Y9 LSM M+I0#7]^.Q>XB_ZE7\J/YG.(YFV6>9VS$SPH2BQ>C=\'VC<&\(/X_OPYVV2-Z ML3Q:?'SQE?\\ZBX=2M3!%"Y)L(["3PO65[Q/*H9G7J^SU,<9>I2$B7# M)Z<"R)U\!OA=MSVSB2_WY5]S_HLE5;ERF:A"1L M*$(+DK*U?_T!)"7Q@2=%JD%'6[,SC@. W;_N!KJ!1N,O?WU>A*,5HC$FT:^O M3K]]\VJ$(I\$.)K]^NK3_357__KW_]MQ/[W ME_\X.1E=810&/X\NB']R'4W)+Z./W@+]//J (D2]A-!?1K][89(LXY]?OWYZ>OHV M(BOOB= O\;<^69@->)]X21IO1WOS_*;X7][]+R&.OOS,__7HQ6C$$KBGY]C M_.LK_MWBLT]OOR5T]OKLS9O3U__[V\V]/T<+[P1''#_?N M=?:WFZ:-EL^/--Q\X^WK#3G;D=G?8D7[$B4Q_CG.R+LAOI=D8M=^9B1MP?]T MLFEVPG]U+4!/T.0DA#=H>F(_Y=);_O594K1(R9<7J_YW[T^ M)TP?&:%9KSE%TU]?\39L\+.W;[Y[^X8/_:=*HV2]9'H98ZY6KT:OVWWVO1=R MA.[G""6Q[O/"QMV3<>M1%"5SE&#?"ZUH$O;LA$!N+FC!!H\GT\F2FSC3(2U@ MZE[=$C:9WB?$_S(G8<#FE\M_ICA9&].GZMPY?N=>/+\*R9,5?(U.'>E=C-G@ MMQ3%[#.9>/0*)^W2"4DWF*$?,/S'4?"!L!7IG##]IEJZ=/VZ$2.>17C*K"M* MQKY/TBAA'[HE(?8QTHO3I',G9-XA'U4^0DG$?O1S9=+1:=:[$T(OT&.B(Z?< MIB-;M)\G>IT<[E#(##U@LW>R?J!>%'N^T?2JZ]<)<PSW)+HZ1$^F8TBGIE^O*\<%2CP^2G%"5.]RV<_3 ,47%&RX(%?FCL*D^FE1R.&:'R+Z/V<>:NF MW/7UP8[AN(X8^"SZ911949C]"K:VI+MNTX*N*7I=#SAOVBT@4])RAB"\%F(,Z%X:Y3@A/>MM@' M/!V=\$W#E+NO[,>\94''AI*0^)6/AWQSC=2VL38;E=D66HS\;V=D]3I ^#4' MB/^0(96AQ/[P1_:A\2,S?P;19J30>T1A-OX?K$VMR>L#4+5!XH&-*":JVJ). M4UEF8^J/"&4*S+#>C.51OR*IYIYCT>+U,MOC.O'G.-P*>W0,X626R )C*,H]<([M"14 WRU MI2'>WT'B+>(-".;_29G'@FBX-D&ZT=@0[.\AP99P"(1WYAMBCH$X,W6AHC_ M .IX2'@$@OQ^CL*0[YEXD9&6B]H;POXC).QR/AT _I+O_5RPI<4<^U(70_A_ M<@7^!K= $KA%%). +>G4 /M&8T/4WT&B+N$0%._+*#!%>]O4./Z!![O&'A#4 M5SCVO3"GZ(K]+E;#+6AN"CE(S*EE$Q3VOR./&H->:FP*.4@8JF'QP("?IY16 MB%'.*O+6II"#!* Z)@^,^664X&3-TSD_IHO'W<9I%>MF*U.,08).&5,@V&YV M&J*$9ZFJ\*VW-,48)-94,0>"\SGCAWKA=12@Y[^AM0KH1E-3I$%B3"5[(%#? M4LP3$^ZQKY\TFFU-P0:)+-4,@J#]X#U?!XRK['">@Z0'7=K%%'N0L-*(71 1 M7$<^H4M2VBX^YPD2='U. N64KNEH*@Z0>-."=1"AC(. P147_[G!$3I5B4+8 MW/B,"$X "C8=@?W,#O8S<]A!XE MFX[ _M8.]K?FL(/$HEHV(6$_9S].Z -Y MDIQ 2QN;0@X2BVI8A 0\6VDF]):2%*%_X>7.D]2W-X4<\# 5<7HH3<8<[GS30M9*E&MB2F^ M(+&JD)U#0\HE3)$G5]]J"U- 00)0$3,'QO.&\+./.8F4^['-5J:X@D22,J8. M/?'R/.)8:OJEOS;.8 .95NML'!C&SQ0GC )^$S"-BCT:R:F8I*DIO"#AGY*] M T-]GUV_X1=Q?F,>(L6["@!5G$7M3$$&"?;DC!T8X5N*N*11<17Z@5\TH)/I M5#;SJMJ;(@X2Z^D9A47^.HY31&WQ%_0RE0)(V&?*]*'GF?S2Y?KT[/&!WYB1 MS#*-5J98@X1\,J8.C.U'\D ]7H;I?KUX)*'\>HBPH2G"( &>@K4#@URA0PQO MK8DIL""1G9 =H#GA\MF?>]$,R;,7Q"U- 0:)]%3,@0SRK%#@2PRSL8'S/!A)Q!:N'OK^77?GA!?KH(J/CBOT@AEW2 MU!1PF"N2*O8.#74:X 0%.4E7./(BGX54NUIC$M2UO4P% '.'TI!ID.W]SR@, M_Q:1I^@>>3&)4)"[^JH=?FD74RD GB%JV 41P>\D3!E*-$L$I1(;D#0UA1SP M[%#"'DSN99[4O%U[\DJL*L1E/4R!!SQ$5#,+E)^6($XS7J$++_$*"E7XRWJ8 MX@]XH*AF%BQ_GIZSA6=&U&?FM8:F: .FP@I9 P'Y?N&%X?LTQA&*E7-+K:$I MR( YKT+60$"^7" Z8Y/:!TJ>DGEQMU,%MJ2#*>B F:U*5F' ?][=(\_OORF1 M%[0VKDX "+N42:BR&]MJ=_=9<7PJ05W5WA1WT(N5M#W,I4"2+AJRC3,VEJZR:]<6BOM3/$&#$Q%C,'?>B+VBDRZ&XJ']"*0L8P",3TE]<-OF[8+_HJ="I^NJ92\/1L=#+: M;HAG%4_9\%&, OY33$(<<#9'Q4BC8JB]M6[JQ8^9C-+X9.9YRUSU4)C$F]_L M=+#XQ1^E=UNV>_FW) \3%*53B^YFO?>WIS:.8H:KGH=X.JMZJ%:150Y)P MTL/$UEX0Q0)H*H]&<["RK6IP11*0L HN"/[P$7\]A/V'U[M>>2&?>+M7.8I#E8B=H6HE%R#"Z/"B>&OAE@K=HVBX>(PQ+NC'86 M-RC7'74OL.*W-CZV M">..V)/.D +W]I'-2_ 9FZP]XC#[)4SICC-]W_TP:GY"'!E=O??2+#%"=S< M2@0;[S.H^L 5[&TK :D 7=V,V 1SM]Z:1W+&86R]/5RA7W.LQ6&LF',7!$-3 M-J4WV%+*1M8%KBCP'N)1\P\N(1O1[".3WO8;K&5B)(RA>2,&;SH+-F%5G> J M%W>S;!F_<@UH?&V\QB[\Q-XV,?:4V0"\P]O-Q)#1JCGE$#:&JYULCG)CNTG& M,[@\2ND8NB.G1DNX2LIM)2'C%EP,XR#(@D$6%GHXN([.O25.A*5N-IZ1K -< M/>6V0M'P#BZ;._Z8;X2"S9OKS"E-%VGV\.\%FO(:/JHC#7U?N +,;25FC@BX M\)J\V;@&D&6:VPI'SO& _7.=8]1^EQ"R)'3G&TQ*;#H5/V2BWVT&ZAPEV"\M M$Y6LO[=MLOY&WU1&_L]C%F"?OC_#>D(S=7]B9!&60."FYK%Z%I=0V?: 3#3N66!4* M)Z6EOB^BX*W-A9'>3@0ZEEO?=TGVW&&Q7_*,.D.G+.XA1 MP7!*D^5*G[ 2= MSMB-X)Q=Y!HTZE8X:0?HY,8N!>78VF9Y$5+&59M5K<<3@N[$9;:D'3@(KH?AW9J'X;L@1F8YV@XZ^^11Y>9D[H("<7X=;$F#?F/SL\I#.;,/&'UFBZU9F!A8 O., M9ZIQ!^$S3N;G:9PPYX%>/OMARCUH?GN"_1,\>,^J,_L6@[ERYM#P,AI']ZV1 M I?R.8E91/6!D*"LKOU7@ZHLBB[.G!_HA*AE&]R"[E$8\E*L*&*4ALS.Q\$" M1YA3R>L\%W0K@D?#_M"G!7I)D%9\.2+&.X8F^SR_\'_!UMJ09/=AM=+3=(,^ M*; 5FA$*X+)J<&4Q!\(?"MC*1,KM2UC-\FW"&R(LBUX'H-S8F;,"XQ6LR2JX M(7TD$:F25^B8WKDPZ I="L%81,8P@ OL XOP8ZY"*)Y$E\^*:&MZ,P 9=;]G +BO7^8*,A M>!F$MI*1L&SO=+S+G8X(S?B!,:C;T<+R.C"ZWK9"VHK6QMZ&YEE^1(F)3UEK M!EYBP=Q7$?$W8'EM[J)MT@;?>S'VY7*3- -0WA)?1ODGX)/!E A87<^R*41Q3!2S2KIL<6?VF#;6JTP<21MK(X!<@?C[223B MZ:F27+(Z,^)N0Q2+F)-^LLQL'+XJ6=)LLXV_)&[NF$!4RE9W ,4,E8[OP!/Z M=7E0@J;.Y&182$+*,;@;+BFMHI.+IILSF1L6,C)" EQ>]<(JVD1"27MGTC(L M)*3F'5PT!RHD Y]LUD,!D67VQBVC@":@>T06%\S:WRJ#3U@SN3@V3 &.@W^D M<5Z4\H%(IO3-;A@*^+2#HC@34*;5DV5VI>P.,;6.<8**3,K\">8[Y)-9E(VH M6AD/1( S,[A.V0XL$O!UH#V_NP=A,LX_,<9@5+$E(=")@P=0R;U$!*Z:&Z+E+)Y/R#'VPT&G*MHY.FWAXK;D/ P.7=ZWDT?':C[CAZB$'?'V<#RET4D]])W' 9P6;K[!/V6$ZVJ:RC_T$K_+*M?I$\19CN7(K5R'(YCK8$C'PQ;+?C+G>(8>_C'/DH&"\(3?"_-&)5=H+>0CR@; W Q?P]OWXSY2Y MNQ?D22%745OHK;X#BE,.%;@4^:TUSNH=REY@>2 WC*%9?L2"$A89<8#D@C7L M#KW/=T!96P$ZZ'M,##N*V/IS@?+_EM JSDF,JET:CP&]'7G0"<,66O")I$GR MYGEX/?+>Y"_&)T7I@*UA])Y1--XF[O-VJ >#_S2>X_+A0F2X"Z! M^=97%QOW+ER%[W [V!*Y 5^^EC#+5\:XHW,>Y5CN7+O?^Z3' #/P68%-79OL M.O^?*::(,<'T.EG?AEZ4L!F-)Q LU=L.-F. W\K?0U:D-=/CBG_/]<^5=>B+)@>I.0Q_^"&4;U%Z66>1I?T\\J"EE?/OMS M+YJA.V8,E],I4BT]AZ;#5%T/\:Z4Z;(%(ZNO5;FWT%S@>$EB+_Q 2;KD555Q M[).(S00L<&B^P-2Q:EM38:K8AWB!ZR"*W5).@[^0]?4IMT5"Z&G_6;UNJO>+ MR1S>"S1]J-O1\*;JV'^"\H'4T;F N""X3B9SX2E=,[/)[A2I]<"@NW$>7%]R M[E9H384PAG#@TTH5([E>U-N9*D!OV^%]*H 8E(%+>B_ >EHXS/6HMUWVOB>2 MO2$?N-K=I\MEGJ;DA9L5^3+_AIDKDTIZ[#2[@3D6>D_3@/:.87UW_ MB+1/#E?;F@JHOPO[-F@WCDTEO,,70>4U6>/)]+8TXI:XRD6T'TZ'&%?8C? M"?R!J=5[1N&7GF 2?@GXQENG:E5_XJ$GL<#/*#>8>2 !+U,;!1\(SRTAD8^H M9%KYJ3ZM;+N/O"@890.,-B.T,2!.7V85;[Y[^R:SC-M/=Y=_[+XIHU17B*?7Y"GB=/\>H=S/S] M\O%GQ4;>U6VD-,9H-\AH.PK,YG>)J%F;3!SE5B<9F*JW8SNC"&;*T,C.Z<[ ME.$-O_*R7<6\3^OFG34%NHS\F.Q(T1NKK#W45>HR-0:6)NT ;#QJ,33N0"NY MAM=\PT=L3L\:[F3YA9H__71V^N/FB1H@Z]@2-YE6"UIF5UC/29S$6;6!1UYM M8).%:F!%>XX+9&VF5+\O4VUBE?L.#&V]G:A)W:$MTW7-^L^ROJ/*@, G3*+V=%;O;XGU+FYF"ZKE=5J$&![-15AXRC= M&B=XZ^.OJ.!DZT-G664S%$GW>$Z_JQM@:81L)[0Z!MAC.!*F;)Q9RV'@'O[1 M$FE@H+;C -MH*Q$+7A"RAP[>9I5;7,H=VM/O+7=H1]]L?@*JRODR-FOOT I% M*;IB6LS5C)/R&2?S\S1.R +1C,RUT2IJ-XXS>SZ&F[?M< +/&?D4,R?\,D[P M@CD B@2R>COH*IS6\A$S"HY__55F8WO2=H0N@FDM(4,HP$6VK>QF+"MY#_#: ME;9"TC$/+AW9AH*QL(P' *]-:2L[2V@<$&7$SP;S.T)W./YR3E& $_Z32GR* M3N#U)^U%IH4 7$SW:,8#D3NTY!5+"];,)T?#[N#E)*U/\VU@<3PRRYY]EL1E M/UC'9?EHQZAL'YOSYRA(0\2SBDF0^LEU-"5TD2E"!J^)X5F,,;1HS!X?^&ET M2_*8<1K@,$WP"MTC/Z59V8[+9WZE%@5YA+E8IIODU;K?;"7Z[KXUN(BP/\ = MTJ6MOWZ>4@ZB_>2@&V%P<:8M. ZLS8VL ]6"W+A%(L\] %Z+CTD(8J/=T:9X M:[1R*W'W^FA1YVEM;^A]?/4EIB\<0DX.K2#ZMYCW5+E68T-[&X?0K#U =U)_ M"A2RMU++K/!*#;G@XCA=Y+_;1Y?V^0ZT-W,PO=I?&/!^D>Q*T@5*/!S&'SW* M-\Y62.PGV5R+&WU3C#G:#MK.9QKL5;D.#I(9@!$*-M$3\]O319II]06:,L== MF5^F[SO,FW46##:L;I#E78?TXF,GHM4]\S@\*6I2'?)]$UYR-HX1^R=X\)Y; MYX6(!P-;I3LR]M;XM2XSLT+TD<1HN+6-7G[5WNX/^3O1UJ'4[W5H@G2JNE_W M^0>=J56;\GU06[#I8N'1]61:3-[OU\7!4A$7B$.,9E6!?!A>TJ<8:/2X'A5# M;8.,X]%HGT>C>YR(ZHVNH:^NG7E(.2N_I 7T2DB#-&:TZ#I!"T6LH.SDAK2, M-;+^]H>*M7+MU@[%%=.D)"KVIYV8V!\V(IK0>T17V$?C9RR2#6LJ;CE0@4CY M*86>!Q<"O_E1$!-?D(6'18\Q[R@7-0<6AQ16&?HB'G;[.EV6@.+_^F^^-9K2 MJ>>CW]#B$5$!OKR=I"W8MH4:KRJV"OJ[.4F0X'N/P]]Y;! ID6VT @NE;#&5 M\ =^+E-XG8H%==<"^/#6P!T0;ZRH;G<<.FRHY!B=[)%DI(HSSAI5E3;?Y8%& MY/BM@-COW$NWNK MYD=O@:0AL!*7D,65D^HFQ>1&+2E*;,A:4MH9.!315R7)XJ&'= M@3"QF;%Z=_])*J!M *;L!G[;V5)29EPY(K(]YXWQ@CO6O2W/F^&A+Y)U[#QW MN_969=!QK@?8SL?FE@VO3:3:Q&C4CBUO8I0&.>Y#=%K%XLY[^LU+$,5>J/#. M)!N*WL_9_1=VE@@9&-P3.FE6<=:4-.KHE<%RCCJD\QU2>8RH/6*6E]^L' M]CGUAJVRT[#%I60-? ^T01VG3;?]J>SDAK0,M% GIS)3>VY:[B^FXCY'@TC= M+IJV(W09,P,%K O*# MP3U^@@N]1Y,\7'OUB/1O6>KIA9!U.B37^2A&-*\+; M$&@].39ZNB$\4_74RJ[.'O1<>>^%*"[2MUC\J9LA)D5V(]!;;YT5P%("+&MLNL7GS'RC8J;/V49SG^$W[Q^$;CQ$6980:RAJ MY\:ZW.9"B8B;T@'XX>#GY]^3:84<: [Y[FM^;7WYX(I:(EWH8(OZ3@X@W^#X: M(G'H%!%X7< MLC<._L'FL:R,Y$SH.CBQDFP6B(U4U%P Y_"+R*N8?MF$KIQ+8U?JWD& M@KIQ*H&_0IHF4U70=IAB$7$"GYU?(4J;>2IL[88XY$JEE$//14.\$#-?),+> M>R_BCZL]4!9 J0\]E%V@=P14^E)Q@@T8!W=^^?)W';%%+\T>EU+.0Z*V;BB^ M[3PDX@0\&[Y*E$F%)'D/-\0B5RZE//HO9'3KK?TY\K^P8"E!/@>%_32CWD*= MMZOK!3TSZ32HDKYK!@'X!,6H\A$*8KX/?D.\2'T=M=X4^## R"5OWCP5,PPN MBJIZ7:#8ISBKA64Z0U6Z0!M+&]EH$7!,1M=1@ABL"7^NYS[AS^PH]R.%7*K' M@-[)WU^*)A@Y)M8'1!>FXLO;0N_F[R^F,L_P&Y*[^P/UQZ.+5WZ5A;.^4Q7. MV@V8OP,_V@P)74;K^/B[S7O;8TKY0VD9K>_7XF=\C4NB[/T)1^(!B#>X+5"" MW\/5LB#CH#&9"M2I@['=T*/.;:^N4AT@!;_%G+.IK0I3:_9U2+C&-/@>='LN M=YQ$P6WH12;[1OU\S0W-$6J]K7VWXA^Z) -H">C>PO0^+<.=LM&:&[]97,H9 MNV>!J4SK:^35T'"IRA>(A]/,0I4-[05S>%O:"MU MKXR_G(E^-O%_9^:* F;H6GO-_#GI M9+W;ZHDGR9Q?QO.B_*F%^".)5AGS>:I:#R&./0G )PO=!8I=Q3YMI=@Z&7Z9 M/57/IB>:@";$]X?8!S9$$E]'MQFG$&I?I\!Y;] ]M1<+L:=$]/[8X(L."A2Z MF#VB>K#/0Y\[=:^(A\7OQ?L,5X1.$4Z4*MN[[0N(@#Z)&^ ,*A7E"U9?]US> M/\[@KR$-4'D%*';B]UY&@2OO195>Q3,Z_OY>=?R=GWGGHQV/OH]'W\>C[^/1 M]_'H^WCT;908_]S8]L7;SK%FD9A*\^ST*>7@B#W.2 MQEX4W/.R] E"T<8SY:FL>(4X(;HJ7C9C0.\$JD]T6S T])"RB#6?.IZ*6$KEZSW]:"+S&>'9G!]QKA#U9NCR&5$?Q^B68E\5*AR* .@9 M;PC*;2+"KU[EMP?YE\]+Q-.-'@C_50G&\6Q&T8P%AM=10G$48Y_7$NO1"/8@ MZ>6=Q,!C>C04P='I!TKB/F)\U<>.IS7VHG'?A99&SD+F>G)+NB3BZSV7Z5Z4 M\.K+3T#R\_J+E/)WIO/IG+,9E\Y:X@WYJJ/M%F-!5[#K3YE: VN_$K_+5^(H M6][K)W4#FPXW<$#/B)9T&.IQ]\6^G9\46PD4?E[X(-7-E[$NK@)V#(HPF+[+7>7MEU=OH5 MHM53EMI@5=;ITPD+]3[M_M6E >FW#L2CUK^P PH;R_CZCN[V@O6EY3%?>9AF MS(WC.%WD "D3F7]0)3+ST4;9<*/2>,=,9J$G! M'J9$FX\#)^3TD_9\.*D--^82\IR&$/24[E< M=^NF]):$.JBZ*1H/ZH'OET^FUU' #Z!2+Y1[O)*F;LQ6?7J\$L9+-T(!Y?49 M)_-L7Y3*?8 M1S2^P!3YK'?,YNMS1DD:)OQ6K7):M!T$+D>S#?#-6;,=:.#^^!6.O,C'7BA^ MI[WI[TD[O/"I5,=^Z58TC"0?&&/Q%&7Z=H_H"OLXFDVF H)COM\5B_]*Y^YW M^Q4W=$9C S4-Z!8!Z/W@TK5WW1ZPH"EX8GT?2B^J&B!""'SN;GT".<#J\^"9 MS.Y=X>C@P26@,^3/L[?RK55F7L &Q]06>%Z".)$>A5 MMHU;G4_N2,SP5M$S].('DGAA^>]YSM!'DOP=)7?()[,(_TM5,Z?'3T*G%/>F MD;V+J:<-P-[HOD/[A[S3LL?HXLG?TY"X-]:_ % M%K7K[ZW!@SL QW<*7UHQ/>!W"H?GPO8'UL#?.'R!E?=Z?>/0E]'C-)D3J@Z^>_WH MUUN2;G]1#5<==^7V+OJY4E[_ '2*CWMJ)A;!<%4J^Q>?N;=%I'67PCO[RK'* MFXTTAJMBFYFYF(]7'@YY6@+S$[,@O\<55/I%\-->]U3/4$K#5<-#[0[NMP=X M.KP3DWXDXH:BM2GH42E(N&%K6^6CCYHKVB^:*M^ #DUZQ\PE-=S7E[CCI6+[ MJ)4@^HBILGU%QQUR6;BA7PT#JL?.GR(FLU+^&+\V$5=*#M]Q#$K55@O[JE4I MWIY&GI,HJW*2>B$OBRE2/!W1TX@2N7Z7*0SL>^Q!H:@@# M/>UQ 6+X$VIW\XN+T)C0XE>\G6+1.#0=IM8QO$,J&(G"EYDMZF/>>C199]>B MF*GBW0L6FF*S/]6+S1;#C;+Q1N4!W2DV*V-97TY6WQ-F.LK2@FZP]YB]1'"> M4FY)!;'C*&!J2TN4\ZI+*9O3F9K$F$W@EU&Z0/DYJYSU#C\!?"7+5/RU":)S MC,&=P@I'&,4%3X8Z4.X ?66J"Y$V ;":G(N_X?_B/A;[S?\#4$L! A0#% M @ 3('.5K6S,=Z_!P &"D H ( ! &5X,S$M,2YH M=&U02P$"% ,4 " !,@#,R+3$N:'1M4$L! A0#% @ 3('.5KL.??V: M!0 M18 H ( !QA4 &5X,S(M,BYH=&U02P$"% ,4 M" !,@'-D4$L! A0#% @ 3('.5MJQ%L&^"@ MU'0 !4 ( !)?8 '!U&UL4$L! M A0#% @ 3('.5OYLIOW )0 =X " !4 ( !C4\! '!U I